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A B S T R A C T
Background
Polycystic ovary syndrome (PCOS) is the most common cause of infrequent periods (oligomenorrhoea) and absence of periods
(amenorrhoea). It affects about 4% to 8% of women worldwide and often leads to anovulatory subfertility. Aromatase inhibitors (AIs)
are a novel class of drugs that were introduced for ovulation induction in 2001. Over the last ten years clinical trials have reached
differing conclusions as to whether the AI letrozole is at least as effective as the first-line treatment clomiphene citrate (CC).
Objectives
To evaluate the effectiveness and safety of aromatase inhibitors for subfertile women with anovulatory PCOS.
Search methods
We searched the following sources from inception to September 2014 to identify relevant randomised controlled trials (RCTs): the
Menstrual Disorders and Subfertility Group Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE,
EMBASE, PsycINFO, Pubmed, LILACS, Web of Knowledge, the World Health Organisation (WHO) clinical trials register and
Clinicaltrials.gov. Furthermore, we manually searched the references of relevant articles. The search was not restricted by language or
publication status.
Selection criteria
We included all RCTs of aromatase inhibitors used alone or with other medical therapies for ovulation induction in women of
reproductive age with anovulatory PCOS.
Data collection and analysis
Two review authors independently selected trials, extracted the data and assessed trial quality. Studies were pooled where appropriate
using a fixed effect model to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs) for most outcomes and risk
differences (RDs) for ovarian hyperstimulation syndrome (OHSS). The primary outcomes were live birth and OHSS. Secondary
outcomes were pregnancy, miscarriage and multiple pregnancy. The quality of the evidence for each comparison was assessed using
GRADE methods.
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Main results
We included 26 RCTs (5560 women). In all studies the aromatase inhibitor was letrozole.
Live birth (12 RCTs)
One RCT compared letrozole with placebo in women who were clomiphene resistant and the results were inconclusive (OR 3.17, 95%
CI 0.12 to 83.17, n=36)
Nine RCTs compared letrozole with clomiphene citrate (with or without adjuncts in one or both arms) followed by timed intercourse.
The birth rate was higher in the letrozole group (OR 1.64, 95% CI 1.32 to 2.04, n=1783, I²=3%)
Two RCTs compared letrozole with laparoscopic ovarian drilling. There was no evidence of a difference between the groups in live
birth rate (OR 1.19, 95% CI 0.76 to 1.86, n=407, I²=0%)
OHSS (16 RCTs)
There was no evidence of a difference in OHSS rates when letrozole (with or without adjuncts) was compared with placebo (one RCT,
n=36), clomiphene citrate (with or without adjuncts) followed by timed intercourse (nine RCTs, n=2179) or intrauterine insemination
(IUI) (two RCTs, n=1494), laparoscopic ovarian drilling (one RCT, n=260) or anastrozole (one RCT, n=220). Events were absent or
very rare, and no study had more than 2 cases of OHSS.
Clinical pregnancy (25 RCTs)
One RCT compared letrozole versus placebo in women who were clomiphene resistant and the results were inconclusive (OR 3.17,
95% CI 0.12 to 83.17, n=36)
FifteenRCTs compared letrozole versus clomiphene citrate (with or without adjuncts in one or both arms) followed by timed intercourse.
The pregnancy rate was higher in the letrozole group (OR 1.40, 95% CI 1.18 to 1.65, n=2816, I²=26%)
Three RCTs compared letrozole versus clomiphene citrate (with or without adjuncts) followed by IUI. The pregnancy rate was higher
in the letrozole group (OR 1.71, 95% CI 1.30 to 2.25, n=1597)
Three RCTs compared letrozole (with or without metformin) versus laparoscopic ovarian drilling. There was no evidence of a difference
in the clinical pregnancy rate (OR 1.14, 95% CI 0.80 to 1.65, n=553, I²=0%)
Two RCTs compared letrozole versus anastrozole, one RCT compared a five day versus a 10 day administration protocol for letrozole
and another RCT compared 5 mg of letrozole versus 7.5 mg of letrozole. There was no evidence of a difference in the clinical pregnancy
rate in these comparisons.
The quality of the evidence was rated as low for live birth and pregnancy outcomes. The reasons for downgrading the evidence were
poor reporting of study methods, possible publication bias and the tendency for studies that reported live birth to report higher clinical
pregnancy rates in the letrozole group than studies that failed to report live birth (suggesting that results might be somewhat less
favourable to letrozole if all studies reported live birth).
Authors’ conclusions
Letrozole appears to improve live birth and pregnancy rates in subfertile women with anovulatory PCOS, compared to clomiphene
citrate. The quality of this evidence is low and findings should be regarded with some caution. There appears to be no difference in
effectiveness between letrozole and laparoscopic ovarian drilling, though there were few relevant studies. OHSS was a very rare event,
with no occurrences in most studies.
P L A I N L A N G U A G E S U M M A R Y
Aromatase inhibitors for subfertility treatment in women with polycystic ovary syndrome
Review question: Cochrane authors examined the evidence about aromatase inhibitors for subfertile women with polycystic ovary
syndrome (PCOS).
Background: PCOS is the most common cause of infrequent or absent menstrual periods, and affects about 4% to 8% of women
worldwide. It often causes anovulatory subfertility (subfertility related to failure to ovulate). Aromatase inhibitors are used to induce
2Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ovulation. Over the last ten years clinical trials have reached differing conclusions as to whether the AI letrozole is at least as effective
for treating subfertility as the most commonly used treatment, clomiphene citrate.
Study characteristics: The review included 26 randomised controlled trials (RCTs) with 5560 women. In all trials the aromatase
inhibitor used was letrozole. Comparators included clomiphene citrate, which was used in 17 of the RCTs, and laparoscopic ovarian
drilling, which was used in three RCTs. Several studies included co-treatments in one or both arms.
Key results: Letrozole appears to improve live birth and pregnancy rates compared to clomiphene citrate. However the quality of
this evidence was low and findings should be regarded with some caution.There appeared to be no difference between letrozole and
laparoscopic ovarian drilling, though there were few relevant studies. OHSS was a very rare event and there were no occurrences in
most studies. The evidence is current to September 2014.
Quality of the evidence: The overall quality of the evidence ranged from low to moderate.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Aromatase inhibitors compared to clomiphene citrate with or without adjuncts for subfertile women with polycystic ovary syndrome
Population: Subfertile women with polycystic ovary syndrome
Intervention: Aromatase inhibitors compared to clomiphene citrate (with or without adjuncts in one or both arms) followed by timed intercourse
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Clomiphene citrate
with or without adjuncts
Aromatase inhibitors
(Letrozole)
with or without adjuncts
Live birth rate 188 per 1000 275 per 1000
(234 to 321)
OR 1.64
(1.32 to 2.04)
1783
(9 studies)
⊕⊕©©
low1
Ovarian hyperstimula-
tion syndrome rate
0 per 1000 0 per 1000
(0 to 0)
See comment 2179
(9 studies)
⊕⊕⊕©
moderate2
Risks were calculated
from pooled risk differ-
ences.Two events oc-
curred in the clomiphene
group in one study. The
other eight studies re-
ported no events in either
arm.
Clinical pregnancy rate 202 per 1000 262 per 1000
(230 to 295)
OR 1.4
(1.18 to 1.65)
2816
(15 studies)
⊕⊕©©
low2,3
Miscarriage rate per
woman randomised
25 per 1000 33 per 1000
(23 to 46)
OR 1.32
(0.92 to 1.88)
2385
(12 studies)
⊕⊕⊕©
moderate2
Miscarriage rate per
pregnancy
134 per 1000 123 per 1000
(86 to 174)
OR 0.91
(0.61 to 1.36)
696
(12 studies)
⊕⊕⊕©
moderate2
4
A
ro
m
a
ta
se
in
h
ib
ito
rs
fo
r
su
b
fe
rtile
w
o
m
e
n
w
ith
p
o
ly
c
y
stic
o
v
a
r
y
sy
n
d
ro
m
e
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Multiple pregnancy rate 18 per 1000 7 per 1000
(3 to 15)
OR 0.38
(0.17 to 0.84)
2385
(11 studies)
⊕⊕⊕©
moderate2
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Most studies failed to report their methods in adequate detail. Studies that reported live birth tended to report higher clinical pregnancy
rates in the letrozole group than studies that failed to report live birth, suggesting that results might be less favourable to letrozole if all
studies reported live birth.
2 Most studies failed to report their methods in adequate detail.
3 A funnel plot analysis strongly suggests that there might be more publications without a significant effect which were not published.
5
A
ro
m
a
ta
se
in
h
ib
ito
rs
fo
r
su
b
fe
rtile
w
o
m
e
n
w
ith
p
o
ly
c
y
stic
o
v
a
r
y
sy
n
d
ro
m
e
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Polycystic ovary syndrome (PCOS) is the most common cause
of infrequent periods (oligomenorrhoea) and absence of periods
(amenorrhoea), affecting about 4-8% of women worldwide in
their fertile years Abu 2012. Many of these women are subfertile,
but for most of them it just takes longer to become pregnant nat-
urally and only a small percentage needs fertility treatment.
The mechanisms causing PCOS are very complex and the exact
pathogenesis remains unknown. But some of the symptoms are
believed to be caused by abnormal levels of the pituitary hormones
luteinizing hormone (LH) and of the male hormones (androgens)
which interfere with the normal function of the ovaries.
The diagnosis can be made based on the “Rotterdam criteria
2003”, jointly proposed by European Society for Human Repro-
duction and Embryology and the American Society for Reproduc-
tive Medicine Rotterdam 2003. The woman must have two of the
following three criteria to be diagnosed with PCOS:
• Oligoovulation (infrequent ovulation) and/or anovulation
(absence of ovulation)
• High male hormone levels (hyperandrogenism) diagnosed
either clinically (excessive hair growth, hirsutism) or
biochemically (raised serum testosterone levels)
• Ovaries which appear to be polycystic on vaginal sonogram
defined by the presence of 12 or more antral follicles in an ovary
or an ovarian volume of >10mL. Antral follicles are defined as
measuring between 2 and 9 mm in diameter.
Description of the intervention
There are many possible options for treatment of subfertility in
women with anovulatory PCOS.
Clomiphene citrate (CC) is a selective oestrogen receptor modula-
tor or SERM and is the most common medication used for treat-
ing the condition. It was first introduced in 1960 for treatment of
WHO (World Health Organisation) type II anovulation (a type
of subfertility where hormone levels remain to be normal) in sub-
fertile women and it has been first line treatment ever since. CC
is given orally and it is relatively safe and inexpensive, but there
are also adverse effects found with CC such as negative changes in
endometrium and cervical mucus due to the down-regulation of
oestrogen receptors that might impair implantation after success-
ful induction of ovulation Casper 2006.
Aromatase inhibitors (AIs) are a newer class of drugs that were in-
troduced for ovulation induction in 2001 byMitwally and Casper
Mitwally 2001. Over the last ten years data from many clinical
trials have been collected and there is evidence that the AI letrozole
might be as effective as CC, but the outcome data vary. AIs are like
CC administered orally, but due to their short half-life elimina-
tion time of 48 hours there are fewer adverse effects on oestrogen
target tissues such as endometrium and cervix compared to CC
Baruah 2009; Jirge 2010; Samani 2009. In 2005 a study published
by Biljan et al. including 150 babies raised some concerns about
teratogenicity of letrozole, but there were major methodological
flaws in this study as the intervention group was not well con-
trolled Biljan 2005. Furthermore, two other large studies includ-
ing 911 and 470 infants compared use of letrozole to CC and
spontaneously conceiving women. Both reported no higher levels
of minor or major congenital malformations or cardiac abnormal-
ities in newborns after usage of letrozole for ovulation induction
Tulandi 2006; Forman 2007. Additionally, due to the short half-
life elimination time of letrozole it should be completely cleared
out of the system before implantation takes place. Some authors
recommend to test the blood levels of ß-hCG prior to treatment
with letrozole to exclude pregnancy Casper 2011. CC and AIs are
usually both given for five days starting on day 3 of the cycle. The
doses for CC and letrozole range from 50mg to 150mg per day
and 2.5mg to 7.5 mg per day, respectively Lee 2011.
Since many patients with PCOS experience insulin resistance or
impaired glucose tolerance, metformin and other insulin sensitis-
ing agents were thought to be a superior drug for treatment of
ovulation induction Velázquez 1997. However, the latest version
of the Cochrane Review on oral agents for ovulation induction
concluded that the use of metformin and other insulin sensitising
agents as an adjunct is limited and might be favourable only in
patients that are resistant to CC alone Brown 2009.
Humanmenopausal gonadotrophins (hMG)were introduced into
clinical practice in 1961 for ovulation induction. They exert a
central role in ovulation induction in CC resistant subfertile nor-
mogonadotropic anovulatory women Lunenfeld 2004. However,
women with PCOS are at particular risk for complications such as
OHSS and multiple pregnancies and a low-dose step-up protocol
was introduced to reach the FSH (follicle stimulating hormone)
threshold gradually in order to minimize the risk for OHSS and
multiple pregnancies White 1996.
Finally, another possible option for ovulation induction in cases
of CC resistance is laparoscopic ovarian diathermy (or drilling),
during which the damaging of localized areas in the ovarian cortex
and stroma seem to have similar success rates compared with go-
nadotropin therapy Farquhar 2002. However, it is not fully clari-
fied how the partial destruction of the ovary results in follicle de-
velopment and ovulation induction, and there are concerns on the
long-term effects of the technique on ovarian function Farquhar
2012.
How the intervention might work
AIs down-regulate the production of oestrogen by inhibiting the
cytochrome P450 isoenzymes 2A6 and 2C19 of the aromatase
enzyme complex Cole 1990. They inhibit the negative feedback
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loop of oestrogen in the hypothalamus and result in stronger go-
nadotropin releasing hormone (GnRH) pulses. The elevated levels
of GnRH stimulate the pituitary gland to produce more follicle
stimulating hormone (FSH), which induces development of folli-
cles in the ovaries. Because AIs do not deplete oestrogen receptors,
in contrast to CC, the central feedback mechanism remains intact
and as the dominant follicle grows and oestrogen levels rise, nor-
mal negative feedback occurs centrally. This results in suppression
of FSH and the smaller growing follicles will undergo atresia, lead-
ing to a single dominant follicle and monoovulation (ovulation of
a single egg) in most cases Casper 2006; Lee 2011. Therefore, by
leaving the central mechanism intact, the AIs might lower the risk
of high multiple ovulation and OHSS compared to CC.
Why it is important to do this review
Because evidence for and against the effectiveness and safety of
these agents has fluctuated over the last decade and new data based
on recent randomised controlled trials have become available, a
systematic Cochrane Review is necessary to provide up to date
information for daily practice. Therefore, this review evaluates
the effectiveness and safety of AIs compared to other agents for
ovulation induction or laparoscopic ovarian drilling, to provide
evidence as to whether AIs should be used as first-line treatment
in subfertile women with PCOS.
O B J E C T I V E S
To evaluate the effectiveness and safety of aromatase inhibitors for
subfertile women with anovulatory PCOS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCT) were considered for inclusion
in the review. Not appropriately randomised (quasi-randomised)
trials were excluded. Cross-over trials were excluded unless phase
one data were available separately. Multi-centre trials were also
considered for inclusion in the review.
Types of participants
Women of reproductive age with anovulatory PCOS (WHO type
II anovulation in women with normogonadotropic normoestro-
genic anovulation) diagnosed according to the Rotterdam Criteria
2003, the NIH consensus criteria or the AES criteria Rotterdam
2003; Zawadski 1992; Azziz 2009.
Exclusion criteria
Women with hyperprolactinaemia or Cushing’s syndrome, or
both, were excluded and trials which report on women with
these two conditions were excluded from the review. Trials con-
taining women with WHO type I anovulation were also ex-
cluded (Hypogonadotropic hypogonadal anovulation: women in
this group have amenorrhoea, low or low-normal serum follicle-
stimulating hormone (FSH) concentrations and low serum estra-
diol concentrations due to decreased hypothalamic secretion of
gonadotropin-releasing hormone (GnRH) or pituitary unrespon-
siveness to GnRH). Studies using methods other than ovulation
induction followed by intercourse were also excluded, for example
IUI or IVF.
Types of interventions
Aromatase inhibitors for ovulation induction (alone or in con-
junction with medical adjuncts, e.g. metformin, FSH) followed
by sexual intercourse in women with anovulatory subfertility were
considered for inclusion in the review. AIs were compared to each
other and to other choices of treatment, including CC, tamoxifen,
recombinant and urinary gonadotropin (FSH), insulin-sensitizing
agents such as metformin and laparoscopic ovarian drilling.
Types of outcome measures
Primary outcomes
Effectiveness:
1. Live birth rate per woman randomised, defined as delivery of a
live fetus after twenty completed weeks of gestational age.
Adverse effects:
2. Ovarian hyperstimulation syndrome (OHSS) rate per woman
randomised, defined according the definition adopted by the re-
porting authors.
Secondary outcomes
3. Clinical pregnancy rate per woman randomised, where clinical
pregnancywas defined as the presence of a fetal heart onultrasound
scan at 7 weeks of gestation.
4. Miscarriage rate per woman randomised, where miscarriage was
defined as the involuntary loss of a clinical pregnancy before 20
weeks gestation, including partial loss of a multiple pregnancy.
5. Miscarriage rate per pregnancies, where miscarriage was defined
as the involuntary loss of a clinical pregnancy before 20 weeks
gestation, including partial loss of a multiple pregnancy.
6. Multiple pregnancy rate per woman randomised, where mul-
tiple pregnancy was defined as more than one intrauterine preg-
nancy, confirmed by ultrasound or delivery.
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Search methods for identification of studies
We searched for all published and unpublished RCTs studying
use of AIs for ovulation induction in anovulatory women with
PCOS. The following search strategy was used, without language
restriction. The Cochrane Menstrual Disorders and Subfertility
Group (MDSG) Trials Search Co-ordinator was consulted.
Electronic searches
1.MenstrualDisorders andSubfertilityGroupSpecialisedRegister
(MDSG) (inception to 9 September 2014, Appendix 1)
2. The Cochrane Central Register of Controlled Trials (CEN-
TRAL) (inception to 9 September 2014, Appendix 2)
3. MEDLINE(R) In-Process & Other Non-Indexed Citations,
Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (inception
to 9 September 2014, Appendix 3)
4. EMBASE (inception to 9 September 2014, Appendix 4)
5. PsycINFO (inception to 9 September 2014, Appendix 5)
The MEDLINE search was combined with the Cochrane highly
sensitive search strategy for identifying randomised trials which
appears in The Cochrane Handbook of Systematic Reviews of Inter-
ventions (Version 5.1.0 chapter 6, 6.4.11). The EMBASE search
was combined with trial filters developed by The Scottish In-
tercollegiate Guidelines Network (SIGN) http://www.sign.ac.uk/
mehodology/filters.html#random. There was no language restric-
tion in these searches.
Searching other resources
The references of relevant systematic reviews and RCTs obtained
by the search were looked through manually and experts in the
field and manufacturers of aromatase inhibitors were contacted
personally to pick up any additional, relevant data. Additionally,
the databases of the WHO, clinicaltrials.gov, web of knowledge,
PubMed and LILACS were also searched (up to September 2014).
Data collection and analysis
Data collection and analysiswas conducted in accordancewithThe
Cochrane Handbook for Systematic Reviews of Interventions Higgins
2011.
Selection of studies
The trials to be included were independently selected by three
review authors (SF, WN, CF) in accordance with the aforemen-
tioned criteria. Trials were excluded from the systematic review if
they made comparisons other than those specified above. Studies
from non-English language journals were translated if necessary.
If a specific trial was published more than once we only included
the most complete and up to date data. Authors of primary stud-
ies were contacted if papers contained insufficient information to
enable an accurate assessment of eligibility for inclusion. We pro-
vided a list of excluded studies and the reasons for exclusion are
shown in the ’Characteristics of excluded studies’ table.
Data extraction and management
The data obtained were extracted by three review authors inde-
pendently and any disagreement between these review authors was
resolved by a third party. Extraction of the data from eligible stud-
ies was done by using a data extraction form designed and pilot-
tested by the authors. All data collected for our analyses were di-
chotomous. If studies had multiple publications, only the main
trial report was included. The review authors contacted study in-
vestigators to resolve any data queries, as required.
Assessment of risk of bias in included studies
Included studies were assessed for risk of bias, using the Cochrane
risk of bias tool. Seven domains of possible biases were assessed,
including:
• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective reporting
• Other bias
The different types of biases were judged using the criteria from
the Cochrane Handbook Table 8.5.d: Criteria for judging risk of
bias in the ‘Risk of bias’ assessment tool Higgins 2011. These do-
mains of biases were evaluated by two authors (SF and CF orWN)
independently and characterized as “high risk of bias”, “low risk of
bias” or “unclear risk of bias”. The assessments were compared and
any disagreements resolved by consensus or by discussion with a
third review author (CF or WN). The conclusions are presented
in the ’Risk of bias’ table and were incorporated into the interpre-
tation of review findings by means of sensitivity analyses.
Measures of treatment effect
Where dichotomous data measures were used, we have expressed
the results in the control and intervention groups of each study
as odds ratios (OR) with 95% confidence intervals (CIs). For the
very rare outcome OHSS we have used a risk difference analysis
to allow CIs for the difference in percentage points. Based on the
specified outcomes there were no continuous data measures.
Unit of analysis issues
The primary analysis was per woman randomised. The secondary
outcomemiscarriage rate was also analysed per pregnancy. Authors
of studies that used cycles as the denominator rather than women
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were contacted for additional information or otherwise not in-
cluded in the analysis. If there are multiple cycles then the unit
of analysis is still per woman randomised. Only the first phase of
crossover-trials was included in the analysis as successful treatment
prevents a crossover. Multiple live births were treated as one event.
Dealing with missing data
If data were missing from included studies, the original investi-
gators were contacted to request the relevant missing data. If this
was not possible, we imputed individual values for the primary
and secondary outcomes. In participants without a reported out-
come we assumed that live births have not occurred. For other
outcomes, only the available data were analysed. Any imputation
that was undertaken was subjected to sensitivity analysis. The data
was analysed on an intention-to-treat (ITT) basis, as far as possi-
ble.
Assessment of heterogeneity
The results of the included studies were tested for heterogeneity
by measuring the scatter in the data points on the graph and the
overlap in their CIs. This was done by using I2 statistics which
describe the percentage of total variation across the trials that is
due to heterogeneity rather than chance Higgins 2011. The values
of the I2 statistics lie between 0% (no heterogeneity) and 100%
(heterogeneity). Values above 50% were taken to indicate moder-
ate heterogeneity and were explored within a sensitivity and sub-
group analysis.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publica-
tion bias and other reporting biases, the authors aimed to min-
imise their potential impact by ensuring a comprehensive search
for eligible studies and by being alert for duplication of data. We
compared all outcome measures stated in the methods section to
the outcomes reported in the results section to ensure compara-
bility. If there were more than 10 trials included in a comparison,
a funnel plot was produced.
Data synthesis
A fixed-effect model to combine the data from the primary studies
was used if the studies were sufficiently similar. Statistical analysis
was performed with Review Manager 5 in accordance with the
guidelines for statistical analysis developed by The Cochrane Col-
laboration Higgins 2011.
Our comparisons were:
1. AIs compared to placebo;
2. AIs compared to other ovulation induction agents followed by
intercourse
3. AIs compared to other ovulation induction agents followed by
IUI
4. AIs compared to laparoscopic ovarian drilling;
5. Letrozole compared to anastrozole;
6. Five days administration compared to 10 days administration
protocol of letrozole; and
7. Different doses of AIs
Increases in the odds of an outcome, either beneficial (e.g. live
birth) or detrimental (e.g. OHSS) will be shown in the forest plots
of the meta-analysis on the right of the centre-line.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was done for primary outcomes only to evalu-
ate the evidence for a study population with an average BMI >25
compared to women with an average BMI <25 within their study
group.We further did a subgroup analysis comparing women with
no previous treatment for ovulation induction to women that were
CC resistant. We intended to perform subgroup analyses on fur-
ther parameters, such as age of the woman, duration of subfertility
and the duration and doses of drugs administration, but that was
not possible due to the lack of data. All the reported subgroup-
characteristics of the different studies are shown in Table 1.
Sensitivity analysis
A sensitivity analysis was conducted for the primary outcomes to
evaluate whether the conclusions are robust to arbitrary decisions
made regarding the eligibility and analysis of studies. This analysis
includes consideration of whether the review conclusions would
have differed if:
1. Eligibility were restricted to studies without high or unclear risk
of bias
2. A random effects model had been used
3. Alternative imputation strategies had been implemented
4. The summary effectmeasure was risk ratio instead of odds ratio.
Overall quality of the body of evidence: Summary of
Findings Table
A Summary of findings table was generated using GRADEPRO
software. This table evaluates the overall quality of the body of
evidence for the main review outcomes, using GRADE criteria
(study limitations (i.e. risk of bias), consistency of effect, impre-
cision, indirectness and publication bias). Judgements about evi-
dence quality (high, moderate or low) were justified, documented,
and incorporated into reporting of results for each outcome.
R E S U L T S
Description of studies
9Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Results of the search
The initial search yielded 341 articles, of which 52 were poten-
tially eligible and retrieved in full text. Twenty six studies met our
inclusion criteria, 11 studies were excluded and 8 studies are on-
going. Seven studies await assessment (Figure 1).
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Figure 1. Study flow diagram.
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See study tables: Characteristics of included studies;
Characteristics of excluded studies; Characteristics of studies
awaiting classification; Characteristics of ongoing studies.
Included studies
Study design and setting
We included 26 parallel-designed randomised controlled trials
(RTCs) in the review.
The studies were done in different parts of the world:
• Egypt (Abdellah 2011; Abu Hashim June 2010; Abu
Hashim Sept 2010; Badawy 2008; Badawy July 2009; Badawy
Sept 2009; Elgafor 2013; Selim 2012)
• India (Begum 2009; Ganesh 2009; Kamath 2010; Kar
2012; Ray 2012; Roy 2012; Sh-El-Arab Elsedeek 2011)
• Iraq (Al-Omari 2004)
• Iran (Davar 2011; Dehbashi 2009; Foroozanfard 2011;
Ramezanzadeh 2011; Sohrabvand 2006; Zeinalzadeh 2010)
• Turkey (Atay 2006; Bayar 2006; Nazik 2012)
• USA (Legro 2014)
The following different settings recruited women into the trials:
• Not stated (Atay 2006; Ray 2012; Roy 2012; Selim 2012)
• Subfertility clinic (Begum 2009; Davar 2011; Dehbashi
2009; Foroozanfard 2011; Ganesh 2009; Kar 2012; Nazik 2012;
Ramezanzadeh 2011; Sh-El-Arab Elsedeek 2011; Sohrabvand
2006; Zeinalzadeh 2010)
• Outpatient department (Abu Hashim June 2010; Abu
Hashim Sept 2010; Badawy 2008; Badawy July 2009; Badawy
Sept 2009; Bayar 2006)
• Department of obstetrics and gynaecology (Al-Omari
2004; Elgafor 2013; Legro 2014)
• Division of reproductive endocrinology (Kamath 2010)
• Women’s health institute (Abdellah 2011)
It was confirmed by AbuHasim and Badawy that their five studies
conducted from 2008 till 2010 were independent and did not
include the same women.
Participants
The studies included 5560 women who were subfertile due to
anovulatory PCOS. The ages of the women ranged from 18 to 40
years.
Interventions
•1/26 studies compared aromatase inhibitors versus placebo.
(Kamath 2010)
•15/26 studies compared aromatase inhibitors to other ovula-
tion induction agents followed by intercourse. (Abu Hashim
Sept 2010; Atay 2006; Badawy Sept 2009; Bayar 2006; Begum
2009; Davar 2011; Dehbashi 2009; Foroozanfard 2011; Legro
2014; Nazik 2012; Ray 2012; Roy 2012; Selim 2012; Sh-El-Arab
Elsedeek 2011; Sohrabvand 2006)
•3/26 studies compared aromatase inhibitors to other ovulation
induction agents followed by IUI (Ganesh 2009; Kar 2012;
Zeinalzadeh 2010)
•3/26 studies compared aromatase inhibitors versus laparoscopic
ovarian drilling. (Abdellah 2011; Abu Hashim June 2010; Elgafor
2013)
•2/26 studies compared letrozole versus anastrozole. (Al-Omari
2004; Badawy 2008)
•1/26 studies compared a 5 versus 10 days administration protocol
of letrozole. (Badawy July 2009)
•1/26 studies compared different doses of aromatase inhibitors.
(Ramezanzadeh 2011)
(See Characteristics of included studies)
Outcomes
• 12/26 studies reported live birth rate per woman randomised.(
Abdellah 2011; Abu Hashim June 2010; Abu Hashim Sept 2010;
Bayar 2006; Begum 2009; Dehbashi 2009; Foroozanfard 2011;
Legro 2014; Kamath 2010; Ray 2012; Roy 2012; Sohrabvand
2006)
• 16/26 studies reported OHSS rate per woman randomised.(Abu
Hashim June 2010; Abu Hashim Sept 2010; Badawy 2008;
Badawy July 2009; Badawy Sept 2009; Bayar 2006; Begum
2009; Foroozanfard 2011; Ganesh 2009; Kamath 2010; Legro
2014; Nazik 2012; Ramezanzadeh 2011; Roy 2012; Selim 2012;
Zeinalzadeh 2010)
• 25/26 studies reported clinical pregnancy rate per woman ran-
domised. (Abdellah 2011; Abu Hashim June 2010; Abu Hashim
Sept 2010; Al-Omari 2004; Atay 2006; Badawy 2008; Badawy
July 2009; Badawy Sept 2009; Bayar 2006; Begum 2009; Davar
2011; Dehbashi 2009; Elgafor 2013; Foroozanfard 2011; Ganesh
2009; Kamath 2010; Kar 2012;Nazik 2012; Ramezanzadeh 2011;
Ray 2012; Roy 2012; Selim 2012; Sh-El-Arab Elsedeek 2011;
Sohrabvand 2006; Zeinalzadeh 2010)
• 20/26 studies reported miscarriage rate per woman randomised
and per pregnancies. (Abdellah 2011; Abu Hashim June 2010;
AbuHashimSept 2010; Badawy 2008; Badawy July 2009; Badawy
Sept 2009; Bayar 2006; Begum 2009; Davar 2011; Dehbashi
2009; Elgafor 2013; Foroozanfard 2011; Ganesh 2009; Kamath
2010; Kar 2012; Nazik 2012; Ramezanzadeh 2011; Ray 2012;
Roy 2012; Sohrabvand 2006)
• 21/26 studies reported multiple pregnancy rate per woman ran-
domised. (Abdellah 2011; Abu Hashim June 2010; Abu Hashim
Sept2010; Al-Omari 2004; Atay2006; Badawy 2008; Badawy July
2009; Badawy Sept 2009; Bayar 2006; Begum 2009; Dehbashi
2009; Foroozanfard 2011;Ganesh 2009; Kamath 2010; Kar 2012;
Legro 2014; Nazik 2012; Ramezanzadeh 2011; Roy 2012; Selim
2012; Zeinalzadeh 2010)
(See Characteristics of included studies)
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Excluded studies
We excluded eleven studies from the review for the following rea-
sons:
• 6/11 were not RCTs (Anwary 2012; Azargoon 2012; Badawy
2009; Mittal 2004; Yang 2008; Foroozanfard 2013)
• 3/11 were quasi-randomised (Randomisation was based on at-
tendance order of thewomen) (Baruah 2009; Bigawy 2008;Nahid
2012)
• 2/11 did not include women with anovulatory infertility due to
PCOS (Angel 2014; Ozdemir 2013)
(See Characteristics of excluded studies)
Risk of bias in included studies
See Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Twenty one studies were at low risk of selection bias related to
sequence generation. They used computer randomisation, a ran-
dom numbers table or lottery. The remaining 5 studies did not
further describe their method of randomisation and the contacted
authors did not respond, therefore they were at unclear risk of this
bias (Figure 2).
Ten studies were at low risk of selection bias related to allocation
concealment. They used sequentially numbered, sealed (opaque)
envelopes and the list was kept by a third party during the proce-
dure. The other 16 studies did not describe allocation concealment
sufficiently and the authors did not respond to e-mail, therefore
they were at unclear risk of bias (Figure 2).
Blinding
We think that blinding is not likely to influence findings for the
primary and secondary review outcomes (live birth, OHSS, mis-
carriage, pregnancy and multiple pregnancy). Four out of 26 stud-
ies described blinding of participants and personnel and were thus
rated to be at low risk of performance bias. Thirteen studies did
not mention blinding of participants of personnel and the authors
did not respond to e-mail, therefore they were at unclear risk of
bias. Nine studies stated that there was no blinding of participants
and/or personnel and were at high risk of bias (Figure 2).
Six of 26 studies described that the outcome assessors were blinded
and were therefore at low risk of bias. Thirteen studies did not
mention blinding of outcome assessors and the authors did not
respond to e-mail contact, therefore they were at unclear risk of
bias. Three studies were of high risk of detection bias because it
was reported that the outcome assessors were not blinded. Another
four studies were also of high risk of bias because the participants
were not blinded and therefore it is not credible that the outcome
assessors were blinded. (Figure 2).
Incomplete outcome data
Twenty four of 26 studies included all or nearly all women they had
randomised (>90%) and were therefore at low risk of attrition bias.
One study was of unclear risk of bias because they had peculiar
group numbers and all the other biases were not addressed as well,
so we tried to contact the authors, without success (Ray 2012).
Another study was of high risk of bias because 13 of 80 women
were not analysed. Four womenwere excluded after randomisation
due to an ovarian cyst on sonography on day 3. Nine more women
were lost to follow up without any reasons given (Ramezanzadeh
2011; Figure 2).
Selective reporting
Twenty three of the 26 studies we included in this review reported
the outcomes they have stated in the methods section and were
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therefore judged to be at low risk of bias. In 3 of 26 studies only
a few outcomes were presented and the contacted authors did
not respond, therefore they were at unclear risk of reporting bias
(Figure 2).
Other potential sources of bias
In one study there were substantial baseline differences in age and
duration of infertility between the two groups and the risk of bias
was deemed high (Nazik 2012). We found no potential sources of
within-study bias in the other 25 studies (Figure 2).
Effects of interventions
See: Summary of findings for the main comparison Aromatase
inhibitors compared to clomiphene citrate with or without
adjuncts for subfertile women with polycystic ovary syndrome
1. Aromatase inhibitors compared to placebo
Only one trial compared an aromatase inhibitor (letrozole) and
placebo (Kamath 2010). This trial reported only one pregnancy,
in the letrozole group, therefore although the trial showed no im-
portant difference we cannot conclude that there was no treat-
ment effect. This was probably due to the small sample size (n=
36) of the trial. There was no evidence to suggest a difference in
live birth rate (OR 3.17 95% CI 0.12 to 83.17, Analysis 1.1). A
risk difference analysis for OHSS rate showed no evidence of a
difference in frequency of this adverse event (RR 0.00, 95% CI -
0.10 to 0.10). Pregnancy rate was the same as live birth rate (OR
3.17, 95% CI 0.12 to 83.17, Analysis 1.2). Miscarriage rates and
multiple pregnancy rate were not estimable because there were no
cases reported.
2. Aromatase inhibitors compared to clomiphene
citrate with or without adjuncts followed by
intercourse
Fifteen trials including 2816 women compared the AI letrozole
to CC with or without adjuncts (Abu Hashim Sept 2010; Atay
2006; Badawy Sept 2009; Bayar 2006; Begum 2009; Davar 2011;
Dehbashi 2009; Foroozanfard 2011; Legro 2014; Nazik 2012;
Ray 2012; Roy 2012; Selim 2012; Sh-El-Arab Elsedeek 2011;
Sohrabvand 2006).
• Aromatase inhibitors (2.5mg to 7.5mg/day) versus
clomiphene citrate (50mg to 150mg/day) either alone or in
combination with metformin (1500mg daily) or 150 IU hMG
in one or both arms.
Primary outcomes
2.1 Live birth
Nine studies including 1783 women compared the AI letrozole
to CC (with or without adjuncts in one or both arms) and re-
ported live birth (Abu Hashim Sept 2010; Bayar 2006; Begum
2009;Dehbashi 2009; Foroozanfard 2011; Legro 2014; Ray 2012;
Roy 2012; Sohrabvand 2006). Aromatase inhibitors resulted in an
increased live birth rate compared to other agents for ovulation
induction (OR 1.64, 95% CI 1.32 to 2.04, I²=3%, NNT = 10,
Figure 4, Analysis 2.1)
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Figure 4. Forest plot of comparison: 2 Aromatase inhibitors compared to other ovulation induction agents,
outcome: 2.1 Live birth rate.
Subgroup analysis showed no evidence to suggest a difference by
BMImean (P=0.81) or in study populations thatwereCC resistant
or had no previous treatment for ovulation induction (P=0.50)
(Analysis not shown). Sensitivity analysis excluding one study with
high risk of detection bias (Begum 2009) showed no substantive
influence on the conclusion of treatment effect. But a sensitivity
analysis comparing studies with unclear and low risk for allocation
bias suggested a difference in treatment effect between the two
subgroups (P = 0.01), which might indicate an overestimation of
treatment effect (analysis not shown).
An additional sensitivity analysis showed that studies that reported
live birth tended to report higher clinical pregnancy rates in the
letrozole group than studies that failed to report live birth, suggest-
ing that results might be less favourable to letrozole if all studies
reported live birth, with a more modest treatment effect.
2.2 Ovarian hyperstimulation syndrome
Nine studies including 2179 patients compared the AI letrozole
to CC (with or without adjuncts in one or both arms) and re-
ported the occurrence of ovarian hyperstimulation syndrome (Abu
Hashim Sept 2010; Badawy Sept 2009; Bayar 2006; Begum 2009;
Foroozanfard 2011; Legro 2014; Nazik 2012; Roy 2012; Selim
2012). Our risk difference analysis showed no evidence for a dif-
ference in frequency of this adverse event (RR 0.00, 95% CI -0.01
to 0.00, Figure 5, Analysis 2.7). A subgroup analysis showed no
evidence to suggest a difference by BMI mean (P = 0.80) (analysis
not shown).
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Figure 5. Forest plot of comparison: 2 Aromatase inhibitors compared to other ovulation induction agents,
outcome: 2.6 Ovarian hyperstimulation syndrome rate.
Secondary outcomes
2.3 Clinical pregnancy
Clinical pregnancy rate was reported in fifteen studies, including
2816 women (Abu Hashim Sept 2010; Atay 2006; Badawy Sept
2009; Bayar 2006; Begum 2009; Davar 2011; Dehbashi 2009;
Foroozanfard 2011; Legro 2014; Nazik 2012; Ray 2012; Roy
2012; Sh-El-Arab Elsedeek 2011; Sohrabvand 2006; Selim 2012).
Use of letrozole resulted in a higher clinical pregnancy rate com-
pared to clomiphene citrate (with or without adjuncts in one or
both arms) (OR 1.40, 95% CI 1.18 to 1.65, n=2816, I²=26%;
Figure 6, Analysis 2.9).
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Figure 6. Forest plot of comparison: 2 Aromatase inhibitors compared to other ovulation induction agents,
outcome: 2.8 Clinical pregnancy rate.
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2.4 Miscarriage rate per woman randomised and per
pregnancy
Miscarriage rate was reported in twelve studies, including 2385
women (Abu Hashim Sept 2010; Badawy Sept 2009; Bayar 2006;
Begum 2009; Davar 2011; Dehbashi 2009; Foroozanfard 2011;
Legro 2014;Nazik 2012;Ray 2012;Roy 2012; Sohrabvand 2006).
The analysis of miscarriage rate per woman randomised showed
no evidence of a difference between aromatase inhibitors and
clomiphene citrate (with or without adjuncts in one or both arms)
(OR 1.32, 95% CI 0.92 to 1.88, I²=0%, Analysis 2.11). The re-
sults of the analysis of miscarriage rate per pregnancy also showed
no evidence of a difference between the groups (OR 0.91, 95%
CI 0.61 to 1.36, I²=0%, Analysis 2.12).
2.5 Multiple pregnancy rate
Multiple pregnancy rate was reported in eleven studies, including
2385 women (Abu Hashim Sept 2010; Atay 2006; Badawy Sept
2009; Bayar 2006; Begum 2009; Dehbashi 2009; Foroozanfard
2011; Legro 2014; Nazik 2012; Roy 2012; Selim 2012). The anal-
ysis of multiple pregnancy rate per woman randomised showed
evidence of a reduction in multiple pregnancies for aromatase in-
hibitors compared to other agents for ovulation induction (OR
0.38, 95% CI 0.17 to 0.84, I²=0%, Analysis 2.13).
Publication bias
A funnel plot was produced for the outcome pregnancy rate. Fun-
nel plots for the primary outcomes live birth rate and ovarian hy-
perstimulation syndrome were not done because there were only
nine studies in each outcome. The funnel plot for the secondary
outcome pregnancy rate showed strong asymmetries with a gap
on the left side Figure 7. This indicates that there were possibly
some studies with significant effects in favour of CC which were
not reported, and therefore the results of our meta-analysis might
have overestimated the effect of aromatase inhibitors on pregnancy
rate.
Figure 7. Funnel plot of comparison: 2 Aromatase inhibitors compared to other ovulation induction agents,
outcome: 2.8 Clinical pregnancy rate.
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3. Aromatase inhibitors compared to other agents for
ovulation induction followed by IUI
Three studies including 1597 women compared use of the aro-
matase inhibitor letrozole with or without adjuncts to other agents
for ovulation induction (Ganesh 2009; Kar 2012; Zeinalzadeh
2010).
• Aromatase inhibitor (letrozole, 2.5mg - 5mg daily, cycle
days 3 to 7 or 2 to 6) versus clomiphene citrate (50mg - 150mg
daily, cycle days 3 to 7 or 2 to 6) with or without adjuncts or
rFSH only (rFSH 75IU/100IU from day 2 until the day of hCG
administration)
Primary outcomes
3.1 Live birth
No studies comparing letrozole to anastrozole reported live birth
rate.
3.2 Ovarian hyperstimulation syndrome
Two studies reported ovarian hyperstimulation syndrome rate
comparing use of letrozole to other agents for OI (Ganesh 2009;
Zeinalzadeh 2010). Our risk difference analysis showed no evi-
dence of a difference in frequency of this adverse event between the
two treatment groups (RD 0.00, 95% CI -0.01 to 0.00, Analysis
3.1). Subgroup analyses were not possible because there were too
few studies.
Secondary outcomes
3.3 Clinical pregnancy
Clinical pregnancy rate was reported in three studies comparing
use of letrozole to other agents for OI (Ganesh 2009; Kar 2012;
Zeinalzadeh 2010). There was no evidence of a difference between
the two groups (OR 1.71, 95% CI 1.30 to 2.25, 3 RCTs, 1597
women, I²=0%, Analysis 3.2).
3.4 Miscarriage rate per woman randomised and per
pregnancies
Miscarriage rate was reported in two studies comparing use of
letrozole to other agents for OI (Ganesh 2009; Kar 2012). There
was no evidence of a difference between the two groups for mis-
carriage rate per woman randomised (OR 1.22, 95% CI 0.62 to
2.40, 2 RCTs, 1490 women, I²=0%, Analysis 3.3) or per pregnan-
cies (0.76, 95% CI 0.37 to 1.57, 2 RCTs, 1490 women, I²=30%,
Analysis 3.4).
3.5 Multiple pregnancy rate
Multiple pregnancy rate was reported in three studies comparing
use of letrozole to clomiphene citrate with or without adjuncts
(Ganesh 2009; Kar 2012; Zeinalzadeh 2010).There was no evi-
dence of a difference between the two groups (OR 1.03, 95% CI
0.49 to 2.13, I²=0%) (Analysis 3.5).
4. Aromatase inhibitors compared to laparoscopic
ovarian drilling
Three studies including 553 women compared use of the aro-
matase inhibitor letrozole with or without metformin to laparo-
scopic ovarian drilling (Abdellah 2011; Abu Hashim June 2010;
Elgafor 2013).
• Aromatase inhibitor (letrozole, 2.5mg - 5mg daily, cycle
days 3 to 7) with or without metformin (850mg to 1700mg
daily for 6-8 weeks) versus laparoscopic ovarian drilling
Primary outcomes
4.1 Live birth
Live birth rate was reported in two studies comparing use of an aro-
matase inhibitor to laparoscopic ovarian drilling (Abdellah 2011;
Abu Hashim June 2010). Our analysis did not show evidence of
a difference in live birth rate between the treatment groups (OR
1.19, 95%CI 0.76 to 1.86, 2 RCTs, 407 women, I²=0%, Figure 8,
Analysis 4.1). Subgroup analyses were not possible because there
were only two studies.
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Figure 8. Forest plot of comparison: 3 Aromatase inhibitors compared to laparoscopic ovarian drilling,
outcome: 3.1 Live birth rate.
4.2 Ovarian hyperstimulation syndrome
Only one study reported ovarian hyperstimulation syndrome rate
comparing use of letrozole to laparoscopic ovarian drilling (Abu
Hashim June 2010). Our risk difference analysis showed no evi-
dence of a difference in frequency of this adverse event for the two
treatment groups (RD 0.00, 95% CI -0.01 to 0.01, Analysis 4.2).
Secondary outcomes
4.3 Clinical pregnancy
Clinical pregnancy rate was reported in three studies comparing
use of letrozole with or without metformin to laparoscopic ovarian
drilling (Abdellah 2011; Abu Hashim June 2010; Elgafor 2013).
There was no evidence of a difference between the two groups
(OR 1.14, 95% CI 0.80 to 1.65, 3 RCTs, 553 women, I²=0%,
Analysis 4.3).
4.4 Miscarriage rate per woman randomised and per
pregnancies
Miscarriage rate was reported in three studies comparing use
of letrozole with or without metformin to laparoscopic ovarian
drilling (Abdellah 2011; Abu Hashim June 2010; Elgafor 2013).
There was no evidence of a difference between the two groups for
miscarriage rate per woman randomised (OR 0.91, 95% CI 0.38
to 2.19, 3 RCTs, 553 women, I²=0%, Analysis 4.4) and per preg-
nancies (OR 0.81, 95% CI 0.32 to 2.01, 3 RCTs, 553 women,
I²=0%, Analysis 4.5).
4.5 Multiple pregnancy rate
Multiple pregnancy ratewas reported in two studies comparing use
of letrozole to laparoscopic ovarian drilling (Abdellah 2011; Abu
Hashim June 2010). However, no cases of multiple pregnancies
occurred and therefore an analysis was not possible.
5. Letrozole compared to anastrozole
Two studies including 270 women compared use of the aro-
matase inhibitor letrozole to the aromatase inhibitor anastrozole
(Al-Omari 2004; Badawy 2008).
• Letrozole, 2.5mg/day versus anastrozole, 1mg/day for five
days starting on cycle day three.
Primary outcomes
5.1 Live birth
No studies comparing letrozole to anastrozole reported live birth
rate.
5.2 Ovarian hyperstimulation syndrome
Only one study comparing letrozole to anastrozole reported the
occurrence of ovarian hyperstimulation syndrome (Badawy 2008).
A risk difference analysis showed no evidence of a difference be-
tween the two treatment groups (RD 0.00, 95% CI -0.02 to 0.02,
Analysis 5.1)
Secondary outcomes
5.3 Clinical pregnancy
Clinical pregnancy rate was reported in two studies comparing
letrozole to anastrozole (Al-Omari 2004; Badawy 2008). There
was no evidence of a difference between the two groups (OR 0.85,
95% CI 0.51 to 1.43, 2 RCTs, 260 women, I²=3%, Analysis 5.2)
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5.4 Miscarriage rate per woman randomised
Miscarriage rate was reported only in one study comparing letro-
zole to anastrozole (Badawy 2008). There was no evidence of a
difference between the two groups for miscarriage rate per woman
randomised (OR 0.98, 95% CI 0.24 to 4.03, Analysis 5.3) or per
pregnancies (OR 1.19, 95% CI 0.27 to 5.13, Analysis 5.4).
5.5 Multiple pregnancy rate
Multiple pregnancy rate was reported in two studies comparing
letrozole to anastrozole (Al-Omari 2004; Badawy 2008). One
study did not report any cases of multiple pregnancy rate and an
odds ratiowas therefore not estimable (Al-Omari 2004). The other
study reported no evidence to suggest a difference between the
two treatment groups (OR 5.00, 95% CI 0.24 to 105.35; Badawy
2008, Analysis 5.5)
6. Five days compared to 10 days administration
protocol of aromatase inhibitors
There was only one trial comparing a 5 day letrozole admin-
istration protocol to a 10 day letrozole administration protocol
(Badawy July 2009). This study did not report live birth rate. A
risk difference analysis on OHSS rate showed no evidence to sug-
gest a difference in occurrence of OHSS between the two treat-
ment groups (RD 0.00, 95% CI -0.02 to 0.02, Analysis 6.1).The
analysis showed furthermore no evidence of a difference between
the groups in clinical pregnancy rate (OR 0.63, 95% CI 0.35 to
1.13, Analysis 6.2), miscarriage rate per woman randomised (OR
0.69, 95% CI 0.21 to 2.24, Analysis 6.3), miscarriage rate per
pregnancies (OR 0.96, 95% CI 0.27 to 3.42, Analysis 6.4) or
multiple pregnancy rate (OR 0.32, 95% CI 0.01 to 8.05, Analysis
6.5).
7. Dosage studies of letrozole
There was only one trial comparing a 5mg/daily administration of
letrozole to a 7.5mg/daily administrationprotocol (Ramezanzadeh
2011). This study did not report on live birth rate. A risk difference
analysis on OHSS rate showed no evidence to suggest a difference
in occurrence of OHSS between the two treatment groups (RD
0.00, 95% CI -0.05 to 0.05, Analysis 7.1). Their results show
furthermore no evidence of a difference between the groups in
clinical pregnancy rate (OR 1.00, 95% CI 0.32 to 3.17, Analysis
7.2), miscarriage rate per woman randomised (OR 0.33, 95% CI
0.01 to 8.22, Analysis 7.3), miscarriage rate per pregnancies (OR
0.29, 95% CI 0.01 to 8.39, Analysis 7.4) or multiple pregnancy
rate (OR 1.00, 95% CI 0.06 to 16.56, Analysis 7.5).
D I S C U S S I O N
Summary of main results
Aromatase inhibitors compared to placebo
Only one trial compared Letrozole to placebo Kamath 2010. It
showed no evidence of a difference in rates for live birth, ovar-
ian hyperstimulation syndrome, pregnancy, miscarriage or multi-
ple pregnancy. But the sample size might have been too small to
show any effects because there were only 18 women in each group.
However, based on the studies comparing letrozole to clomiphene
citrate in women with no previous treatment for ovulation induc-
tion, which show that letrozole is equally effective as clomiphene
citrate, further research comparing letrozole to placebo is unneces-
sary and might even be unethical Badawy Sept 2009; Bayar 2006;
Dehbashi 2009; Nazik 2012; Sh-El-Arab Elsedeek 2011.
Aromatase inhibitors compared to clomiphene citrate
followed by timed intercourse
The results of our analysis of fifteen trials comparing letrozole to
CC followed by timed intercourse suggests that letrozole improves
live birth rate and pregnancy rate compared to CC Summary of
findings for the main comparison.
However, we noted that studies that reported live birth tended
to report higher clinical pregnancy rates in the letrozole group
than studies that failed to report live birth, with no evidence of a
difference in miscarriage rates. This suggests that findings might
be less favourable to letrozole if all studies reported live birth.
Moreover in subgroup analysis comparing studies with low and
unclear risk of bias for the outcome of live birth, the studies with
unclear methods of allocation concealment tended to be more
favourable to letrozole. Therefore, our findings on live birth rate
should be regarded with some caution as they may overestimate
the benefits of letrozole relative to CC.
Furthermore, the funnel plot for clinical pregnancy rate (Figure
7) was asymmetrical, suggesting that our findings might be in-
fluenced by publication bias. A second funnel plot, investigating
the impact of possible allocation bias on clinical pregnancy rate
(Figure 9) also showed strong asymmetry with a gap on the left
side, suggesting that the results might be influenced by allocation
bias.
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Figure 9. Funnel plot of comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or
without adjuncts, outcome: 2.10 Impact of allocation bias for clinical pregnancy rate.
Risk difference analysis suggested that letrozole and clomiphene
citrate are equally safe in terms of ovarian hyperstimulation and
miscarriage. On the other hand, there was moderate quality ev-
idence that fewer multiple pregnancies occurred in the letrozole
group (Summary of findings for the main comparison).
All analyses had absent or low levels of statistical heterogeneity
(I²<25%).
Five of our fifteen studies in this analysis includedwomen thatwere
resistant to clomiphene citrate (Abu Hashim Sept 2010; Begum
2009; Davar 2011; Foroozanfard 2011; Sohrabvand 2006), the
other ten studies included women that were not resistant to
clomiphene citrate (Badawy Sept 2009; Bayar 2006; Dehbashi
2009; Legro 2014; Nazik 2012; Sh-El-Arab Elsedeek 2011) or
it was not mentioned (Atay 2006; Selim 2012; Ray 2012; Roy
2012).
Our subgroup analyses did not show evidence of a difference in
effectiveness related to BMI, though there were too few trial in
some subgroups to allow comparison, or the study sizes were too
small with low, or zero, event rates. Furthermore, two studies ex-
cluded women with a high BMI. Therefore, our subgroup analyses
of BMIs were inconclusive. Subgroup analysis by CC resistance
showed no evidence for a difference in treatment effect for live
birth.
In sensitivity analyses findings for live birth were not influenced by
use of a random effects model, alternative imputation strategies,
or risk ratio rather than odds ratio.
Unpublished data, apparently based on preliminary findings from
Legro 2014, found that the interventions had comparable treat-
ment costs. This suggests that given its higher effectiveness Letro-
zole is more cost-effective than clomiphene citrate (Reproductive
Medicine Network 2013).
Aromatase inhibitors compared to other agents for
ovulation induction followed by IUI
Three trials compared letrozole to clomiphene citrate for ovulation
induction followed by IUI Ganesh 2009; Kar 2012; Zeinalzadeh
2010. None reported live birth. Two reported OHSS: only 3 cases
occurred and there was no evidence of a difference despite a study
population of 1494 women. Clinical pregnancy rates were in-
creased in women treated with letrozole, compared to CC and
FSH. We found no evidence of a difference in rates of miscarriage
or multiple pregnancy.
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Aromatase inhibitors compared to laparoscopic ovarian
drilling
Three trials compared letrozole to laparoscopic ovarian drilling in
clomiphene citrate resistant women Abdellah 2011; Abu Hashim
June 2010; Elgafor 2013. OHSS was reported only in Abdellah
2011, but no cases ofOHSSwere found despite a study population
of 260 women. We found no evidence of a difference in rates of
live birth, pregnancy or miscarriage. Multiple pregnancy rate was
reported in two studies, but with zero events. More and larger
studies are needed in this area.
Letrozole compare to anastrozole
Letrozole was compared to anastrozole in two studies including
260 women Al-Omari 2004; Badawy 2008. Neither study re-
ported live birth and OHSS was only reported in Badawy 2008
but with zero events, so further research is needed. Rates of clinical
pregnancy and multiple pregnancies were compared in both trials,
but we found no evidence of difference. Miscarriage rates were
reported only in the study of Badawy 2008, with no difference
betweent the groups.
Five days compared to 10 days letrozole administration
protocol
A single study including 218 women compared a 5 days adminis-
tration protocol to a 10 days administration protocol for letrozole
Badawy July 2009. There was no evidence of increased effective-
ness or reduced side effects for any of our outcomes. Addition-
ally, there might be some concern about the longer administration
protocol because of the possible teratogenic effects of letrozole. In
combination with a 10 day protocol, letrozole might not be com-
pletely removed from the human body by the time of implantation
of the embryo. Therefore, further research is needed to investigate
whether a long term protocol for letrozole is beneficial or even
harmful for treatment of subfertility.
Dosage studies of letrozole
We intended to analyse different doses of letrozole in the range
from 2.5 to 5 mg/day, but only one study including 80 women
was published comparing a dosage of 5mg/day to 7.5mg/day
Ramezanzadeh 2011. There was no evidence of a difference in
effectiveness as seven pregnancies were reported in each group.
There was also no evidence of a difference in adverse events, but
the size of the study population might have been too small because
only one or zero cases were reported in each group for OHSS,mis-
carriage and multiple pregnancy rate. Therefore, further research
is needed to find out more about dosage of letrozole.
Overall completeness and applicability of
evidence
Altough we cannot give a definite answer on the likelihood of
the occurrence of OHSS in the different treatment groups we
compared, further research is unlikely to give a conclusive answer
since OHSS is a very rare event and only very few or no cases
were reported even in the bigger studies. For our main comparison
of aromatase inhibitors compared to other agents for ovulation
induction,we found sufficient studies for our analysis to tentatively
answer our research question, but additional studies are likely to
have an impact on the effect estimate.
It might be unethical to compare letrozole to placebo because
the efficiency of letrozole is proven in comparison to clomiphene
citrate or laparoscopic ovarian drilling, but additional studies are
needed for all the other comparisons to give a more conclusive
answer, since our analyses were based on one to three published
studies.
Another point of concern was that almost all of our studies in-
cludedwere conducted in Egypt or theMiddle East. Therefore, the
overall results might vary if the trials were conducted elsewhere.
Quality of the evidence
We included 26 studies with in total 5560 women. The overall
quality of the evidence varied and was rated as low to moderate
(see Summary of findings for the main comparison). The reasons
for downgrading the evidence included poor reporting of study
methods (especially with respect to allocation concealment and
blinding) and possible publication bias. Morevoer there was a ten-
dency for studies that reported live birth to report higher clini-
cal pregnancy rates in the letrozole group than studies that failed
to report live birth, suggesting that results might be somewhat
less favourable to letrozole if all studies reported live birth. Our
conclusions therefore require cautious interpretation, as additional
studies may alter the effect estimates.
Many comparisons included only one or two studies, and more
research is needed.
Potential biases in the review process
We conducted a comprehensive search with the help of an expe-
rienced trials search coordinator and, in addition, extensive man-
ual searching,in an effort to minimise the risk of publication bias.
However, we generated a funnel plot for the outcome pregnancy
rate in the comparison of aromatase inhibitors to other ovulation
induction agents, which indicated that there might be some stud-
ies not published that reported results in favour of clomiphene cit-
rate. There are several studies awaiting classification which could
also have an influence on our results. Therefore, there might be
some publication bias in this review.
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We followed the guidelines of theCochraneCollaboration to select
studies, extract data and assess the quality and potential risk of
different types of biases in all our included studies, in order to
minimise the chance of reviewer error and bias.
Agreements and disagreements with other
studies or reviews
Our meta analysis shows some evidence for increased live birth
rates in favour of letrozole when compared to clomiphene citrate
in women with PCOS. This differs from a previous review, which
did not report a difference (Misso 2012). Our review showed no
evidence for a difference in effect between letrozole and laparo-
scopic ovarian drilling for subfertility treatment in women who
are resistant to clomiphene citrate, which is in agreement with the
results of an earlier meta-analysis (Misso 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our findings suggest that letrozole is superior to clomiphene cit-
rate for the treatment of subfertility in women with PCOS who
have had no previous treatment for ovulation induction or are re-
sistant to clomiphene citrate. However, this conclusion should be
regarded with some caution because the quality of the evidence
was low.
Implications for research
Further research including large studies is needed to compare letro-
zole with CC specifically in women with PCOS who have had
no previous treatment for ovulation induction to help determine
whether letrozole or CC should be first line medical ovulation in-
duction agent in anovulatory PCOS women.
Further research including large studies is needed to investigate
the effect of different doses of aromatase inhibitors and whether
either letrozole or anastrozole should be used.
More randomised clinical trials investigating a 5 or 10 days admin-
istration protocol of letrozole could also be conducted, but with
caution due to the concerns of teratogenic effects of letrozole.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abdellah 2011
Methods Randomised controlled trial
Participants Inclusion criteria: All patients met the Rotterdam consensus criteria for the diagnosis
of PCOS. Other inclusion criteria included primary or secondary infertility because of
anovulation for at least 1 year and clomiphene resistance. Clomiphene resistance was
defined as lack of ovulation after 6 consecutive induction cycles with 50mg of CC, then
with 150mgofCC each day for 5 days in each cycle. Themale partner of each participant
was required to have a normal result on semen analysis and each woman was required to
have patent tubes on hysterosalpingography or on a diagnostic laparoscopy
Exclusion criteria: Exclusion criteria included age below 20 years or above 35 years;
hormonal treatment within 3 months prior to the study; hyperprolactinaemia (morning
plasma prolactin concentration 30ng/mL or more); any other endocrine, hepatic, or
renal disorder; presence of an organic pelvic mass; and a history of abdominal surgery
that might have caused pelvic factor infertility
Number of women randomised: 147, 74 in the letrozole group and 73 in the LOD
group.
Number of women analysed: 70 in the letrozole group and 70 in the LOD group.
Number of withdrawals/exclusions/loss to follow up and reasons: 7 women were lost
to follow up.
Number of centres: One, Women’s Health Center, Assiut University, Assiut
Age (y): Group A letrozole: 23.9±3.2, Group B LOD: 23.6±3.2
BMI (kg/m²): Group A letrozole: 27.3±2.6, Group B LOD: 27.1±2.6
Duration of infertility (y): Group A letrozole: 4.2±1.7, Group B LOD: 4.2±1.7
Country: Egypt
Interventions Group A: Letrozole, 5mg/day given orally for 5 days during cycle days 3-7 for up to 6
cycles
Group B: LOD, triple-puncture laparoscopy, monopolar diathermy, needle electrode
set at 40W pressed against border of ovary for 4 sec to achieve penetration depths of 7-
8mm, punctured at 4-6 points
Outcomes Primary outcomes: Ovulation rate
Secondary outcomes: endometrial thickness on the day of hCG injection, rates of
clinical pregnancy, spontaneous abortion, live birth and multiple pregnancies
Notes Ethical approval:Yes, the studywas approvedbyMansouraUniversityHospital Research
Ethics Committee
Informed consent: Yes, all participants gave informed consent before inclusion in the
trial
Source of funding:No, but “Conflict of interest statement: We declare that we have no
conflict of interest”
Authors contacted about information on OHSS
Power calculation: “The sample size required to detect a 25% difference between the 2
groups with a power of 80% was estimated to be 68 patients per group.”
31Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abdellah 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using a computer-gener-
ated random numbers table
Allocation concealment (selection bias) Low risk Allocation concealment was achieved using serially num-
bered opaque envelopes that were only opened once the
interventions were assigned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7 women lost to follow up, but similar (3 vs 4) in both
groups; losses due to noncompliance
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk not stated
Abu Hashim June 2010
Methods Randomised controlled clinical trial
Participants Inclusion criteria: Infertile women with CC-resistance and PCOS based on the Rotter-
dam criteria 2003. Patent fallopian tubes proved by hysterosalpingography and normal
semen analysis for their partners according to the modified criteria of WHO
Exclusion criteria: Other causes of infertility, age over 40 years, BMI > 35, contraindi-
cation to general anaesthetic, previous history of LOD and women who had received
metformin, gonadotropin, oral contraceptives or other hormonal drugs during the pre-
ceding 6 months. Women who intended to start a diet or a specific program of physical
activity were also excluded
Number of centres: Two, Outpatient clinic in Mansoura University hospitals and a
private practice setting
Number of women randomised: 260, 128 in the letrozole group and 132 in the LOD
group
Number of women analysed: 128 in the letrozole group and 132 in the LOD group
Number of withdrawals/exclusions/loss to follow up and reasons: None
Age (y): Group A letrozole: 27.3±2.6, Group B LOD: 26.4±2.4
BMI (kg/m²): Group A letrozole: 26.4±3.3, Group B LOD: 26.6±3.6
Duration of infertility (y): Group A letrozole: 4.3±1.11, Group B LOD: 4.5±1.24
Country: Egypt
32Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abu Hashim June 2010 (Continued)
Interventions Group A: Letrozole, 2.5mg/day orally given for 5 days starting from day 3 of the cycle
GroupB: LOD, laparoscopy was performed using three-puncture technique. Each ovary
was cauterized at four points, each for 4s at 40W for a depth of 4mm with a mixed
current, using a monopolar electrosurgical needle
Outcomes Primary outcome: Ovulation rate
Secondary outcomes: midcycle endometrial thickness (mm), biochemical pregnancy/
cycle, clinical pregnancy/patient, biochemical miscarriage/cycle, clinical miscarriage/pa-
tient and live birth rates
Notes Ethical approval:Yes, the studywas approvedbyMansouraUniversityHospital Research
Ethics Committee
Informed consent: Yes, all participants gave informed consent before inclusion in the
trial
Source of funding:No, but “Conflict of interest statement: We declare that we have no
conflict of interest”
Power calculation: ”Sample size was calculated based on the fact that with an expected
rate of ovulation of 70% in the LOD group we needed 244 women to show an absolute
increase of 15% in ovulation rate in the letrozole group, with a power of 80% at con-
fidence interval of 95% using a two tailed chi-square test with a 5% significance level
(type alfa error)
We had contact with Prof. Abu Hashim, all questions were answered in detail
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Women were randomised according to a com-
puter-generated random numeric table prepared
by an independent statistician
Allocation concealment (selection bias) Low risk Concealment of treatment allocation was done
by using sealed opaque envelopes that were given
to a third party (nurse) who assigned patients to
study arms
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Once allocated, the treatment was revealed to
both the investigator and the patient.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Once allocated, the treatment was revealed to
both the investigator and the patient.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All expected outcomes reported
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Abu Hashim June 2010 (Continued)
Other bias Low risk not stated
Abu Hashim Sept 2010
Methods Randomised controlled clinical trial
Participants Inclusion criteria: Infertile women with PCOS based on the Rotterdam 2003 criteria.
Additionally, diagnosed as CC resistant, patent fallopian tubes proved by hysterosalpin-
gography and normal semen analysis for their partners according to the modified criteria
of WHO 1999
Exclusion criteria: None stated
Number of centres: Two, Outpatient clinic in Mansoura University hospitals and a
private practice setting
Number ofwomen randomised:250, 123 in the letrozole group and127 in theCC+Met
group
Number of women analysed: 123 in the letrozole group and 127 in the CC+Met group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A letrozole: 28.3±2.7, Group B CC+Met: 26.2±2.2
BMI (kg/m²): Group A letrozole: 29.1±3.2, Group B CC+Met: 30.1±2.3
Duration of infertility (y): Not stated
Country: Egypt
Interventions Group A: Letrozole, 2.5mg/day for 5 days from cycle days 3 to 7
Group B: Metformin HCl, 500mg thrice daily for 6-8 weeks, followed by 150mg of
CC orally given for 5 days starting on day 3 of menstruation
Patients continued treatment for three successive cycles using the same protocol
Outcomes Primary outcomes:Ovulation rate, number of growing and mature follicles, serum E2,
serum P and endometrial thickness
Secondary outcomes: Pregnancy and miscarriage rates, multiple pregnancies and cases
of ovarian hyperstimulation syndrome
Notes Ethical approval: Yes, the study was approved by the local Research Ethics Committee
Informed consent: Yes, all participants gave informed consent before inclusion in the
trial
Source of funding: No, but “All authors have nothing to disclose”
Power calculation: The sample size was based on the fact that for an expected rate of
ovulation of 70% in the combined metformin-CC group we needed 244 women to
show an absolute increase of 15% in ovulation rate in the letrozole group, with a power
of 80% at confidence interval of 95% using a two-tailed x² test with a 5% significance
level
We had contact with Prof. Abu Hashim, all questions were answered in detail
Risk of bias
Bias Authors’ judgement Support for judgement
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Abu Hashim Sept 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Computer generated random table
Allocation concealment (selection bias) Low risk “Dark, sealed envelopes containing the interven-
tion and taken from a computer-generated ran-
domnumeric table were prepared by a third party
(independent statistician) not involved in the al-
location process.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “patients were not blinded because of the differ-
ence in shape, colour and size of letrozole, CC
and metformin tablets” (E-mail with Prof. Abu
Hashim)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk It is not credible that outcome assessors were
blinded if participants were not
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk not stated
Al-Omari 2004
Methods Randomised, double blind, clinical trial
Participants Inclusion criteria: Non-fertile clomiphene-resistant women with PCOS
Exclusion criteria: Tubal, peritoneal and uterine causes of infertility were excluded by
laparoscopic hysterosalpingogram or by ultrasonography. Specific endocrine abnormali-
ties and male factor causes for infertility were also excluded. Patiets had to ed clomiphene
treatment at least 2 months before enrolment
Number of centres: “The study was done in the Baghdad teaching hospital/ Medical
city which is a tertiary ref. hospital affiliated with Baghdad Med college/ University of
Baghdad.” (E-mail)
Number of women randomised: 22 in the letrozole group and 18 in the anastrozole
group
Number of women analysed: 22 in the letrozole group and 18 in the anastrozole group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A letrozole: 28.4±5.18, group B anastrozole: 25.56±6.26
BMI (kg/m²): Group A let: 29.95±3.73, group B anastrozole: 27.90±5.29
Duration of infertility (y): Group A let: 3.95±2.70, group B anastrozole: 4.50±3.61
Country: Iraq
Interventions Group A: Letrozole 2.5mg/day orally given for 5 days during cycle days 3-7
Group B: Anastrozole 1mg/day orally given for 5 days during cycle days 3-7
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Al-Omari 2004 (Continued)
Treatment was continued for three months.When ovulation or pregnancy did not occur,
the same treatment protocol was used with the doubling of the first dose for a maximum
of two treatment cycles
Outcomes Primary outcomes:Ovulation rate/cycle, endometrial thickness (mm)measured on day
of hCG administration
Secondary outcomes: Multiple pregnany rate, pregnancy rate/cycle, E2 (pmol/l), Pro-
gesterone (nmol/l), LH (U/l), Number and size of follicles, Pulsatility index, Day of
hCG administration
Notes Ethical approval: “Ethical approval was obtained from the Iraqi Board for medical
specialization/ Scientific committee” (E-mail contact)
Informed consent: “written consent was obtained from all patients” (email contact)
Source of funding: “The study was partialy funded by the Iraqi Board for medical
specialization as well as the Drug Scientific Office of the Iraqi Ministry of Health.”
Power calculation: Not stated
We hadE-mail contact withDr. Al-Omari, but there was no further information available
about the outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Actually, we just put all envelopes in a box,
mixing them then the patient herself selected
one.” (E-mail with Dr. Al-Omari)
Allocation concealment (selection bias) Unclear risk “My associate informedme that for randomi-
sation we distributed blank envelops con-
taining the medications at our Gyn.clinic
on twice weekly basis.” (e-mail with Dr. Al-
Omari)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk It is not credible that outcome assessors were
blinded if participants were not
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk Not stated
36Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Atay 2006
Methods Randomised controlled clinical trial
Participants Inclusion criteria: Women with primary infertility and PCOS with no other known
cause of infertility were enrolled into the study. All patients had a history of oligo- or
amenorrhoea and ovaries with at least 10 subcapsular cysts 2-10mm in diameter and
hyperechogenic stroma
Exclusion criteria: None declared
Number of centres: Setting unknown, tried to contact authors via e-mail
Number of women randomised: 51 in the letrozole group and 55 in the CC group
Number of women analysed: 51 in the letrozole group and 55 in the CC group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A letrozole: 27.1±0.9, group B CC: 26.2±1.1
BMI (kg/m²): Group A let: 26.1±1.91, group B CC: 25.8±1.77
Duration of infertility (y): Group A let: 2.2±0.7, group B CC: 2.4±0.9
Country: Turkey
Interventions Group A: Letrozole, 2.5mg/day orally given for 5 days starting on cycle day 3
Group B: Clomiphene citrate, 100mg/day orally given for 5 days starting on cycle day
3
Outcomes Outcomes: Number of mature follicles, endometrial thickness (mm), day of hCG ad-
ministration, ovulation rate, pregancy rate, multiple pregnancies
Notes Ethical approval: Yes, the study protocol was approved by the institutional ethics com-
mittee
Informed consent: Yes, informed consent was obtained from all study participants
Source of funding:No, but “Conflicts of interest: No conflicts of interest were declared
in relation to this article”
Power calculation: Not stated
We contacted Dr. V Atay via e-mail about the study setting, about how randomisation
and allocation was done, blinding and if data is available on OHSS, miscarriage rate and
live birth rate, but no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear how it was done exactly
Allocation concealment (selection bias) Unclear risk Unclear how it was done exactly
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
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Atay 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Unclear risk Protocol of the study was not available
Other bias Low risk not stated
Badawy 2008
Methods Randomised controlled trial
Participants Inclusion criteria: Diagnosis of PCOS based on the revised 2003 consensus on diag-
nostic criteria and long-term health risks related to PCOS. All women were previously
treated with 100mg of CC daily for 5 days per cycle, for two to three cycles with per-
sistent anovulation or ovulate with very thin endometrium <5mm at the time of hCG
administration. They had patent fallopian tubes proved by hysterosalpingography and
normal semen analysis for their partners according to the modified criteria of WHO
Exclusion criteria: No exclusion criteria stated.
Number of centres: 2, Outpatient clinic inMansoura University Hospitals and a private
practice setting
Number of women randomised: 111 in the letrozole group and 109 in the anastrozole
group
Number of women analysed: 111 in the letrozole group and 109 in the anastrozole
group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Letrozole: 28.2±2.8, Group B Anastrozole: 26.3±2.5
BMI (kg/m²): Group A Let: 29.1±3.1, Group B Anastrozole: 30.1±2.1
Duration of infertility (y): Not stated
Country: Egypt
Interventions Group A: Letrozole 2.5mg/day orally given for 5 days during cycle days 3-7
Group B: Anastrozole 1mg/day orally given for 5 days during cycle days 3-7
Treatment was continued for three months.
Outcomes Primary Outcomes:Number of growing and mature follicles, serum E2 (pg/ml), serum
P (ng/mL), and endometrial thickness (mm)
SecondaryOutcomes:Pregnancy rate,miscarriage rate,multiple pregnancy rate, ovarian
hyperstimulation syndrome rate
Notes Ethical approval: Yes, the study was approved by the hospital ethics research committee
Informed consent: Yes, all participants gave informed consent before inclusion in the
trial
Source of funding: Not stated
Power calculation: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Badawy 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Patients were randomly allocated using a computer-gen-
erated random table into two treatment groups
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk not stated
Badawy July 2009
Methods Randomised controlled study
Participants Inclusion criteria: Infertile women with clomiphene- resistant PCOS, diagnosis of
PCOS based on the 2003 Rotterdam Criteria. Normal serum PRl, TSH and 17OH-P
Exclusion criteria: Infertility caused by fallopian tube problems, infertility problems
caused by male partner
Number of centres: 2, Outpatient clinic inMansoura University Hospitals and a private
practice setting
Number of women randomised: 110 in the short letrozole group ad 108 in the long
letrozole group
Number of women analysed: 110 in the short letrozole group and 108 in the long
letrozole group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A short Letrozole: 25.1±3.2, Group B long Let: 25.3±3.0
BMI (kg/m²): Group A short Let: 33.9±3.1, Group B long Let: 34.2±2.6
Duration of infertility (y): Not stated
Country: Egypt
Interventions Group A: Letrozole orally given, 5mg/day for 5 days, from cycle days 3-7
Group B: Letrozole orally given, 2.5mg/day for 10 days, from cycle days 3-12
Outcomes Primary Outcomes:Number of growing andmature follicles, serumE2 (pg/mL), serum
P (ng/mL), and endometrial thickness (mm)
Secondary Outcomes: Pregnancy rate, miscarriage rate, Multiple pregnancies, ovarian
hyperstimulation syndrome rate
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Badawy July 2009 (Continued)
Notes Ethical approval: Yes, the study was approved by the hospital ethics research committee
Informed consent: Yes, all participants gave informed consent before inclusion in the
trial
Source of funding:No, but Conflicts of Interest: ”All authors have nothing to disclose“
Power calculation: ”Sample size calculation, using StatCalc 3.02 computer package
8Acastat software, Leesburg, VA), showed that each arm should contain at least 103
patients to have 80% power of the study at 95% confidence interval (CI)
Authors were contacted, but information on live birth was not collected
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly allocated into two treatment
groups using a computer-generated random table: short
letrozole group and long letrozole group
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All stated outcomes were reported
Other bias Low risk not stated
Badawy Sept 2009
Methods Prospective randomised trial
Participants Inclusion criteria: Diagnosis of PCOS based on the 2003 Rotterdam Criteria. All
women had patent fallopian tubes proved by hysterosalpingography and their partners
had normal semen analysis parameters according to the modified criteria of the WHO.
All patients had normal serum prolactin, thyroid stimulating hormone (TSH) and 17-
OH progesterone
Exclusion criteria: Not stated
Number of centres: Multiple, University teaching hospital and private practices
Number of women randomised: 218 in the Letrozole group and 220 in theClomiphene
Citrate group
Number of women analysed: 218 in the Letrozole group and 220 in the Clomiphene
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Badawy Sept 2009 (Continued)
Citrate group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Letrozole: 27.1±3.2, Group B Clomiphene Citrate: 29.3±2.9
BMI (kg/m²): Group A Let: 28.1±3.2, Group B CC: 27.1±3.1
Duration of infertility (y): Not reported
Country: Egypt
Interventions Group A: Letrozole orally given 5mg/day for 5 days from cycle days 3-7
Group B: Clomiphene Citrate orally given 100mg/day for 5 days from cycle days 3-7
Outcomes Primary Outcomes: Number of growing and mature follicles, the concentrations of
serum E2 (pg/mL) and progesterone (ng/mL), and the endometrial thickness (mm)
Secondary Outcomes: Ovulation rate, Ovarian hyperstimulation rate, pregnancy rate,
miscarriage rate, Multiple pregnancy rate
Notes Ethical approval: Yes, the study was approved by the hospital research ethics committee
Informed consent: Yes, all participants gave informed consent before inclusion in the
trial
Source of funding: The study was self-funded
Power calculation: Not stated
Authors were contacted via e-mail and gave all information, but they did not measure
the live birth
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly allocated using a computer gen-
erated random table into two groups
Allocation concealment (selection bias) Low risk “Allocation concealment was done by sequentially num-
bered opaque sealed envelopes opened by the chief nurse”
(via e-mail contact with authors)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded, e-mail with Prof. Badawy
Blinding of outcome assessment (detection
bias)
All outcomes
High risk It is not credible that outcome assessors were blinded if
participants were not
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All expected outcomes were reported, LB was not mea-
sured
Other bias Low risk Not stated
41Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bayar 2006
Methods Randomised controlled study
Participants Inclusion criteria: Anovulatory PCOS patients diagnosed by using 2003 Rotterdam
criteria
Exclusion criteria: Tubal, peritoneal and uterine cause of infertility. Male factor in-
fertility. Specific endocrine abnormalities (Cushings disease/syndrome, hypothyroidism,
hyperthyroidism, prolactinoma)
Number of centres:One,Outpatient clinics of the Infertility andReproductiveMedicine
Unit of the Zonguldak Karaelmas University Hospital (Zonguldak, Turkey)
Number of women randomised: 80, 40 in Group A Let and 40 in Group B CC
Number of women analysed: 38 in Group A Let and 36 in Group B CC
Number of withdrawals/exclusions/loss to follow up and reasons: 6 lost to follow
up, no reasons given
Age (y): Group A Letrozole: 32.2±3.9, Group B Clomiphene Citrate: 30.6±4.0
BMI (kg/m²): Not stated
Duration of infertility (y):Group A Letrozole: 5 (1-10), Group B Clomiphene Citrate:
3 (3-11)
Country: Turkey
Interventions Group A: Letrozole, 5mg/day orally given for 5 days during cycle days 3-7
Group B: Clomiphene citrate, 100mg/day orally given for 5 days during cycle days 3-7
Outcomes Outcomes: Ovulation rate per cycle, pregnancy rate per cycle, delivery rate per cycle,
miscarriage rate, multiple pregnancy rate, endometrial thickness on the day of hCG
(mm), No. of follicles sized >15 mm in diameter on the day of hCG, E2 level on the day
of hCG (pg/mL), E2 per follicle sized >15 mm in diameter on the day of hCG (pg/mL)
Notes Ethical approval: Yes, the study was approved by the institutional ethics committee of
karelmal university
Informed consent: Not stated
Source of funding: No funding source or conflicts of interest stated.
Power calculation: Sample-size determination was based on the difference between the
median number of follicles sized >15 mm and E2 concentration on hCG day. A sample
size of 60 patients (30 patients in each group) was targeted to be able to detect a difference
of at least one follicle or of 200 pmol/L between the two groups, with alfa (type I error)
set at 0.05 and 80% power
Dr. Bayar was contacted via e-mail for additional information, but he did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple randomisation performed by a computer
Allocation concealment (selection bias) Unclear risk Allocation concealment was achieved by using central
consultation for treatment of eligible patients
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Bayar 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double blind not it is not clear who is actually
blinded and how this was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated as double blind not it is not clear who is actually
blinded and how this was achieved
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 Patients lost to follow up, 4 and 2 respectively
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk Not stated
Begum 2009
Methods Randomised not blinded, controlled trial
Participants Inclusion criteria: Infertile female women with PCOS diagnosed by the Rotterdam
criteria 2003 who failed to ovulate by taking 100mg of CC/day for 5 days in two
consecutive cycles
Exclusion criteria: Patients with hyperprolactinaemia, thyroid disorder, male factor in-
fertility, known or suspicious tubal factor infertility (endometriosis and pelvic inflam-
matory disease), and unexplained infertility were excluded from the study
Number of centres: One, private infertility care setting
Number of women randomised: 32 in each group
Number of women analysed: 32 in each group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Letrozole: 25.47±3.98, Group B Clomiphene Citrate: 26.09±3.62
BMI (kg/m²):Group A Letrozole: 22.72±2.77, Group B Clomiphene Citrate: 23.63±3.
23
Duration of infertility (y): Group A Letrozole: 2.66±1.11, Group B Clomiphene Cit-
rate: 2.58±1.10
Country: India
Interventions Group A: Letrozole, 7.5mg/day orally given for 5 days from cycle days 3 to 7
Group B: Clomiphene Citrate, 150mg/day orally given for 5 days from cycle days 3 to
7
Outcomes Primary Outcomes: Ovulation and pregnancy rate
Secondary Outcomes: Follicular development by day 16 (mm), Serum E2 on day of
hCG (pg/mL), Endometrial development by day 16 (mm), Serum P on day 21 (ng/mL)
, Multiple pregnancies,, ovarian hyperstimulation syndrome cases. Live birth rate was
provided via email contact
Notes Ethical approval:Yes, the study protocol was approved by the institutional review board
(IRB) of Dhaka medical college
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Begum 2009 (Continued)
Informed consent: Yes, patients were counselled and informed consent was obtained
before recruitment
Source of funding: The study was self-funded
Power calculation: A study population of 57 women was calculated considering an
average of 60% of PCOS women are associated with insulin resistance, allowing an alfa
value of 0.05
Authors were contacted via e-mail, additional information was provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done
by lottery method. They put the name of
letrozole and CC in a sealed unleveled enve-
lope. By calculating sample size they made
64 pieces of paper. 32 for letrozole and 32
for CC
Allocation concealment (selection bias) Unclear risk “All unleveled envelop were put together
and the patients drew one piece of envelop
from them. Then we opened the envelop to
see the name of the drug.” (via e-mail con-
tact with Prof. Rashida)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “There was no blinding” (via e-mail contact
with Prof. Rashida)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “There was no blinding” (e-mail with Prof.
Rashida)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk not stated
Davar 2011
Methods Single blind randomised clinical trial
Participants Inclusion criteria:Patients who received 150mg cc daily for 3 cycles and failed to become
pregnant, and were diagnosed with anovulatory PCOS based on Rotterdam 2003
Exclusion criteria: “We excluded patients with liver and kidney dysfunction, cardiovas-
cular disease, diabetics, and those who use metformin or drugs affecting insulin secretion
and clomiphene citrate in recent 2 cycles.”
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Davar 2011 (Continued)
Number of centres: One, Research and clinical centre for infertility, shahid sadoughi
University of medical sciences, Yazd
Number of women randomised: 100 women, 50 in Group A Met-Let, 50 in Group B
Met-CC
Number of women analysed: 48 in Group A Met-Let, 50 in Group B Met-CC
Number of withdrawals/exclusions/loss to follow up and reasons: 2, experienced side
effects with metformin before Let was started
Age (y):Group AMetformin-Letrozole: 28.54±3.13, Group BMetformin-Clomiphene
Citrate: 29.55±3.47
BMI (kg/m²):Group AMet-Letrozole: 28.98±3.83, Group BMet-Clomiphene Citrate:
29.21±2.92
Duration of infertility (y): Group A Met-Letrozole: 3.81, Group B Met-Clomiphene
Citrate: 3.76
Country: Iran
Interventions Group A:Metformin 1500mg daily for 6-8 weeks, followed by 5mg letrozole daily orally
given for 5 days during cycle days 3-7 if pregnancy did not occur
Group B:Metformin 1500mg daily for 6-8 weeks, followed by 100mg CC daily orally
given for 5 days during cycle days 3-7 if pregnancy did not occur
Outcomes E2 (pg/mL) on day of hCG administration, Number of follicles >18mm in diameter,
Endometrhial thickness on day of hCG administration (mm), clinical pregnancy rate,
miscarriage rate
Notes Ethical approval: Yes, the study was approved by ethical board of shahid sagoughi
university of medical sciences, yazd
Informed consent: No, at least nothing written about it - authors contacted
Source of funding: “the study was fully supported and funded by shahid sadoughi
university of medical sciences, yazd, iran”
Power calculation: “In this study, 50 cases were needed in each group so as to gain a
significant difference of 22% in pregnancy rate at a significant level of 5% and a power
of 80%”
Dr Davar was contacted via e-mail to get additional information, but we did not get a
response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done using a random num-
bers table
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated who was blinded in this single
blinded trial
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated who was blinded in this single
blinded trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 patients lost to follow up due to side effects ex-
perienced with metformin before letrozole was
started
Selective reporting (reporting bias) Low risk All outcomes reported stated in the protocol
Other bias Low risk not stated
Dehbashi 2009
Methods Double blind randomised study
Participants Inclusion criteria: Infertility for at least one year, diagnosis of PCOS by the rotterdam
criteria 2003, having patent tubes on hysterosalpingogram, and normal semen analysis
of the patients husbands
Exclusion criteria: Patients must not have received any other medication for ovulation
induction before enrolment to the study
Number of centres: One, outpatient infertility clinics at Shiraz University of Medical
Scieces
Number of women randomised: 100 women, 50 in each group
Number of women analysed: 100 women, 50 in each group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Letrozole: 23.62±2.92, Group B CC: 24.32±3.43
BMI (kg/m²): Group A Let: 27.45±4.61, Group B CC: 27.09±3.61
Duration of infertility (y): Group A Let: 2.00±1.34, Group B CC: 2.30±1.85
Country: Iran
Interventions Group A: Letrozole, 5mg/day orally given for 5 days during cycle days 3-7
Group B:Clomiphene Citrate, 100mg/day orally given for 5 days during cycle days 3-7
Outcomes Total number of follicles with diameter ≥14 mm, endometrial thickness on the day of
hCG injection, pregnancy rate, miscarriage rate, multiple pregnancy rate, live birth rate
Notes Ethical approval: Yes, “The study was approved by the Institutional Ethics Committee
of the University.”
Informed consent: Yes, “An informed written consent was obtained from each patient”
Source of funding: No, but “Conflicts of interest: None declared”
Power calculation: Not stated
Authors contacted about randomisation, allocation, and information about OHSSr
Risk of bias
Bias Authors’ judgement Support for judgement
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Dehbashi 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated how it was done exactly
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Only the pharmacist knew the name of the medica-
tion that had been taken by the patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only the pharmacist knew the name of the medica-
tion that had been taken by the patients
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients excluded or lost to follow up
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk not stated
Elgafor 2013
Methods Randomised controlled trial
Participants Inclusion criteria: Clomiphene citrate resistant women with infertility due to PCOS,
diagnosed according to the Rotterdam 2003 criteria. Clomiphene citrate resistance was
defined as failure to achieve adequate follicular maturation after 3 consecutive induction
cycles with CC at 150 mg/day for 5 days
Exclusion criteria: Exclusion criteria includes women with other causes of infertility as
male factor or tubal factor, those with endocrine disorders as thyroid dysfunction and
hyperprolactinaemia, women who received hormonal treatment or ovulation induction
drugs 3 months before the study
Number of centres: One, Zagazig University Hospital, Egypt
Number of women randomised: 146 women, 73 in each group
Number of women analysed: 146 women, 73 in each group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Metformin + Letrozole: 24.7±1.8, Group B LOD: 25.1±2.1
BMI (kg/m²): Group A Metformin + Letrozole: 31.5±3.3, Group B LOD: 32.4±4.4
Duration of infertility (y): Group A Metformin + Letrozole: 3.4±0.9, Group B LOD:
3.9±1.1
Country: Egypt
Interventions Group A: Metformin 850 to 1700mg daily for 6-8 weeks, followed by 5mg letrozole
daily orally given for 5 days during cycle days 3-7 if pregnancy did not occur
Group B: LOD, laparoscopy was performed using three-puncture technique
Outcomes Cycle regularity, ovulation rate, clinical pregnancy rate, miscarriage rate
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Notes Ethical approval: Yes, “Ethics Committee of Zagazig University approved the
study”
Informed consent: Yes, “written informed consent was obtained from
each patient at the start of the study”
Source of funding: No, but “Conflicts of interest: None”
Power calculation: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The participant women were randomised according to a
computer-generated random numeric table
Allocation concealment (selection bias) Low risk The random allocation sequence was concealed in sealed
dark envelopes, then patients were assigned randomly
into group 1 (n = 73) received metformin plus letrozole,
and group 2 (n = 73) underwent LOD
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All expected outcomes reportes
Other bias Low risk Not stated
Foroozanfard 2011
Methods Randomised controlled clinical trial
Participants Inclusion criteria:Our inclusion criteria were age 20-35 years, infertility for at least one
year and resistance to Clomiphene (at least 3 cycles Clomiphene usage, 150mg/day with
no ovulatory response)
Exclusion criteria: Exclusion criteria were BMI >27, endocrine disorders such as hy-
pothyroidism, hyperprolactinemia, infertility due to male factors, uterine factors and
adhesive diseases due to pelvic surgery
Number of centres: One, outpatient infertility clinic in Kashan
Number of women randomised: 60 in each group
Number of women analysed: 60 in each group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
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Foroozanfard 2011 (Continued)
Age (y): Group A Let+Gon: 25.8±3.75, Group B CC+Gon: 25.33±4.14
BMI (kg/m²): Group A Let+Gon: 24.12±2.33, Group B CC+Gon: 24.87±2.00
Duration of infertility (y):Group A Let+Gon: 2.76±2.27, Group B CC+Gon: 2.60±2.
07
Country: Iran
Interventions Group A: Letrozole, 5mg/day orally given for 5 days from cycle days 3-7 + 150 IU hMG
intramuscularly during cycle days 5-8
Group B: Clomiphene citrate, 100mg/day orally given for 5 days from cycle days 3-7 +
150 IU hMG intramuscularly during cycle days 5-8
Outcomes Life birth rate, ovarian hyperstimulation syndrome rate, pregnancy rate, miscarriage rate,
multiple birth rate, number of dominant follicles, endometrial thickness (mm), ectopic
pregnancies
Notes Ethical approval: Yes,” approval was obtained from the Institute Research Board to
perform this study. “
Informed consent: Yes, “All patients were informed about possible side effects ad also
off label use of letrozole for the purpose of inducing ovulation and written consent were
obtained for all participants.”
Source of funding: Yes, “Authors acknowledge the research deputy of KashanUniversity
of Medical Sciences for providing the financial support.”
Power calculation: Not stated
Authors contacted via e-mail, all information provided.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple randomisation was performed by a com-
puter .
Allocation concealment (selection bias) Low risk Via sequentially numbered opaque sealed en-
velopes (e-mail with authors)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Before commence of the study all patients were
informed of the study and were told about this
issue that it is possible to be enrolled in letrozole
or clomiphene group but none of them knew
which group she allocated to and the researcher
was blinded also to patients’ treatment approach.
(e-mail contact with authors)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
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Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk Not stated
Ganesh 2009
Methods Randomised controlled trial
Participants Inclusion criteria: 1387 women with PCOS diagnosed by the Rotterdam criteria who
had previously failed to conceive or ovulate with cc treatment and undergoing IUI were
included in the study. Specific inclusion criteria for the study were normal TSH and
prolactin levels and normozoospermic male partners as per WHO guidelines
Exclusion criteria: Patients with pre-existing ovarian cyst on day 3 and previous history
of ovarian drilling were carefully identified and excluded
Number of centres: One, a tertiary infertility care unit, Institute of Reproductive
Medicine, Kolkata, India
Number of women randomised: 1378 in total
Number of women analysed: 1378 in total
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y):Group A Let: 30.25±4.90, Group BCC: 30.38±5.18, Group C rFSH: 30.82±4.
56
BMI (kg/m²): Group A Let: 24.49±3.83, Group B CC: 24.75±4.05, Group C rFSH:
24.08±3.43
Duration of infertility (y): Not reported.
Country: India
Interventions Group A: Letrozole, 5mg/day orally given for 5 days from cycle days 3-7
Group B: Clomiphene citrate, 100mg/day orally given for 5 days from cycle days 3-7 +
75 or 100 IU rFSH during cycle days 3 and 8
Group C: One ampoule rFSH 75IU/100IU from day 2 until the day of hCG adminis-
tration
Outcomes The primary outcome measures including ovulation rate, cancellation rate, miscarriage
rate and pregnancy rate were compared amongst the three groups. Secondary outcomes
were OHSS rate and multiple pregnancy rate
Notes Ethical approval: Yes, approval was obtained from the institutional Research ethics
board
Informed consent: Yes, “Written informed consent was taken from all women included
in this study.”
Source of funding: No, but ”This study was not funded by any funding agency.”
Power calculation: Not stated
Authors contacted via e-mail, all information provided.
Risk of bias
Bias Authors’ judgement Support for judgement
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Ganesh 2009 (Continued)
Random sequence generation (selection
bias)
Low risk “The subjects recruited for the study were randomly and
blindly assigned to one of the treatment protocols. The
procedure was carried out by requesting the patient to
pick up randomly an opaque, sealed envelope. Each en-
velope contained a piece of paper with one of the three
protocols written on it. Many such sealed envelopes were
prepared and placed randomly. Once the patient picked
the envelope, the seal was opened in front of the patient
and the coordinator, the content showed and the proto-
col allocated.” (Information via email from the author)
Allocation concealment (selection bias) Low risk “the allocation was done using sealed envelopes where
the person allocating was blinded to the type of protocol
received by the patients.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Only researcher was blinded and the patient aware of
the protocol followed since the route of administration
was different in all the three groups.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Only researcher was blinded and the patient aware of
the protocol followed since the route of administration
was different in all the three groups.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk Not stated
Kamath 2010
Methods A randomised, double-blind, placebo-controlled trial
Participants Inclusion criteria: Women with PCOS and clomiphene resistance who were being
treated with ovulation induction were invited to participate. Additionally, women had
to have normal hormone profile and a male partner with normal semen parameters by
WHO criteria. Normal hormone profile was defined as a FSH level of <12IU/L, serum
prolactin level of <25ng/mL, and a thyroid-stimulating hormone (TSH) value between
0.3 and 4.5µIU/mL
Exclusion criteria: Women with other endocrine disorders such as Cushing syndrome
and congenital adrenal hyperplasia were excluded
Number of centres: One, Reproductive medicine unit, Christian Medical college, Vel-
lore, Tamil Nadu, India
Number of women randomised: 18 in each group
Number of women analysed: 17 in each group
Number of withdrawals/exclusions/loss to follow up and reasons: 2 lost to follow up
before treatment started
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Age (y): Group A Letrozole: 25.61±3.58, Group B Placebo: 25.72±3.72
BMI (kg/m²): Group A Letrozole: 26.06±3.73, Group B Placebo: 24.67±4.17
Duration of infertility (y): Group A Letrozole: 5.17±3.17, Group B Placebo: 3.56±2.
15
Country: India
Interventions Group A: Letrozole, orally given 2.5mg/day for 5 days from cycle days 2 to 6
Group B: Placebo, also given for 5 days from cycle days 2 to 6
Outcomes Primary Outcome: Ovulation rate
Secondary Outcomes: Live birth rate, ovarian hyperstimulation syndrome rate, preg-
nancy rate, miscarriage rate, multiple pregnancy rate, endometrial thickness (mm), day
21 serum progesterone (nmol/L), number of patients with mature follicle (%)
Notes Ethical approval:Yes, the protocol of the study was approved by the institutional review
board
Informed consent: Yes, written informed consent was obtained from each patient
Source of funding: No, but Conflicts of interest stated:. “The Authors have nothing to
disclose”
Power calculation: “Our literature pointed to a 75% ovulation rate when 2.5 mg of
letrozole was used in women with PCOS who had clomiphene resistance. We hypoth-
esized an ovulation rate of 60& with letrozole and 10% with placebo. On this basis,
a sample size of 17 women in each arm (80% and alpha .05 for a two-sided test) was
calculated.”
Contacted authors aboutOHSS rate and how randomisation and allocation concealment
was done in detail. All information provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly distributed using a com-
puter-generated randomisation sequence
in blocks of six, into two groups
Allocation concealment (selection bias) Low risk Allocation concealment was done by using
consecutively numbered sealed opaque en-
velopes containing the treatment packets
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The randomisation code was maintained
by the pharmacy department, which re-
vealed the group assignments at the end of
the trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The code was revealed after the statistical
analysis had been performed
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Incomplete outcome data (attrition bias)
All outcomes
Low risk One women in each group was lost to
follow up, after randomisation and before
treatment started
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk Not stated
Kar 2012
Methods Randomised controlled trial
Participants Inclusion criteria: “PCOS was diagnosed according to Rotterdam criteria. All women
were treatment-naive i.e. had not undergone any significant treatment for infertility/
ovulation induction earlier.”
Exclusion criteria: “Patients with hyperprolactinaemia, thyroid disorder, male factor,
suspected tubal factor, endometriosis, unexplained infertility were not included in the
study.”
Number of centres: “This study was conducted at a private hospital with a large gyne-
cological practice.”
Number of women randomised: 103 women, 52 in the Let group and 51 in the CC
group.
Number of women analysed: 103 women, 52 in the Let group and 51 in the CC group.
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Letrozole: 26.26±2.41, Group B CC: 26.27±2.47
BMI (kg/m²): Group A Letrozole: 25.91±3.57, Group B Placebo: 25.95±3.31
Duration of infertility (y): Group A Letrozole: 3.08±1.92, Group B CC: 3.14±2.16
Country: India
Interventions Group A: Letrozole, 5mg/day orally given for 5 days from cycle days 2-6
Group B: Clomiphene citrate, 100mg/day orally given for 5 days from cycle days 2-6
Outcomes Primary outcomes: ovulation rate, endometrial thickness, mono vs. multi-follicular
rate, and days to ovulation
Secondary outcomes: pregnancy and miscarriage rate
Notes Ethical approval: Yes, “Study protocol was approved by the institutional ethics com-
mittee.”
Informed consent: Not stated.
Source of funding: “Nil”
Power calculation: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized by lottery”
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Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Low risk Not stated
Legro 2014
Methods A randomized, double-blind multi-center trial
Participants Inclusion criteria:Women with PCOS defined by the Rotterdam criteria and at least 1
patent fallopian tube and normal uterine cavity and a male partner with sperm concen-
tration of more than 14 million/mL
Exclusion criteria: “We will exclude subjects with medical conditions that represent
contraindications to CC,letrozole and/or pregnancy or who are unable to comply with
the study procedures.”
Number of centres: Multi-center trial
Number of women randomised: 750, 374 in the Let group and 376 in the CC group
Number of women analysed: 750, 374 in the Let group and 376 in the CC group
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Let: 29±5, Group B CC: 28±4
BMI (kg/m²): Group A Let: 35±10, Group B CC: 35±9
Duration of infertility (y): Not reported
Country: USA
Interventions Group A: Letrozole, orally given 2.5mg/day for 5 days during cycle days 3-7
Group B:Clomiphene Citrate, orally given 100mg/day for 5 days during cycle days 3-7
Outcomes Live birth, ovulation rate, clinical pregnancy rate, miscarriage rate, multiple pregnancy
rate
Notes Ethical approval:
Informed consent:
Source of funding: The study is funded through a cooperative agreement by the Eu-
nice Kennedy ShriverNational Institutes of Child Health and Human Development
(NICHD)
Power calculation: A sample size of 300 subjects in each arm of the randomization
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yields 81% statistical power to prospectively demonstrate a 0.10 absolutedifference in
live birth proportions between treatment arms (0.20 for CC and 0.30 forletrozole) using
the Pearson’s chi-square test with a two-sided significance level of 0.05
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Almac statisticians will generate the ran-
domization scheme for the study
Allocation concealment (selection bias) Low risk third party
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk In order to maintain the double-blind, CC
and letrozole will beoverencapsulated and
packaged in identically appearing num-
bered study kits (using AlmacClinical Ser-
vices, Durham NC) which will then be di-
rectly shipped to each clinical site
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk In order to maintain the double-blind, CC
and letrozole will beoverencapsulated and
packaged in identically appearing num-
bered study kits (using AlmacClinical Ser-
vices, Durham NC) which will then be di-
rectly shipped to each clinical site. The ran-
domization scheme (including block size)
will be disclosed to theDCC data manager,
but not to any RMNinvestigators or staff,
including the Protocol Lead Investigator
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts were reported
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Low risk Not stated
Nazik 2012
Methods A partly randomised controlled clinical trial.
Participants Inclusion criteria: Infertile patientswith PCOS, diagnosis based on the 2003Rotterdam
criteria
Exclusion criteria: Patients who had ovarian or adnexal surgery, hypothyroidism, hyper-
prolactinaemia, bilateral tubal occlusion diagnosed with hysterosalpingography and un-
explained infertility were excluded from the study, as were patients with follicles greater
than 10mm
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Number of centres: One, Infertility Polyclinic of Atatürk University Medical Faculty
Erzurum
Number of women randomised: 31 in Group A, 33 in Group B
Number of women analysed: 31 in Group A, 33 in Group B
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Letrozole: 25.55±4.45, Group B CC: 27.80±6.18
BMI (kg/m²): Group A Letrozole: 24.66±3.57, Group B CC: 24.90±4.80
Duration of infertility (y): Group A Letrozole: 3.40±3.04, Group B CC: 4.40±3.58
Country: Turkey
Interventions Group A: Letrozole, orally given 2.5mg/day for 5 days during cycle days 3-7
Group B:Clomiphene Citrate, orally given 100mg/day for 5 days during cycle days 3-7
Outcomes Primary Outcomes: Ovulation rate and pregnancy rate
Secondary Outcomes:Ovarian hyperstimulation syndrome rate, Miscarriage rate,Mul-
tiple Pregnancy rate, number of follicles on day of hCG (≥17mm), E2 (pg/mL) on hCG
day, endometrial thickness (mm), other side effects
Notes Ethical approval: Yes, “Ethical approval was obtained from the institutional review
board of Atatürk University Medical Faculty in order to conduct this study.”
Informed consent: “Instead of written consent verbal approval was obtained from the
patients prior to study begin and treatment” - correspondence with Dr. Hakan Nazik
Source of funding: “This study was done by researchers without any funding”
Power calculation: Not stated
All questions were answered by Dr. Hakan Nazik
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The patients were randomly allocated us-
ing a computer random list into first and
second groups”
Allocation concealment (selection bias) Unclear risk “The patients were randomly allocated us-
ing a computer random list into first and
second groups”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “There was no blinding in our study” (E-
mail with Dr. Hakan Nazik)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “There was no blinding in our study” (E-
mail with Dr. Hakan Nazik)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
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Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias High risk Patients in Group 2 Letrozole were sig-
nificantly Younger and had a significantly
shorter duration of infertility
Ramezanzadeh 2011
Methods Randomised controlled trial
Participants Inclusion criteria: PCOS patients with infertility who underwent ovulation induction
and timed intercourse for the first time. PCOS was diagnosed by the Rotterdam 2003
criteria. Participants were less than 35 years old with at least one year of infertility with
no other infertility factor
Exclusion criteria: Ovarian cysts on cycle day 3 found by transvaginal ultrasound ex-
amination
Number of centres: One, an infertility clinic of a tertiary referral centre
Number of women randomised: 80; Group A letrozole 5mg: 40, Group B letrozole 7.
5mg: 40
Number of women analysed:Group A letrozole 5mg: 30, Group B letrozole 7.5mg: 37
Number of withdrawals/exclusions/loss to follow up and reasons: 4 Excluded in
group A due to a cyst before treatment, 6 lost to follow up in Group A and 3 lost to
follow up in group B
Age (y): Group A letrozole 5mg: 28.27±4.98, Group B letrozole 7.5mg: 28.22±4.45
BMI (kg/m²): Group A letrozole 5mg: 25.87±4.19, Group B letrozole 7.5mg: 26.69±3.
60
Duration of infertility (y): Group A letrozole 5mg: 3.64±2.30, Group B letrozole 7.
5mg: 4.74±3.16
Country: Iran
Interventions Group A: Letrozole orally given, 5mg/day for 5 days from cycle days 3-7
Group B: Letrozole orally given, 7.5mg/day for 5 days from cycle days 3-7
Outcomes Number and size of follicles and endometrial thickness on days 12-14, the number of
days to reachmature follicle, day 7 testosterone level, day 21 progesterone level, ovulation
rate, pregnancy rate, miscarriage rate, multiple pregnancy rate, ovarian hyperstimulation
syndrome rate
Notes Ethical approval: Yes, the hospital research ethics board approved the study.
Informed consent: All participants gave informed consent before inclusion in trial
Source of funding: No, but “Conflict of interest: All of the authors do not have any
conflict of interest”
Power calculation: “Using PASS software and based on two previous studies, a sample
size of 30 subjects in each group would provide 80% power to detect a significant
difference in the number of mature follicles and duration of stimulation between two
groups with a significant level of 0.05.”
Risk of bias
57Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ramezanzadeh 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly allocated using computer-gener-
ated random table into two Letrozole treatment groups
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk 4 patients excluded due to ovarian cyst on day 3 sonog-
raphy. 9 patients lost to follow up, 6 in Group A and 3
in Group B without reasons given
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk Not stated
Ray 2012
Methods A comparative, randomised, phase III, open labelled trial study
Participants Inclusion criteria: Infertile females aged 20-35 with PCOS diagnosis based on the
Rotterdam criteria 2003
Exclusion criteria: Patients who had hyperprolactinaemia, thyroid disorder, male factor
infertility, known or suspicious tubal factor infertility (endometriosis and pelvic inflam-
matory disease) were excluded from the study. Exclusion also include patients with a
history of liver and kidney failure, cardiovascular diseases, diabetes or patients who con-
sumed metformin or drugs effecting insulin secretion or CC in the previous 2 months
Number of centres: One, Eden Hopsital, Mecial College Kolkata
Number of women randomised: 147; Group A Let: 69, Group B CC: 78
Number of women analysed: Group A Let: 69, Group B CC: 78
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Let: 28 (19-35), Group B CC: 29 (20-35)
BMI (kg/m²): Group A Let: 28.8 (23.2-34.6), Group B CC: 28.5 (24.2 - 33.6)
Duration of infertility (y):Group A Let: 2.2, Group B CC: 2.4 (Std or range not given)
Country: India
Interventions Group A: Letrozole, 2.5mg/day given orally for 5 days from cycle day 3 to 7
Group B: Clomiphene Citrate, 100mg/day given orally for 5 days from cycle day 3 to 7
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Outcomes Primary Outcomes: Ovulation rate, average follicular diameter on day 16, number of
mature follicles produced per cycle, mean estradiol level on the day of hCG administra-
tion, mean endometrial thickness, pregnancy rate
Secondary Outcomes: miscarriage rate, live birth rate,
Notes Ethical approval: Yes, the study protocol was approved by the ethical committee of
Medical college Kolkata
Informed consent: Yes, Patients were counselled and informed consent was obtained
before recruitment
Source of funding: “Conflict of interest: the authors hereby declare that they have not
received any financial support for this study and there is no conflict of interest.”
Power calculation: Not stated
Dr. Ray was contacted via e-mail about Randomisation, allocation, blinding, MPR and
OHSSr, but he did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear how randomisation was done ex-
actly
Allocation concealment (selection bias) Unclear risk Unclear how allocation was done exactly
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported if anyone was blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported if anyone was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No patients stated as lost, but 147 Patients
is an odd number to start with, so are the
groups of 69 and 78 respectively, authors
contacted for protocol
Selective reporting (reporting bias) Unclear risk All expected outcomes were reported, but
contacted authors for protocol
Other bias Low risk Not stated
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Methods Randomised clinical trial
Participants Inclusion criteria: The inclusion criteria include patients in the age group of 20-35
years having infertility for more than one year, body mass index (BMI) <28, and patients
of anovulatory PCOS
based on the Rotterdam 2003 criteria.
Exclusion criteria: In all patients, a comprehensive infertility work-up was done. This
included a tubal patency test, pelvic ultrasonography, husband semen analysis, and serum
hormone measurements (FSH, LH, prolactin, estradiol, progesterone, and testosterone)
on the 2nd to 5th day of the cycle. Patients having abnormality in any of these tests,
which may be responsible for reproductive failure, were excluded from the study
Number of centres: One, a tertiary care hospital in India
Number of women randomised: 212 women; Group A Let: 104, Group B CC: 108
Number of women analysed: Letrozole group: 98, Clomiphene group: 106
Number of withdrawals/exclusions/loss to follow up and reasons: 8 lost to follow up
Age (y): Group A Letrozole: 26.1±1.8, Group B CC: 26.5±1.3
BMI (kg/m²): Group A Letrozole: 25.8±2.1, Group B CC: 25.4±1.56
Duration of infertility (y): Group A Letrozole: 6.4±3.8, Group B CC: 5.8±3.1
Country: India
Interventions Group A: Letrozole, orally given in doses of 2.5mg/day and 5mg/day for 5 days during
cycle days 3-7
Group B: Clomiphene Citrate, orally given in doses of 50mg/day and 100mg/day for 5
days during cycle days 3-7
Treatment was continued for 3 months.
Outcomes The mean number of follicles, endometrial thickness, ovulatory cycle rate, conception
rate, pregnancy outcome, miscarriage rate, multiple pregnancies and ovarian hyperstim-
ulation syndrome rate were compared in both groups
Notes Ethical approval:Yes, the necessary ethical approval was taken from Institutional Review
Board to conduct this study
Informed consent: Yes, the patients were counselled, and informed consent was taken
before randomisation
Source of funding: “Source of support: Nil, Conflict of interest: None declared.”
Power calculation: “On basis of previous studies, to achieve a statistically valid com-
parison of pregnancy rates in the two groups, with a type I error of 0.05 and a power of
80%, a sample size of at least 40 women in each arm was required.”
We contacted Dr. Roy via e-mail to get additional information, but unfortunately he
did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk They used online software to generate a random number
table (www.randomization.com).
60Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Roy 2012 (Continued)
Allocation concealment (selection bias) Unclear risk “Randomisation codes (A, B) were packed into sealed
opaque envelopes by an individual not involved in enrol-
ment, treatment and follow-up of subjects to ensure con-
cealment of allocation. One resident had the responsibility
for dispensing the trial drugs to the patient based on the
unique randomization code. At the end of allocation, the
resident provided us with a randomization list.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8 losses to follow up of 112 patients
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk Not stated
Selim 2012
Methods Randomised controlled trial
Participants Inclusion criteria:Diagnosis of PCOS relied on Rotterdam criteria provide that anovu-
lation is one of the two required criteria
Exclusion criteria: Exclusion criteria included hyperprolactinaemia, congenital adrenal
hyperplasia, thyroid disease, other causes of amenorrhoea such as premature ovarian fail-
ure, and clinically suspected Cushing’s syndrome or androgen-secreting neoplasm. Ex-
clusion criteria also included all women who had received metformin or ovarian drilling
in the previous 6 months. Other causes of infertility were excluded by documentation of
a normal uterine cavity and at least one patent fallopian tube, and each woman’s current
partner had a semen concentration of at least 2 · 107/mL
Number of centres: Not reported
Number of women randomised: 220; Group A Let: 110, Group B CC: 110
Number of women analysed: Group A Let: 102, Group B CC: 99
Number of withdrawals/exclusions/loss to follow up and reasons: “In the letrozole
group, eight women were excluded because of missed follow-up visits (three women),
treatment suspension (twowomen), and homogenous not triple-line endometrial pattern
(three women). In the CC group, 11 women were excluded because of missed follow-up
visits (four women), treatment suspension (two women), and homogenous not triple-
line endometrial pattern (five women).”
Age (y): Group A Let: 26.0±2.7, Group B CC: 25.1±3.1
BMI (kg/m²): Group A Let: 24.4±4.3, Group B CC: 23.8±3.7
Duration of infertility (y): Group A Let: 2.9±0.6, Group B CC: 2.6±0.7
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Country: Not reported, Saudi Arabia or Egypt
Interventions Group A: 110 patients who were treated with 5 mg/day of letrozole (Femara; Novartis,
Switzerland) in two divided doses from cycle day 3 to 7
Group B: 110 patients who were treated with 100 mg/day of CC (Clomid; Sanofi
Aventis, France) in two divided doses from cycle day 3 to 7
Outcomes “The mean number of follicles, endometrial thickness, theDoppler study of endometrial
and sub endometrial vasculatures,
ovulation rate, and pregnancy rate were compared in both groups.”
Notes Ethical approval: “approval was obtained from the Institutional Review Board of Jeddah
Clinic Hospital, Jeddah, Saudi Arabia.”
Informed consent: Yes, “all participants gave verbal and written informed consent.”
Source of funding: “No competing financial interests exist.”
Power calculation: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly allocated to the letrozole group
or CC group by means of a series of blind envelopes
numbered from 1 to 220
Allocation concealment (selection bias) Low risk Each patient was invited to choose an envelope and was
placed by the clinic secretary in either the letrozole group
or the CC group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The patients were not blinded about the treating drug
in either group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk To remove any inter observational bias, ultrasound in
all patients was demonstrated by a single observer (MF
Selim) who was blinded to the treating drug
Incomplete outcome data (attrition bias)
All outcomes
Low risk All dropouts were reported, reasons given.
Selective reporting (reporting bias) Low risk All expected outcomes were reported.
Other bias Low risk Not stated
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Sh-El-Arab Elsedeek 2011
Methods Randomised controlled double blind trial
Participants Inclusion criteria:Diagnosis of PCOS relied on Rotterdam criteria provide that anovu-
lation is one of the two required criteria
Exclusion criteria: Exclusion criteria were BMI>35, presence of other causes of infer-
tility, >5 years infertility duration and known poor response to either drugs in previous
cycles. Cases found to have baseline ovarian cysts or endometrial pathology were also
excluded
Number of centres: One, an infertility unit of a university hospital
Number of women randomised: 124; Group A Let: 62, Group B CC: 62
Number of women analysed: Group A Let: 59, Group B CC: 57
Number of withdrawals/exclusions/loss to follow up and reasons: 3 in the Let and 5
in the CC group were reported as lost to follow up, but no further explanation given
Age (y): Group A Letrozole: 24.95±3.11, Group B CC: 25±3.59
BMI (kg/m²): Group A Let: 27.7±3.48, Group B CC: 29.18±3.47
Duration of infertility (y): Not reported
Country: India
Interventions Group A: Letrozole, 5mg/day orally given for 5 days, cycle days not given
Group B: Clomiphene citrate, 100mg/day orally given for 5 days, cycle days not given
Outcomes Pregnancy rate, ovulation rate, endometrial thickness (mm), mid luteal progesterone
level (ng/mL), number of follicles ≥ 12 mm
Notes Ethical approval: Yes, institutional review board (IRB) approval was obtained for the
study
Informed consent: Yes, informed consent was taken from all included cases
Source of funding: Not reported, also no conflicts of interest given.
Power calculation: Not stated
Dr. Sheik-el-ArabElsedeekwas contacted via e-mail about allocation concealment, blind-
ing of outcome assessors, information on LBR, MR, OHSSr, MPr and funding/COI,
but he did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised using computer
generated tables to undergo one cycle of
CC or let induction.”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated if personnel was blinded and
how the patients were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Both patients and sonographers were
blinded to this allocation.” - Unclear if the
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other outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8 Patients lost to follow up, reasons un-
known
Selective reporting (reporting bias) Unclear risk Only pregnancy was reported, authors con-
tacted to get study protocol
Other bias Low risk Not stated
Sohrabvand 2006
Methods Single blinded randomised clinical trial
Participants Inclusion criteria: PCOSpatients who had failed to become pregnant after three courses
of 150 mg clomiphene citrate (considered as clomiphene resistant), whereas the values
of hormonal tests were normal. (Tests: thyroid function, prolactin level, hysterosalpin-
gography and husband’s sperm analysis)
Exclusion criteria: Exclusion criteria included patients with a history of liver and kidney
failure, cardiovascular disease, diabetes (based on criteria set by the American diabetic
association) or patients who consumed metformin or drugs effecting insulin secretion
or clomiphene citrate in the previous 2 month
Number of centres: One, infertility clinic of Vali-e-Asr Hospital Tehran
Number of women randomised: 60; Group A Met-Let: 30, Group B Met-CC: 30
Number of women analysed: Group A Met-Let: 29, Group B Met-CC: 30
Number of withdrawals/exclusions/loss to follow up and reasons: 1 because she got
pregnant after met treatment before let was started
Age (y): Group A Met-Letrozole: 28.24±3.11, Group B Met-CC: 29.55±3.47
BMI (kg/m²): Group A Met-Let: 29.98±4.83, Group B Met-CC: 30.21±3.92
Duration of infertility (y): Group A Met-Let: 3.78, Group B Met-CC: 3.81
Country: Iran
Interventions Group A:Metformin 500mg three times a day for 6-8 weeks. If pregnancy did not occur,
2.5mg letrozole from cycle days 3-7 was given orally
Group B:Metformin 500mg three times a day for 6-8 weeks. If pregnancy did not occur,
100mg CC from cycle days 3-7 was given orally
Treatment was continued for 2 cycles.
Outcomes Endometrial thickness on day of hCG administration (cm), Number of follicles >18
mm in diameter, Mean total estradiol level on day of hCG administration (pM/L), mean
estradiol level per mature follicle (pM/l), regular menses after metformin, adverse effects
of metformin, live birth rate, pregnancy rate, miscarriage rate
Notes Ethical approval: Yes, consent from the deputy of research and the medical ethics
committee of Tehran university of medical sciences
Informed consent: Not obtained because “it was the routine treatment protocol and it
was just put in th frame of a structured study” (E-mail with Dr Farnaz Sohrabvand)
Source of funding: “No funding was necessary” (E-mail with Dr Farnaz Sohrabvand)
Power calculation: Not stated
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Authors were contacted about Or, OHSSr, MPr per woman randomised, Informed
consent, funding. No data available on OR, OHSSr and MPr, information retrieved
about informed consent and funding. (E-mail with Dr Farnaz Sohrabvand)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A series of blind envelopes numbered from
1 to 60 had been prepared. Each patient was
invited to pull out an envelope and was placed
by the clinic secretary in either themetformin-
letrozole group (number 1-30) or in the met-
formin-CC group (31-60).”
Allocation concealment (selection bias) Unclear risk “A series of blind envelopes numbered from
1 to 60 had been prepared. Each patient was
invited to pull out an envelope and was placed
by the clinic secretary in either themetformin-
letrozole group (number 1-30) or in the met-
formin-CC group (31-60).”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk It is not credible that outcome assessors were
blinded if participants were not
Incomplete outcome data (attrition bias)
All outcomes
Low risk One patient was excluded due to pregnancy
after start of metformin treatment
Selective reporting (reporting bias) Low risk All outcomes were reported
Other bias Low risk Not stated
Zeinalzadeh 2010
Methods Randomised controlled trial
Participants Inclusion criteria: Patients with primary infertility, documented PCOS, age <35y, <5y
infertility and BMI between 19-26. PCOS was defined on the basis of ultrasonography
findings, oligomenorrhoea and an increased luteinizing hormone (LH)/follicle-stimu-
lating hormone (FSH) ratio (>3)
Exclusion criteria: Moderate or severe case of OHSS during trial, infertility resulting
from male factors, tubular factors and endometriosis
Number of centres: One, Fatemeh Zahra Infertility Center, Babol
Number of women randomised: 107; Group A Let: 50, Group B CC: 57
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Number of women analysed: 107; Group A Let: 50, Group B CC: 57
Number of withdrawals/exclusions/loss to follow up and reasons: 0
Age (y): Group A Letrozole: 23.8±3.6, Group B CC: 23.1±3.6
BMI (kg/m²): Not reported
Duration of infertility (y): Group A Let: 2.4±1, Group B CC: 2.6±1.2
Country: Iran
Interventions Group A: 5mg letrozole from cycle days 3-7 was given orally.
Group B: 100mg CC from cycle days 3-7 was given orally.
Outcomes Ovulation rate, pregnancy rate, number of follicles >17, OHSS rate, multiple pregnancy
rate, endometrial thickness
Notes Ethical approval: Yes, “The study protocol was approved by the ethics committee of
Babol Medical University
Informed consent: Yes, ”All the patients signed a written consent form as to be enrolled
in the study“
Source of funding: No, but ”Financial disclosure: The authors have no connection to
any companies or products mentioned in this article”
Power calculation: Not stated
Authors were contacted for additional information, but they did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The participants were assigned to two groups using sys-
tematic randomization method”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Low risk Not stated
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Angel 2014 RCT, but not about women with PCOS
Anwary 2012 Not a RCT
Azargoon 2012 Not a RCT
Badawy 2009 Not a RCT
Baruah 2009 Quasi-randomised trial (“Based on attendance order, patients with odd numbers were given letrozole and those
with even numbers were given CC”)
Bigawy 2008 Quasi-randomised trial
Foroozanfard 2013 Not randomized for clomiphene or letrotzole
Mittal 2004 Not a RCT
Nahid 2012 Suspected quasi-randomisation based on attendance order
Ozdemir 2013 RCT, but not about women with PCOS
Yang 2008 Not a RCT (“the allocation depended on the patients’ choice” - translated by Prof Taixiang Wu)
Characteristics of studies awaiting assessment [ordered by study ID]
Aygen 2007
Methods Randomised clinical study
Participants 15 infertile patients with polycystic ovarian syndrome
Interventions Patients were randomised into three treatment groups:
In group 1, continuous metformin was used at the dose of 850mg/tid/day for six months; afterwards, daily 2.5mg
letrozole between 3 and 7 days of the menstrual cycle was added to the metformin therapy
Group 2 patients received only daily 2.5 mg letrozole between days 3 and 7 of the menstrual cycle
Group 3 patients received daily 100mg clomiphene citrate only between days 3 and 7 of the menstrual cycle
Outcomes Unclear
Notes The article was written in Turkish, unfortunately we were not able to have it translated properly
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Hazlina 2012
Methods Open label randomized controlled trial
Participants 150 women
Inclusion criteria:
Age > 18 years but < 40 years old
Was diagnosed PCOS
Normal husband’s seminal fluid analysis (SFA)
Exclusion criteria :
Not having medical problems eg- renal disease, tyhroid disorder, hyperprolactinemia, liver disease
Other causes of anovulatory infertility
Interventions Women in group C will assigned CC 100mg and those in L assigned Letrozole 2.5 mg. Both drugs will be given
from days 5 to 9 of menses
Outcomes Primary outcomes: Ovulation induction
Secondary outcomes: Pregnancy rate, endometrial thickness
Notes No study results published yet
Lorzadeh 2011
Methods Randomised clinical trial
Participants 100 infertile women with polycystic ovary syndrome referred to asali hospital and private clinic in 2008
Interventions The women were randomised into two groups of 50 that were treated with 5 mg letrozole or 100 mg clomiphene
citrate from day 3 to 7 of the menstrual cycle
Outcomes Outcomes: Pregnancy rate
Notes The article was written in Persian, unfortunately we were not able to have it translated properly
Parihar 2008
Methods Open lable Randomised clinical trial
Participants 55 females with anovulatory infertility aged 20-38 years.
Inclusion Criteria: Females with anovulatory infertility 20-38 years of age. Diagnosis of anovulatory infertility as
established by standard criteria. Normal Pelvic USG and bilateral tubal patency Willingness and giving written
Informed Consent
Exclusion Criteria: Uterine and adnexal pathology e.g. leiomyomata Ovarian cyst Hyperprolactinaemia Hyperthy-
roidism or Hypothyroidism* FSH >9mIU/ml (during early follicular phase).* (As per Chemoluminescence method)
Previous surgery related to genital tract as per history Appendicitis, peritonitis, genital tuberculosis as per history and/
or having an abnormal pelvic anatomy Impaired hepatic /renal function Diabetes mellitus/Random blood sugar- >
140mg/dl Drugs likely to interfere with ovulation Alcohol intake as per history History of hypersensitivity to the
study drug or to its excipients Planned travel outside the study area for a substantial portion (>5 days) of the study
period by potential participants Lack of willingness to give informed written consent Participation in any clinical
study within the preceding 1 month
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Parihar 2008 (Continued)
Interventions Letrozole 2.5 mg once a day for 5 days for 3 cycles
Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
Outcomes Primary outcomes: ovulationi rate
Secondary outcomes: pregnancy rate, endometrial thickness, safety
Notes No published data found, last updated on clinicaltrials.gov in 2008
Safdarian 2012
Methods Double-blind randomised clinical trial
Participants 59 infertile women who had the inclusion criteria for PCoS were evaluated in the Infertility Clinic of Shariati Hospital
in Tehran, Iran in 2010-2011
Interventions The patients were assigned to two letrozole and one letrozole plus HMG groups
Outcomes Reported no outcomes of our interest.
Notes The article was written in Persian, unfortunately we were not able to have it translated properly
Sharma 2010
Methods Randomised controlled trial
Participants 557 women with PCOS resistant to clomiphene citrate and letrozole undergoing IUI were randomised by simple
randomisation
Interventions Group A received clomiphene citrate (100mg daily from day 3 to day 7) and u-fSh from day onwards
Group B received letrozole (5mg daily from day 3 to day 7) plus u-FSH from day 5 onwards
Group C received continuous u-FSH from day 3 onwards until hCG injection
Outcomes The number of follicles, endometrial thickness, terminal estradiol (E2) levels, pregnancy rate per cycle, cancellation
rates, multiple pregnancy and miscarriage rate were compared between the three groups
Notes Only conference abstract available, full article could not be found. Contact address of authors unknown
Shirin 2009
Methods Randomised clinical trial, “The cases were assigned assigned to two groups through simple random sampling”
Participants 100 infertile, 20-35 year old women with PCOD attending Vali-e-Asr Infertility Clinic from April 2003 to April
2007
Interventions Group A received clomiphene citrate plus HMG, Group B received Loetrozole plus HMG
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Shirin 2009 (Continued)
Outcomes Primary outcomes: none
Secondary outcomes: pregnancy, miscarriage and multiple pregnancy rates
Notes The article was written in Persian, unfortunately we were not able to have it translated properly
Characteristics of ongoing studies [ordered by study ID]
Ali 2012
Trial name or title Letrozole or combined clomiphene citrate metformin as a first line treatment in women with polycystic ovary
syndrome (PCO)
Methods Randomised clinical trial
Participants 200 infertile women with PCOS
Interventions Letrozole versus combined metformin - clomiphene citrate
Outcomes Primary outcome: Ovulation rate
Secondary outcomes: Pregnacy and miscarriage rate
Starting date January 2009
Contact information Ahmed Ali, Principle investigator, Assiut university
Notes Study should be finished, authors were contacted by an e-mail found via google because no contact information
was written in the study protocol: abd ellah98@yahoo.com
Amer 2007
Trial name or title Letrozole versus clomiphene citrate for Ovulation induction
Methods Double-blind Cross-over randomised controlled trial
Participants Unknown number of infertile women with PCOS
Interventions Letrozole versus clomiphene citrate
Outcomes Primary outcome: Pregnancy rate
Secondary outcomes: ovulation rate, number of growing and mature follicles during treatment, miscarriage
rate, live-birth rate, multiple pregnancy rate, endometrial thickness
Starting date 2007
Contact information Authors e-mail address: saad.amer@nottingham.ac.uk
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Amer 2007 (Continued)
Notes I have contacted the authors, but the study is still ongoing (start date: 2007) The study is double blind,
therefore no data available until ~April 2013
Feng 2011
Trial name or title the ovulation-induced therapy for polycystic ovary syndrome
Methods Randomised controlled trial
Participants Still recruiting; but aimed to be 4 groups of each 67 patients
Inclusion criteria: 1 Patients who are diagnosed as PCOS based on the Revised 2003 consensus diagnostic
criteria for PCOS.
2 The PCoS patients who want to give birth to a baby.
3 patients with clinical and/or biochemical signs of hyperandrogenism and/or insulin resistance. And those
patients need to receive a 3-6 months anti-androgen and/or anti-insulin therapy before included in until
above symptoms have been relieved.
Exclusion criteria: 1) with other factors affecting pregnancy: 1 dysfunction of ovarian ducts: hydrosalpinx,
obstructions, stenosis. 2 uterine abnormalities, such as submucous myoma in submucosa or cornua, uterine
malformation, intrauterine adhesions, chocolate cyst. 3 abnormal serum PRL or thyroidal dysfunction 4 a
positive pulmonary or pelvic TB history. 5 abnormal semen.
2) clinical and/or biochemical signs of hyperandrogenism
3) BMI>30kg/m²
4) age>35 years old
Age minimum: 20 years old
Age maximum: 35 years old
Gender: Female
Interventions Group A: 5g letrozole qd from the 3rd day of menstruation for 5 days
Group B: 50-150mg clomiphene qd from the 3rd day of menstruation for 5 days
GroupC: 500mgmetformin tid immediately and 50-150mg clomiphene qd from the 3rd day ofmenstruation
for 5 days. Medication was discontinued when pregnancy was confirmed
Group D: 500mg metformin tid immediately and 5mg letrozole qd from the 3rd day of menstruation for 5
days. Medication was discontinued when pregnancy was confirmed
Outcomes Primary outcomes: ovulation rate, pregnancy rate, live birth rate
Secondary outcomes: pregnancy lost rate, multiple pregnancy rate, OHSS morbidity
Starting date 2011
Contact information Guimei Feng,
17 3rd section, Renmin south road, Chengdu, Chia 610041
Telephone: +8613551344177
Email: guimei.feng@163.com
Wei Huang, West China Women’s and Childrens Hoospital S.C.U
Telephone: +86 028 85501073
Email: weihuang64@163.com
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Feng 2011 (Continued)
Notes
Ghanem 2013
Trial name or title Clomiphene Citrate Plus HPuFSH Versus Letrozole Plus HPuFSH in Clomid Resistant Infertile PCOS
Women
Methods Radomized controlled trial
Participants Approximately 160 infertile clomiphene-resistend women with PCOS
Inclusion Criteria:
• CC resistant PCOS
• Infertile
• Females
• Age 18-38
Exclusion Criteria:
• Hyperprolactinaemia
• Cushing syndrome
• Adult onset adrenal hyperplasia
• Age > 38
• Other infertility factors in the couple than PCOS: male factor,tubal factor,edometriosis
Interventions Control: clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for
10 days
Experimental: letrozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for
days 3-12
Outcomes Primary outcomes: Ovulation rate
Secondary outcomes: endometrial thickness, ongoing cyle pregnancy rate
Starting date March 2013
Contact information Mohamad E Ghanem, MD
Mansoura Integrated fertility center
Mansoura, Dekahlia, Egypt
E-mail: meghanem87@gmail.com
Notes
Hou 2011
Trial name or title Letrozole Versus Chinese Herbal Compound on Polycystic Ovary Syndrome
Methods Randomised, double blind parallel study
Participants 160 infertile women with PCOS, diagnosed using the 2003 Rotterdam criteria
Exclusion criteria are Tubal or male factor infertility or sub-fertility, suspected peritoneal factor infertility and
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Hou 2011 (Continued)
neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent
Interventions Chinese herbal compound versus Chinese herbal compound placebo versus letrozole
Outcomes Primary outcome(s): Live birth rate
Secondary outcome(s): ovulation rate, pregnancy rate
Starting date September 2011
Contact information Lihui Hou
Telephone: +86 451 82130049
E-mail: houlihui2007@hotmail.com
Notes
Li 2013
Trial name or title Letrozole and Berberine in Infertile PCOS Patients
Methods Randomised, double blinded clinical trial
Participants 660 infertile women with PCOS diagnosis based on the 2003 Rotterdam criteria
Exclusion criteria are Tubal or male factor infertility or sub-fertility, suspected peritoneal factor infertility and
neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent
Interventions Berberine versus letrozole versus berberine + letrozole
Outcomes Primary outcome: Live birth rate
Secondary outcome: Ovulation rate, pregnancy rate
Starting date October 2009
Contact information Xiaoke Wu, MD. PhD
Telephone: +86 451 8213 0094
E-mail: xiaokewu2002@vip.sina.com
Notes
Philihawadana 2008
Trial name or title A study on anti-eostrogen clomifene citrate and aromatase inhibitor letrozole in induction of ovulation, in
WHO group II anovulatory subjects, and in augmentation of ovulation in ovulatory infertility
Methods Randomised controlled trial
Participants Inclusion criteria: Phase I: participants with WHO group II anovulatory infertility Phase II: Participants with
unexplained infertility
Exclusion criteria: 1. Previous ovarian surgery 2. Endocrinopathies (other than PCOS) giving rise to anovu-
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Philihawadana 2008 (Continued)
lation
Interventions In phase one: ovulation induction with clomifene citrate followed by letrozole in patients with anovulatory
infertility In phase two: Subjects with unexplained infertility would undergo augmentation of ovulation with
either clomifene citrate or letrozole randomly followed by other agent after a three month drug free interval
Outcomes Primary outcomes phase 1:Ovulation rate, endometrial characteristics Phase 2:Monofolicle development rate,
endometrial characteristicsSecondary outcomes phase 2: Follicular phase and luteal phase endocrinological
changes
Secondary outcomes: Follicular phase and luteal phase endocrinological changes
Starting date 2008
Contact information Dr. Thilina S Palihawadana Faculty of Medicine, No 6, Thalagolla Road, Ragama; palihawadana t@sltnet.lk
Notes
Sarvi 2010
Trial name or title The effect of metformin in different phenotypes of poly cystic ovary syndrome according to Rotterdam criteria
criteria
Methods Randomised controlled trial
Participants Infertile women were included in the patients attending the outpatient clinic of the Infertility Research Centre
of Shariati Hospital. The diagnosis of PCODwas based on the Rotterdam criteria, age between 18 to35 years,
normal thyroid, liver and kidney, normal sperm count according to WHO criteria, taking no metformin in
previous 8 weeks, normal hysterosalpingography
Interventions Intervention 1: metformin tablet 500 mg TDS from two months before starting ovulation induction, then
ovulation induction started on day 2-6 of menstrual cyclewith Letrozole 2.5mg twice per day, when dominant
follicle reached 18 mm, human chorionic gonadotropin 10000 IU was injected.
Intervention 2: In control groups: no drug used before starting ovulation induction, then ovulation induction
started on day 2-6 of menstrual cycle with Letrozole tablet 2.5 mg twice per day, when dominant follicle
reached 18 mm, human chorionic gonadotropin 10000 IU was injected
Outcomes Primary outcomes: none
Secondary Outcomes: clinical pregnancy rate
Starting date 2010
Contact information Fatemeh Sarvi, E-mail: fsarvi@razi.tums.ac.ir; sarvi.fateme@yahoo.com
Notes Authors were contacted about availability of information, but did not respond
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D A T A A N D A N A L Y S E S
Comparison 1. Aromatase inhibitors compared to placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth rate 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Ovarian hyperstimulation
syndrome rate
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
3 Clinical pregnancy rate 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Miscarriage rate per woman
randomised
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Miscarriage rate per pregnancies 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Multiple pregnancy rate 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed
intercourse
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth rate 9 1783 Odds Ratio (M-H, Fixed, 95% CI) 1.64 [1.32, 2.04]
1.1 AIs versus clomiphene
citrate
6 1353 Odds Ratio (M-H, Fixed, 95% CI) 1.80 [1.40, 2.33]
1.2 AI versus clomiphene +
metformin
1 250 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.60, 1.81]
1.3 Aromatase inhibitor
+ metformin compared to
clomiphene + metformin
1 60 Odds Ratio (M-H, Fixed, 95% CI) 4.5 [1.09, 18.50]
1.4 Aromatase inhibitor +
FSH compared to clomiphene
+ FSH
1 120 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [0.53, 2.61]
2 Live birth rate per BMI 8 1703 Odds Ratio (M-H, Fixed, 95% CI) 1.65 [1.32, 2.06]
2.1 BMI > 25 6 1519 Odds Ratio (M-H, Fixed, 95% CI) 1.67 [1.31, 2.11]
2.2 BMI < 25 2 184 Odds Ratio (M-H, Fixed, 95% CI) 1.54 [0.81, 2.93]
3 Live birth rate per first or second
line treatment
5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 No previous Ovulation
induction
2 180 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.68, 3.24]
3.2 CC resistant women 1 64 Odds Ratio (M-H, Fixed, 95% CI) 2.6 [0.83, 8.13]
3.3 Unclear or mixed study
population
2 359 Odds Ratio (M-H, Fixed, 95% CI) 2.31 [1.42, 3.76]
4 Impact of allocation bias for live
birth rate
8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Unclear risk of allocation 6 663 Odds Ratio (M-H, Fixed, 95% CI) 2.22 [1.53, 3.23]
4.2 Low risk of allocation 2 370 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.69, 1.71]
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5 Impact of detection bias for live
birth rate
8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 High risk of detection 1 64 Odds Ratio (M-H, Fixed, 95% CI) 2.6 [0.83, 8.13]
5.2 Low risk of detection 4 530 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.90, 1.97]
5.3 Unclear risk of detection 3 439 Odds Ratio (M-H, Fixed, 95% CI) 2.07 [1.33, 3.24]
6 Impact of attrition bias for live
birth rate
8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Unclear risk of attrition 1 147 Odds Ratio (M-H, Fixed, 95% CI) 2.04 [0.93, 4.50]
6.2 Low risk of attrition 7 886 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [1.19, 2.19]
7 Ovarian hyperstimulation
syndrome rate
9 2179 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.01, 0.00]
7.1 AIs versus clomiphene
citrate
7 1809 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.01, 0.00]
7.2 AI versus clomiphene +
metformin
1 250 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.02, 0.02]
7.3 Aromatase inhibitor +
hMG versus clomiphene +
hMG
1 120 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.03, 0.03]
8 Ovarian hyperstimulation
syndrome rate per BMI
8 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
8.1 BMI > 25 4 1650 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.01, 0.00]
8.2 BMI < 25 4 449 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.02, 0.02]
9 Clinical pregnancy rate 15 2816 Odds Ratio (M-H, Fixed, 95% CI) 1.40 [1.18, 1.65]
9.1 AIs versus clomiphene
citrate
11 2286 Odds Ratio (M-H, Fixed, 95% CI) 1.44 [1.20, 1.73]
9.2 AI versus clomiphene +
metformin
1 250 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.60, 1.71]
9.3 Aromatase inhibitor +
metformin versus clomiphene
+ metformin
2 160 Odds Ratio (M-H, Fixed, 95% CI) 2.88 [0.99, 8.36]
9.4 Aromatase inhibitor +
FSH versus clomiphene + FSH
1 120 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.55, 2.45]
10 Impact of allocation bias for
clinical pregnancy rate
14 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Unclear risk of allocation 10 1057 Odds Ratio (M-H, Fixed, 95% CI) 1.89 [1.41, 2.54]
10.2 Low risk of allocation 4 1009 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.77, 1.29]
11 Miscarriage rate per woman
randomised
12 2385 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.92, 1.88]
11.1 AIs versus clomiphene
citrate
8 1855 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [1.00, 2.20]
11.2 AI versus clomiphene +
metformin
1 250 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.25, 4.23]
11.3 Aromatase inhibitor +
metformin versus clomiphene
+ metformin
2 160 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.03, 2.19]
11.4 Aromatase inhibitor +
FSH versus clomiphene + FSH
1 120 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.27, 3.65]
12 Miscarriage rate per pregnancy 12 696 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.61, 1.36]
12.1 AIs versus clomiphene
citrate
8 549 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.64, 1.60]
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12.2 AI versus clomiphene +
metformin
1 85 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.24, 4.40]
12.3 Aromatase inhibitor +
metformin versus clomiphene
+ metformin
2 20 Odds Ratio (M-H, Fixed, 95% CI) 0.06 [0.00, 0.77]
12.4 Aromatase inhibitor +
FSH versus clomiphene + FSH
1 42 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.21, 3.65]
13 Multiple pregnancy rate 11 2385 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.17, 0.84]
13.1 AIs versus clomiphene
citrate
9 2015 Odds Ratio (M-H, Fixed, 95% CI) 0.41 [0.17, 1.01]
13.2 AI versus clomiphene +
metformin
1 250 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.82]
13.3 Aromatase inhibitor +
FSH versus clomiphene + FSH
1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.04, 5.57]
Comparison 3. Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ovarian hyperstimulation
syndrome rate
2 1494 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.01, 0.00]
1.1 AI versus Clomiphene 1 107 Risk Difference (M-H, Fixed, 95% CI) -0.02 [-0.07, 0.03]
1.2 AI versus Clomiphene
+rFSH and rFSH only
1 1387 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.01, 0.00]
2 Clinical pregnancy rate 3 1597 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [1.30, 2.25]
2.1 AI versus Clomiphene 2 210 Odds Ratio (M-H, Fixed, 95% CI) 2.09 [0.97, 4.53]
2.2 AI versus Clomiphene
+rFSH and rFSH only
1 1387 Odds Ratio (M-H, Fixed, 95% CI) 1.66 [1.23, 2.22]
3 Miscarriage rate per woman
randomised
2 1490 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.62, 2.40]
3.1 AI versus Clomiphene 1 103 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.06]
3.2 AI versus Clomiphene
+rFSH and rFSH only
1 1387 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.66, 2.65]
4 Miscarriage rate per pregnancies 2 260 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.37, 1.57]
4.1 AI versus Clomiphene 1 15 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.00, 3.09]
4.2 AI versus Clomiphene
+rFSH and rFSH only
1 245 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.40, 1.79]
5 Multiple pregnancy rate 3 1597 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.49, 2.13]
5.1 AI versus Clomiphene 2 210 Odds Ratio (M-H, Fixed, 95% CI) 3.48 [0.14, 87.49]
5.2 AI versus Clomiphene
+rFSH and rFSH only
1 1387 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.44, 2.03]
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Comparison 4. Aromatase inhibitors compared to laparoscopic ovarian drilling
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth rate 2 407 Odds Ratio (M-H, Fixed, 95% CI) 1.19 [0.76, 1.86]
2 Ovarian hyperstimulation
syndrome rate
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
3 Clinical pregnancy rate 3 553 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.80, 1.65]
3.1 AI versus LOD 2 407 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.73, 1.72]
3.2 AI + metformin versus
LOD
1 146 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [0.60, 2.39]
4 Miscarriage rate per woman
randomised
3 553 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.38, 2.19]
4.1 AI versus LOD 2 407 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.26, 2.20]
4.2 AI + metformin versus
LOD
1 146 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [0.29, 6.27]
5 Miscarriage rate per pregnancies 3 167 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.32, 2.01]
5.1 AI versus LOD 2 118 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.22, 2.03]
5.2 AI + metformin versus
LOD
1 49 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [0.24, 6.09]
6 Multiple pregnancy rate 2 407 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Letrozole compared to anastrozole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ovarian hyperstimulation
syndrome rate
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
2 Clinical pregnancy rate 2 260 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.51, 1.43]
3 Miscarriage rate per woman
randomised
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Miscarriage rate per pregnancies 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Multiple pregnancy rate 2 260 Odds Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 105.35]
Comparison 6. Five days compared to 10 days administration protocol of letrozole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ovarian hyperstimulation
syndrome rate
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
2 Clinical pregnancy rate 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Miscarriage rate per woman
randomised
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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4 Miscarriage rate per pregnancies 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Multiple pregnancy rate 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 7. Dosage studies of letrozole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ovarian hyperstimulation
syndrome rate
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
1.1 5mg vs 7.5mg letrozole 1 Risk Difference (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Clinical pregnancy rate 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 5mg vs 7.5mg letrozole 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Miscarriage rate per woman
randomised
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 5mg vs 7.5mg letrozole 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Miscarriage rate per pregnancies 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 5mg vs 7.5mg letrozole 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Multiple pregnancy rate 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 5mg vs 7.5mg letrozole 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 1 Live birth rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 1 Aromatase inhibitors compared to placebo
Outcome: 1 Live birth rate
Study or subgroup Letrozole Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kamath 2010 1/18 0/18 3.17 [ 0.12, 83.17 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (Letrozole), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours Placebo Favours Letrozole
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Analysis 1.2. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 2 Ovarian
hyperstimulation syndrome rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 1 Aromatase inhibitors compared to placebo
Outcome: 2 Ovarian hyperstimulation syndrome rate
Study or subgroup Letrozole Placebo
Risk
Difference
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kamath 2010 (1) 0/18 0/18 0.0 [ -0.10, 0.10 ]
-0.2 -0.1 0 0.1 0.2
Favours Letrozole Favours Placebo
(1) Clomiphene resistant women; Letrozole, 2.5mg/day versus placebo
Analysis 1.3. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 3 Clinical pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 1 Aromatase inhibitors compared to placebo
Outcome: 3 Clinical pregnancy rate
Study or subgroup Letrozole Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kamath 2010 (1) 1/18 0/18 3.17 [ 0.12, 83.17 ]
0.01 0.1 1 10 100
Favours Placebo Favours Letrozole
(1) Clomiphene resistant women; Letrozole, 2.5mg/day versus placebo
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Analysis 1.4. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 4 Miscarriage rate per
woman randomised.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 1 Aromatase inhibitors compared to placebo
Outcome: 4 Miscarriage rate per woman randomised
Study or subgroup Letrozole Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kamath 2010 (1) 0/18 0/18 Not estimable
0.5 0.7 1 1.5 2
Favours Letrozole Favours Placebo
(1) Clomiphene resistant women; Letrozole, 2.5mg/day versus placebo
Analysis 1.6. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 6 Multiple pregnancy
rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 1 Aromatase inhibitors compared to placebo
Outcome: 6 Multiple pregnancy rate
Study or subgroup Letrozole Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kamath 2010 (1) 0/18 0/18 Not estimable
0.5 0.7 1 1.5 2
Favours Letrozole Favours Placebo
(1) Clomiphene resistant women; Letrozole, 2.5mg/day versus placebo
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Analysis 2.1. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 1 Live birth rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 1 Live birth rate
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AIs versus clomiphene citrate
Bayar 2006 (1) 8/40 7/40 4.4 % 1.18 [ 0.38, 3.63 ]
Begum 2009 (2) 12/32 6/32 3.0 % 2.60 [ 0.83, 8.13 ]
Dehbashi 2009 (3) 10/50 6/50 3.8 % 1.83 [ 0.61, 5.50 ]
Legro 2014 (4) 103/374 72/376 41.3 % 1.60 [ 1.14, 2.26 ]
Ray 2012 (5) 20/69 13/78 6.9 % 2.04 [ 0.93, 4.50 ]
Roy 2012 (6) 39/104 21/108 10.2 % 2.49 [ 1.34, 4.62 ]
Subtotal (95% CI) 669 684 69.6 % 1.80 [ 1.40, 2.33 ]
Total events: 192 (Aromatase inhibitor), 125 (Other agents for OI)
Heterogeneity: Chi2 = 2.51, df = 5 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.51 (P < 0.00001)
2 AI versus clomiphene + metformin
Abu Hashim Sept 2010 (7) 36/123 36/127 19.9 % 1.05 [ 0.60, 1.81 ]
Subtotal (95% CI) 123 127 19.9 % 1.05 [ 0.60, 1.81 ]
Total events: 36 (Aromatase inhibitor), 36 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
3 Aromatase inhibitor + metformin compared to clomiphene + metformin
Sohrabvand 2006 (8) 10/30 3/30 1.6 % 4.50 [ 1.09, 18.50 ]
Subtotal (95% CI) 30 30 1.6 % 4.50 [ 1.09, 18.50 ]
Total events: 10 (Aromatase inhibitor), 3 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
4 Aromatase inhibitor + FSH compared to clomiphene + FSH
Foroozanfard 2011 (9) 18/60 16/60 8.9 % 1.18 [ 0.53, 2.61 ]
Subtotal (95% CI) 60 60 8.9 % 1.18 [ 0.53, 2.61 ]
Total events: 18 (Aromatase inhibitor), 16 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 882 901 100.0 % 1.64 [ 1.32, 2.04 ]
Total events: 256 (Aromatase inhibitor), 180 (Other agents for OI)
Heterogeneity: Chi2 = 8.25, df = 8 (P = 0.41); I2 =3%
Test for overall effect: Z = 4.43 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.75, df = 3 (P = 0.12), I2 =48%
0.2 0.5 1 2 5
Favours other OI agents Favours aromatase inhib
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(1) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(2) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(3) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(4) Cumulative live birth rate
(5) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(6) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(7) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day with metformin, 1500mg/day
(8) Clomiphene resistant women; Letrozole, 2.5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500mg/day
(9) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
Analysis 2.2. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 2 Live birth rate per BMI.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 2 Live birth rate per BMI
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 BMI > 25
Abu Hashim Sept 2010 (1) 36/123 36/127 20.7 % 1.05 [ 0.60, 1.81 ]
Dehbashi 2009 (2) 10/50 6/50 4.0 % 1.83 [ 0.61, 5.50 ]
Legro 2014 103/374 73/376 43.6 % 1.58 [ 1.12, 2.22 ]
Ray 2012 (3) 20/69 13/78 7.2 % 2.04 [ 0.93, 4.50 ]
Roy 2012 (4) 39/104 21/108 10.6 % 2.49 [ 1.34, 4.62 ]
Sohrabvand 2006 (5) 10/30 3/30 1.7 % 4.50 [ 1.09, 18.50 ]
Subtotal (95% CI) 750 769 87.7 % 1.67 [ 1.31, 2.11 ]
Total events: 218 (Aromatase inhibitor), 152 (Other agents for OI)
Heterogeneity: Chi2 = 6.65, df = 5 (P = 0.25); I2 =25%
Test for overall effect: Z = 4.21 (P = 0.000025)
2 BMI < 25
Begum 2009 (6) 12/32 6/32 3.1 % 2.60 [ 0.83, 8.13 ]
0.01 0.1 1 10 100
Favours other OI agents Favours aromatase inhib
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(. . . Continued)
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Foroozanfard 2011 (7) 18/60 16/60 9.2 % 1.18 [ 0.53, 2.61 ]
Subtotal (95% CI) 92 92 12.3 % 1.54 [ 0.81, 2.93 ]
Total events: 30 (Aromatase inhibitor), 22 (Other agents for OI)
Heterogeneity: Chi2 = 1.24, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 842 861 100.0 % 1.65 [ 1.32, 2.06 ]
Total events: 248 (Aromatase inhibitor), 174 (Other agents for OI)
Heterogeneity: Chi2 = 7.95, df = 7 (P = 0.34); I2 =12%
Test for overall effect: Z = 4.40 (P = 0.000011)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.81), I2 =0.0%
0.01 0.1 1 10 100
Favours other OI agents Favours aromatase inhib
(1) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day with metformin, 1500mg/day
(2) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(3) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(4) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(5) Clomiphene resistant women; Letrozole, 2.5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500mg/day
(6) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(7) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
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Analysis 2.3. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 3 Live birth rate per first or second line treatment.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 3 Live birth rate per first or second line treatment
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No previous Ovulation induction
Bayar 2006 (1) 8/40 7/40 53.8 % 1.18 [ 0.38, 3.63 ]
Dehbashi 2009 (2) 10/50 6/50 46.2 % 1.83 [ 0.61, 5.50 ]
Subtotal (95% CI) 90 90 100.0 % 1.48 [ 0.68, 3.24 ]
Total events: 18 (Aromatase inhibitor), 13 (Other agents for OI)
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
2 CC resistant women
Begum 2009 (3) 12/32 6/32 100.0 % 2.60 [ 0.83, 8.13 ]
Subtotal (95% CI) 32 32 100.0 % 2.60 [ 0.83, 8.13 ]
Total events: 12 (Aromatase inhibitor), 6 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
3 Unclear or mixed study population
Ray 2012 (4) 20/69 13/78 40.2 % 2.04 [ 0.93, 4.50 ]
Roy 2012 (5) 39/104 21/108 59.8 % 2.49 [ 1.34, 4.62 ]
Subtotal (95% CI) 173 186 100.0 % 2.31 [ 1.42, 3.76 ]
Total events: 59 (Aromatase inhibitor), 34 (Other agents for OI)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.36 (P = 0.00078)
Test for subgroup differences: Chi2 = 1.04, df = 2 (P = 0.59), I2 =0.0%
0.01 0.1 1 10 100
Favours other OI agents Favours aromatase inhib
(1) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(2) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(3) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(4) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(5) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
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Analysis 2.4. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 4 Impact of allocation bias for live birth rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 4 Impact of allocation bias for live birth rate
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Unclear risk of allocation
Bayar 2006 (1) 8/40 7/40 14.9 % 1.18 [ 0.38, 3.63 ]
Begum 2009 (2) 12/32 6/32 9.9 % 2.60 [ 0.83, 8.13 ]
Dehbashi 2009 (3) 10/50 6/50 12.7 % 1.83 [ 0.61, 5.50 ]
Ray 2012 (4) 20/69 13/78 23.0 % 2.04 [ 0.93, 4.50 ]
Roy 2012 (5) 39/104 21/108 34.2 % 2.49 [ 1.34, 4.62 ]
Sohrabvand 2006 (6) 10/30 3/30 5.3 % 4.50 [ 1.09, 18.50 ]
Subtotal (95% CI) 325 338 100.0 % 2.22 [ 1.53, 3.23 ]
Total events: 99 (Aromatase inhibitor), 56 (Other agents for OI)
Heterogeneity: Chi2 = 2.54, df = 5 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.20 (P = 0.000027)
2 Low risk of allocation
Abu Hashim Sept 2010 (7) 36/123 36/127 69.1 % 1.05 [ 0.60, 1.81 ]
Foroozanfard 2011 (8) 18/60 16/60 30.9 % 1.18 [ 0.53, 2.61 ]
Subtotal (95% CI) 183 187 100.0 % 1.09 [ 0.69, 1.71 ]
Total events: 54 (Aromatase inhibitor), 52 (Other agents for OI)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 5.75, df = 1 (P = 0.02), I2 =83%
0.01 0.1 1 10 100
Favours other OI agents Favours aromatase inhib
(1) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(2) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(3) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(4) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(5) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(6) Clomiphene resistant women; Letrozole, 2.5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500mg/day
(7) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day with metformin, 1500mg/day
(8) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
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Analysis 2.5. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 5 Impact of detection bias for live birth rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 5 Impact of detection bias for live birth rate
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High risk of detection
Begum 2009 (1) 12/32 6/32 100.0 % 2.60 [ 0.83, 8.13 ]
Subtotal (95% CI) 32 32 100.0 % 2.60 [ 0.83, 8.13 ]
Total events: 12 (Aromatase inhibitor), 6 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
2 Low risk of detection
Abu Hashim Sept 2010 (2) 36/123 36/127 58.2 % 1.05 [ 0.60, 1.81 ]
Dehbashi 2009 (3) 10/50 6/50 11.1 % 1.83 [ 0.61, 5.50 ]
Foroozanfard 2011 (4) 18/60 16/60 26.0 % 1.18 [ 0.53, 2.61 ]
Sohrabvand 2006 (5) 10/30 3/30 4.6 % 4.50 [ 1.09, 18.50 ]
Subtotal (95% CI) 263 267 100.0 % 1.33 [ 0.90, 1.97 ]
Total events: 74 (Aromatase inhibitor), 61 (Other agents for OI)
Heterogeneity: Chi2 = 4.01, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 1.41 (P = 0.16)
3 Unclear risk of detection
Bayar 2006 (6) 8/40 7/40 20.6 % 1.18 [ 0.38, 3.63 ]
Ray 2012 (7) 20/69 13/78 31.9 % 2.04 [ 0.93, 4.50 ]
Roy 2012 (8) 39/104 21/108 47.4 % 2.49 [ 1.34, 4.62 ]
Subtotal (95% CI) 213 226 100.0 % 2.07 [ 1.33, 3.24 ]
Total events: 67 (Aromatase inhibitor), 41 (Other agents for OI)
Heterogeneity: Chi2 = 1.30, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.21 (P = 0.0013)
Test for subgroup differences: Chi2 = 2.78, df = 2 (P = 0.25), I2 =28%
0.01 0.1 1 10 100
Favours other OI agents Favours aromatase inhib
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(1) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(2) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day with metformin, 1500mg/day
(3) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(4) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
(5) Clomiphene resistant women; Letrozole, 2.5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500mg/day
(6) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(7) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(8) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
Analysis 2.6. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 6 Impact of attrition bias for live birth rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 6 Impact of attrition bias for live birth rate
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Unclear risk of attrition
Ray 2012 (1) 20/69 13/78 100.0 % 2.04 [ 0.93, 4.50 ]
Subtotal (95% CI) 69 78 100.0 % 2.04 [ 0.93, 4.50 ]
Total events: 20 (Aromatase inhibitor), 13 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
2 Low risk of attrition
Abu Hashim Sept 2010 (2) 36/123 36/127 38.4 % 1.05 [ 0.60, 1.81 ]
Bayar 2006 (3) 8/40 7/40 8.6 % 1.18 [ 0.38, 3.63 ]
Begum 2009 (4) 12/32 6/32 5.7 % 2.60 [ 0.83, 8.13 ]
Dehbashi 2009 (5) 10/50 6/50 7.4 % 1.83 [ 0.61, 5.50 ]
Foroozanfard 2011 (6) 18/60 16/60 17.2 % 1.18 [ 0.53, 2.61 ]
Roy 2012 (7) 39/104 21/108 19.7 % 2.49 [ 1.34, 4.62 ]
Sohrabvand 2006 (8) 10/30 3/30 3.1 % 4.50 [ 1.09, 18.50 ]
0.01 0.1 1 10 100
Favours other OI agents Favours aromatase inhib
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(. . . Continued)
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 439 447 100.0 % 1.62 [ 1.19, 2.19 ]
Total events: 133 (Aromatase inhibitor), 95 (Other agents for OI)
Heterogeneity: Chi2 = 7.92, df = 6 (P = 0.24); I2 =24%
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
0.01 0.1 1 10 100
Favours other OI agents Favours aromatase inhib
(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(2) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day with metformin, 1500mg/day
(3) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(4) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(5) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(6) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
(7) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(8) Clomiphene resistant women; Letrozole, 2.5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500mg/day
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Analysis 2.7. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 7 Ovarian hyperstimulation syndrome rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 7 Ovarian hyperstimulation syndrome rate
Study or subgroup Aromatase inhibitor Other agents for OI
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AIs versus clomiphene citrate
Badawy Sept 2009 (1) 0/218 0/220 20.1 % 0.0 [ -0.01, 0.01 ]
Bayar 2006 (2) 0/40 0/40 3.7 % 0.0 [ -0.05, 0.05 ]
Begum 2009 (3) 0/32 0/32 2.9 % 0.0 [ -0.06, 0.06 ]
Legro 2014 (4) 0/374 0/376 34.4 % 0.0 [ -0.01, 0.01 ]
Nazik 2012 (5) 0/31 0/33 2.9 % 0.0 [ -0.06, 0.06 ]
Roy 2012 (6) 0/104 2/108 9.7 % -0.02 [ -0.05, 0.01 ]
Selim 2012 (7) 0/102 0/99 9.2 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 901 908 83.0 % 0.00 [ -0.01, 0.00 ]
Total events: 0 (Aromatase inhibitor), 2 (Other agents for OI)
Heterogeneity: Chi2 = 2.03, df = 6 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
2 AI versus clomiphene + metformin
Abu Hashim Sept 2010 (8) 0/123 0/127 11.5 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 123 127 11.5 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Aromatase inhibitor), 0 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Aromatase inhibitor + hMG versus clomiphene + hMG
Foroozanfard 2011 (9) 0/60 0/60 5.5 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 60 60 5.5 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Aromatase inhibitor), 0 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1084 1095 100.0 % 0.00 [ -0.01, 0.00 ]
Total events: 0 (Aromatase inhibitor), 2 (Other agents for OI)
Heterogeneity: Chi2 = 1.84, df = 8 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 0.08, df = 2 (P = 0.96), I2 =0.0%
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(1) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(2) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(3) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(4) Cumulative live birth rate
(5) No previous ovulation induction; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(6) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(7) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus clomiphene,100mg/day
(8) 30% of the women were CC-resistant
(9) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
Analysis 2.8. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 8 Ovarian hyperstimulation syndrome rate per BMI.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 8 Ovarian hyperstimulation syndrome rate per BMI
Study or subgroup Aromatase inhibitor Other agents for OI
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 BMI > 25
Abu Hashim Sept 2010 (1) 0/123 0/127 15.1 % 0.0 [ -0.02, 0.02 ]
Badawy Sept 2009 (2) 0/218 0/220 26.5 % 0.0 [ -0.01, 0.01 ]
Legro 2014 (3) 0/374 0/376 45.5 % 0.0 [ -0.01, 0.01 ]
Roy 2012 (4) 0/104 2/108 12.8 % -0.02 [ -0.05, 0.01 ]
Subtotal (95% CI) 819 831 100.0 % 0.00 [ -0.01, 0.00 ]
Total events: 0 (Aromatase inhibitor), 2 (Other agents for OI)
Heterogeneity: Chi2 = 2.20, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
2 BMI < 25
Begum 2009 (5) 0/32 0/32 14.3 % 0.0 [ -0.06, 0.06 ]
Foroozanfard 2011 (6) 0/60 0/60 26.7 % 0.0 [ -0.03, 0.03 ]
Nazik 2012 (7) 0/31 0/33 14.2 % 0.0 [ -0.06, 0.06 ]
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Study or subgroup Aromatase inhibitor Other agents for OI
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Selim 2012 (8) 0/102 0/99 44.8 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 225 224 100.0 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Aromatase inhibitor), 0 (Other agents for OI)
Heterogeneity: Chi2 = 0.0, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
-1 -0.5 0 0.5 1
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(1) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day with metformin, 1500mg/day
(2) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(3) Cumulative live birth rate
(4) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(5) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(6) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
(7) No previous ovulation induction; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(8) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus clomiphene,100mg/day
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Analysis 2.9. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 9 Clinical pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 9 Clinical pregnancy rate
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AIs versus clomiphene citrate
Atay 2006 (1) 11/51 5/55 1.6 % 2.75 [ 0.88, 8.56 ]
Badawy Sept 2009 (2) 82/218 94/220 25.0 % 0.81 [ 0.55, 1.18 ]
Bayar 2006 (3) 9/40 7/40 2.3 % 1.37 [ 0.45, 4.12 ]
Begum 2009 (4) 13/32 6/32 1.5 % 2.96 [ 0.95, 9.21 ]
Dehbashi 2009 (5) 13/50 7/50 2.2 % 2.16 [ 0.78, 5.98 ]
Legro 2014 117/374 81/376 23.8 % 1.66 [ 1.19, 2.30 ]
Nazik 2012 (6) 7/31 8/33 2.6 % 0.91 [ 0.29, 2.90 ]
Ray 2012 (7) 20/69 14/78 4.0 % 1.87 [ 0.86, 4.06 ]
Roy 2012 (8) 43/104 28/108 6.9 % 2.01 [ 1.13, 3.60 ]
Selim 2012 (9) 29/102 20/99 6.2 % 1.57 [ 0.82, 3.01 ]
Sh-El-Arab Elsedeek 2011 (10) 20/62 16/62 4.6 % 1.37 [ 0.63, 2.98 ]
Subtotal (95% CI) 1133 1153 80.8 % 1.44 [ 1.20, 1.73 ]
Total events: 364 (Aromatase inhibitor), 286 (Other agents for OI)
Heterogeneity: Chi2 = 15.26, df = 10 (P = 0.12); I2 =34%
Test for overall effect: Z = 3.88 (P = 0.00011)
2 AI versus clomiphene + metformin
Abu Hashim Sept 2010 (11) 42/123 43/127 11.9 % 1.01 [ 0.60, 1.71 ]
Subtotal (95% CI) 123 127 11.9 % 1.01 [ 0.60, 1.71 ]
Total events: 42 (Aromatase inhibitor), 43 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 Aromatase inhibitor + metformin versus clomiphene + metformin
Davar 2011 (12) 4/50 1/50 0.4 % 4.26 [ 0.46, 39.54 ]
Sohrabvand 2006 (13) 10/30 5/30 1.4 % 2.50 [ 0.74, 8.50 ]
Subtotal (95% CI) 80 80 1.8 % 2.88 [ 0.99, 8.36 ]
Total events: 14 (Aromatase inhibitor), 6 (Other agents for OI)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.052)
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Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
4 Aromatase inhibitor + FSH versus clomiphene + FSH
Foroozanfard 2011 (14) 22/60 20/60 5.4 % 1.16 [ 0.55, 2.45 ]
Subtotal (95% CI) 60 60 5.4 % 1.16 [ 0.55, 2.45 ]
Total events: 22 (Aromatase inhibitor), 20 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 1396 1420 100.0 % 1.40 [ 1.18, 1.65 ]
Total events: 442 (Aromatase inhibitor), 355 (Other agents for OI)
Heterogeneity: Chi2 = 18.88, df = 14 (P = 0.17); I2 =26%
Test for overall effect: Z = 3.95 (P = 0.000078)
Test for subgroup differences: Chi2 = 3.57, df = 3 (P = 0.31), I2 =16%
0.01 0.1 1 10 100
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(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 100mg/day
(2) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(3) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(4) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(5) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(6) No previous ovulation induction; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(7) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(8) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(9) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus clomiphene,100mg/day
(10) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(11) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day
(12) Clomiphene resistant women; Letrozole, 5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500 mg/day
(13) Clomiphene resistant women; Letrozole, 2.5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500mg/day
(14) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
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Analysis 2.10. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 10 Impact of allocation bias for clinical pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 10 Impact of allocation bias for clinical pregnancy rate
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Unclear risk of allocation
Atay 2006 (1) 11/51 5/55 5.9 % 2.75 [ 0.88, 8.56 ]
Bayar 2006 (2) 9/40 7/40 8.4 % 1.37 [ 0.45, 4.12 ]
Begum 2009 (3) 13/32 6/32 5.5 % 2.96 [ 0.95, 9.21 ]
Davar 2011 (4) 4/50 1/50 1.4 % 4.26 [ 0.46, 39.54 ]
Dehbashi 2009 (5) 13/50 7/50 8.0 % 2.16 [ 0.78, 5.98 ]
Nazik 2012 (6) 7/31 8/33 9.3 % 0.91 [ 0.29, 2.90 ]
Ray 2012 (7) 20/69 14/78 14.5 % 1.87 [ 0.86, 4.06 ]
Roy 2012 (8) 43/104 28/108 25.0 % 2.01 [ 1.13, 3.60 ]
Sh-El-Arab Elsedeek 2011 (9) 20/62 16/62 16.8 % 1.37 [ 0.63, 2.98 ]
Sohrabvand 2006 (10) 10/30 5/30 5.2 % 2.50 [ 0.74, 8.50 ]
Subtotal (95% CI) 519 538 100.0 % 1.89 [ 1.41, 2.54 ]
Total events: 150 (Aromatase inhibitor), 97 (Other agents for OI)
Heterogeneity: Chi2 = 4.36, df = 9 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.22 (P = 0.000024)
2 Low risk of allocation
Abu Hashim Sept 2010 (11) 42/123 43/127 24.6 % 1.01 [ 0.60, 1.71 ]
Badawy Sept 2009 (12) 82/218 94/220 51.5 % 0.81 [ 0.55, 1.18 ]
Foroozanfard 2011 (13) 22/60 20/60 11.2 % 1.16 [ 0.55, 2.45 ]
Selim 2012 (14) 29/102 20/99 12.8 % 1.57 [ 0.82, 3.01 ]
Subtotal (95% CI) 503 506 100.0 % 0.99 [ 0.77, 1.29 ]
Total events: 175 (Aromatase inhibitor), 177 (Other agents for OI)
Heterogeneity: Chi2 = 3.17, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 10.20, df = 1 (P = 0.00), I2 =90%
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(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 100mg/day
(2) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(3) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(4) Clomiphene resistant women; Letrozole, 5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500 mg/day
(5) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(6) No previous ovulation induction; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(7) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(8) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(9) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(10) Clomiphene resistant women; Letrozole, 2.5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500mg/day
(11) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day
(12) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(13) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
(14) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus clomiphene,100mg/day
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Analysis 2.11. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 11 Miscarriage rate per woman randomised.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 11 Miscarriage rate per woman randomised
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AIs versus clomiphene citrate
Badawy Sept 2009 (1) 4/218 4/220 7.4 % 1.01 [ 0.25, 4.09 ]
Bayar 2006 (2) 1/40 0/40 0.9 % 3.08 [ 0.12, 77.80 ]
Begum 2009 (3) 1/32 0/32 0.9 % 3.10 [ 0.12, 78.87 ]
Dehbashi 2009 (4) 3/50 1/50 1.8 % 3.13 [ 0.31, 31.14 ]
Legro 2014 49/374 30/376 49.0 % 1.74 [ 1.08, 2.81 ]
Nazik 2012 (5) 1/31 1/33 1.8 % 1.07 [ 0.06, 17.83 ]
Ray 2012 (6) 0/69 1/78 2.6 % 0.37 [ 0.01, 9.27 ]
Roy 2012 (7) 4/104 7/108 12.4 % 0.58 [ 0.16, 2.03 ]
Subtotal (95% CI) 918 937 76.8 % 1.48 [ 1.00, 2.20 ]
Total events: 63 (Aromatase inhibitor), 44 (Other agents for OI)
Heterogeneity: Chi2 = 4.44, df = 7 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
2 AI versus clomiphene + metformin
Abu Hashim Sept 2010 (8) 4/123 4/127 7.2 % 1.03 [ 0.25, 4.23 ]
Subtotal (95% CI) 123 127 7.2 % 1.03 [ 0.25, 4.23 ]
Total events: 4 (Aromatase inhibitor), 4 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 Aromatase inhibitor + metformin versus clomiphene + metformin
Davar 2011 (9) 0/50 1/50 2.8 % 0.33 [ 0.01, 8.21 ]
Sohrabvand 2006 (10) 0/30 2/30 4.6 % 0.19 [ 0.01, 4.06 ]
Subtotal (95% CI) 80 80 7.4 % 0.24 [ 0.03, 2.19 ]
Total events: 0 (Aromatase inhibitor), 3 (Other agents for OI)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.21)
4 Aromatase inhibitor + FSH versus clomiphene + FSH
Foroozanfard 2011 (11) 5/60 5/60 8.6 % 1.00 [ 0.27, 3.65 ]
Subtotal (95% CI) 60 60 8.6 % 1.00 [ 0.27, 3.65 ]
Total events: 5 (Aromatase inhibitor), 5 (Other agents for OI)
0.5 0.7 1 1.5 2
Favours aromatase inhib Favours other OI agents
(Continued . . . )
97Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1181 1204 100.0 % 1.32 [ 0.92, 1.88 ]
Total events: 72 (Aromatase inhibitor), 56 (Other agents for OI)
Heterogeneity: Chi2 = 7.32, df = 11 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 2.90, df = 3 (P = 0.41), I2 =0.0%
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(1) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(2) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(3) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(4) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(5) No previous ovulation induction; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(6) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(7) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(8) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day
(9) Clomiphene resistant women; Letrozole, 5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500 mg/day
(10) Clomiphene resistant women; Letrozole, 2.5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500mg/day
(11) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
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Analysis 2.12. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 12 Miscarriage rate per pregnancy.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 12 Miscarriage rate per pregnancy
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AIs versus clomiphene citrate
Badawy Sept 2009 (1) 4/82 4/94 7.2 % 1.15 [ 0.28, 4.77 ]
Bayar 2006 (2) 1/9 0/7 1.0 % 2.65 [ 0.09, 75.29 ]
Begum 2009 (3) 1/13 0/6 1.2 % 1.56 [ 0.06, 43.93 ]
Dehbashi 2009 (4) 3/13 1/7 2.0 % 1.80 [ 0.15, 21.48 ]
Legro 2014 49/117 30/81 42.0 % 1.23 [ 0.68, 2.19 ]
Nazik 2012 (5) 1/7 1/8 1.6 % 1.17 [ 0.06, 22.94 ]
Ray 2012 (6) 0/20 1/14 3.5 % 0.22 [ 0.01, 5.80 ]
Roy 2012 (7) 4/43 7/28 15.7 % 0.31 [ 0.08, 1.17 ]
Subtotal (95% CI) 304 245 74.2 % 1.02 [ 0.64, 1.60 ]
Total events: 63 (Aromatase inhibitor), 44 (Other agents for OI)
Heterogeneity: Chi2 = 4.92, df = 7 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
2 AI versus clomiphene + metformin
Abu Hashim Sept 2010 (8) 4/42 4/43 7.3 % 1.03 [ 0.24, 4.40 ]
Subtotal (95% CI) 42 43 7.3 % 1.03 [ 0.24, 4.40 ]
Total events: 4 (Aromatase inhibitor), 4 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
3 Aromatase inhibitor + metformin versus clomiphene + metformin
Davar 2011 (9) 0/4 1/1 3.9 % 0.04 [ 0.00, 2.82 ]
Sohrabvand 2006 (10) 0/10 2/5 6.3 % 0.07 [ 0.00, 1.75 ]
Subtotal (95% CI) 14 6 10.2 % 0.06 [ 0.00, 0.77 ]
Total events: 0 (Aromatase inhibitor), 3 (Other agents for OI)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
4 Aromatase inhibitor + FSH versus clomiphene + FSH
Foroozanfard 2011 (11) 5/22 5/20 8.3 % 0.88 [ 0.21, 3.65 ]
Subtotal (95% CI) 22 20 8.3 % 0.88 [ 0.21, 3.65 ]
Total events: 5 (Aromatase inhibitor), 5 (Other agents for OI)
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Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
Total (95% CI) 382 314 100.0 % 0.91 [ 0.61, 1.36 ]
Total events: 72 (Aromatase inhibitor), 56 (Other agents for OI)
Heterogeneity: Chi2 = 9.75, df = 11 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 4.59, df = 3 (P = 0.20), I2 =35%
0.5 0.7 1 1.5 2
Favours aromatase inhib Favours other OI agents
(1) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(2) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(3) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(4) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(5) No previous ovulation induction; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(6) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(7) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(8) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day
(9) Clomiphene resistant women; Letrozole, 5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500 mg/day
(10) Clomiphene resistant women; Letrozole, 2.5 mg/day + metformin, 1500 mg/day versus clomiphene, 100 mg/day + metformin, 1500mg/day
(11) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
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Analysis 2.13. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without
adjuncts, followed by timed intercourse, Outcome 13 Multiple pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse
Outcome: 13 Multiple pregnancy rate
Study or subgroup Aromatase inhibitor Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AIs versus clomiphene citrate
Atay 2006 (1) 0/51 1/55 6.5 % 0.35 [ 0.01, 8.86 ]
Badawy Sept 2009 (2) 0/218 3/220 15.8 % 0.14 [ 0.01, 2.77 ]
Bayar 2006 (3) 0/40 0/40 Not estimable
Begum 2009 (4) 0/32 0/32 Not estimable
Dehbashi 2009 (5) 1/50 1/50 4.4 % 1.00 [ 0.06, 16.44 ]
Legro 2014 (6) 4/374 6/376 26.8 % 0.67 [ 0.19, 2.38 ]
Nazik 2012 (7) 0/31 1/33 6.5 % 0.34 [ 0.01, 8.76 ]
Roy 2012 (8) 0/104 3/108 15.5 % 0.14 [ 0.01, 2.83 ]
Selim 2012 (9) 0/102 0/99 Not estimable
Subtotal (95% CI) 1002 1013 75.5 % 0.41 [ 0.17, 1.01 ]
Total events: 5 (Aromatase inhibitor), 15 (Other agents for OI)
Heterogeneity: Chi2 = 1.92, df = 5 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.052)
2 AI versus clomiphene + metformin
Abu Hashim Sept 2010 (10) 0/123 3/127 15.6 % 0.14 [ 0.01, 2.82 ]
Subtotal (95% CI) 123 127 15.6 % 0.14 [ 0.01, 2.82 ]
Total events: 0 (Aromatase inhibitor), 3 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
3 Aromatase inhibitor + FSH versus clomiphene + FSH
Foroozanfard 2011 (11) 1/60 2/60 8.9 % 0.49 [ 0.04, 5.57 ]
Subtotal (95% CI) 60 60 8.9 % 0.49 [ 0.04, 5.57 ]
Total events: 1 (Aromatase inhibitor), 2 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 1185 1200 100.0 % 0.38 [ 0.17, 0.84 ]
Total events: 6 (Aromatase inhibitor), 20 (Other agents for OI)
Heterogeneity: Chi2 = 2.49, df = 7 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Chi2 = 0.48, df = 2 (P = 0.78), I2 =0.0%
0.01 0.1 1 10 100
Favours aromatase inhib Favours other OI agents
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(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 100mg/day
(2) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(3) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(4) CC-resistant women; Letrozole, 7.5 mg/day versus clomiphene, 150mg/day
(5) No previous ovulation induction; Letrozole, 5 mg/day versus clomiphene, 100mg/day
(6) Cumulative live birth
(7) No previous ovulation induction; Letrozole, 2.5 mg/day versus clomiphene, 100mg/day
(8) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5-5 mg/day versus clomiphene, 50-100mg/day
(9) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus clomiphene,100mg/day
(10) 30% of the women were CC-resistant; Letrozole, 2.5mg/day versus clomiphene, 150mg/day
(11) Clomiphene resistant women; Letrozole, 5 mg/day + 150 UI hMG versus clomiphene, 100 mg/day + 150 UI hMG
Analysis 3.1. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts
followed by IUI, Outcome 1 Ovarian hyperstimulation syndrome rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI
Outcome: 1 Ovarian hyperstimulation syndrome rate
Study or subgroup Aromatase inhibitors Other agents for OI
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus Clomiphene
Zeinalzadeh 2010 0/50 1/57 8.9 % -0.02 [ -0.07, 0.03 ]
Subtotal (95% CI) 50 57 8.9 % -0.02 [ -0.07, 0.03 ]
Total events: 0 (Aromatase inhibitors), 1 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2 AI versus Clomiphene +rFSH and rFSH only
Ganesh 2009 0/372 2/1015 91.1 % 0.00 [ -0.01, 0.00 ]
Subtotal (95% CI) 372 1015 91.1 % 0.00 [ -0.01, 0.00 ]
Total events: 0 (Aromatase inhibitors), 2 (Other agents for OI)
Heterogeneity: not applicable
-0.1 -0.05 0 0.05 0.1
Favors Aromatase inhib Favours other OI agents
(Continued . . . )
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(. . . Continued)
Study or subgroup Aromatase inhibitors Other agents for OI
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 422 1072 100.0 % 0.00 [ -0.01, 0.00 ]
Total events: 0 (Aromatase inhibitors), 3 (Other agents for OI)
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
-0.1 -0.05 0 0.05 0.1
Favors Aromatase inhib Favours other OI agents
Analysis 3.2. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts
followed by IUI, Outcome 2 Clinical pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI
Outcome: 2 Clinical pregnancy rate
Study or subgroup Aromatase inhibitors Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus Clomiphene
Kar 2012 11/52 4/51 4.3 % 3.15 [ 0.93, 10.66 ]
Zeinalzadeh 2010 10/50 8/57 8.1 % 1.53 [ 0.55, 4.24 ]
Subtotal (95% CI) 102 108 12.4 % 2.09 [ 0.97, 4.53 ]
Total events: 21 (Aromatase inhibitors), 12 (Other agents for OI)
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
2 AI versus Clomiphene +rFSH and rFSH only
Ganesh 2009 87/372 158/1015 87.6 % 1.66 [ 1.23, 2.22 ]
Subtotal (95% CI) 372 1015 87.6 % 1.66 [ 1.23, 2.22 ]
Total events: 87 (Aromatase inhibitors), 158 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 3.36 (P = 0.00077)
Total (95% CI) 474 1123 100.0 % 1.71 [ 1.30, 2.25 ]
0.2 0.5 1 2 5
Favours other OI agents Favours Aromatase inhib
(Continued . . . )
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(. . . Continued)
Study or subgroup Aromatase inhibitors Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 108 (Aromatase inhibitors), 170 (Other agents for OI)
Heterogeneity: Chi2 = 1.06, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.84 (P = 0.00012)
Test for subgroup differences: Chi2 = 0.31, df = 1 (P = 0.58), I2 =0.0%
0.2 0.5 1 2 5
Favours other OI agents Favours Aromatase inhib
Analysis 3.3. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts
followed by IUI, Outcome 3 Miscarriage rate per woman randomised.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI
Outcome: 3 Miscarriage rate per woman randomised
Study or subgroup Aromatase inhibitors Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus Clomiphene
Kar 2012 0/52 1/51 10.4 % 0.32 [ 0.01, 8.06 ]
Subtotal (95% CI) 52 51 10.4 % 0.32 [ 0.01, 8.06 ]
Total events: 0 (Aromatase inhibitors), 1 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 AI versus Clomiphene +rFSH and rFSH only
Ganesh 2009 12/372 25/1015 89.6 % 1.32 [ 0.66, 2.65 ]
Subtotal (95% CI) 372 1015 89.6 % 1.32 [ 0.66, 2.65 ]
Total events: 12 (Aromatase inhibitors), 25 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 424 1066 100.0 % 1.22 [ 0.62, 2.40 ]
Total events: 12 (Aromatase inhibitors), 26 (Other agents for OI)
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
0.2 0.5 1 2 5
Favours Aromatase inhib Favours other OI agents
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Analysis 3.4. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts
followed by IUI, Outcome 4 Miscarriage rate per pregnancies.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI
Outcome: 4 Miscarriage rate per pregnancies
Study or subgroup Aromatase inhibitors Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus Clomiphene
Kar 2012 0/11 1/4 11.7 % 0.10 [ 0.00, 3.09 ]
Subtotal (95% CI) 11 4 11.7 % 0.10 [ 0.00, 3.09 ]
Total events: 0 (Aromatase inhibitors), 1 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
2 AI versus Clomiphene +rFSH and rFSH only
Ganesh 2009 12/87 25/158 88.3 % 0.85 [ 0.40, 1.79 ]
Subtotal (95% CI) 87 158 88.3 % 0.85 [ 0.40, 1.79 ]
Total events: 12 (Aromatase inhibitors), 25 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Total (95% CI) 98 162 100.0 % 0.76 [ 0.37, 1.57 ]
Total events: 12 (Aromatase inhibitors), 26 (Other agents for OI)
Heterogeneity: Chi2 = 1.42, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Chi2 = 1.42, df = 1 (P = 0.23), I2 =30%
0.2 0.5 1 2 5
Favours Aromatase inhib Favours other OI agents
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Analysis 3.5. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts
followed by IUI, Outcome 5 Multiple pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI
Outcome: 5 Multiple pregnancy rate
Study or subgroup Aromatase inhibitors Other agents for OI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus Clomiphene
Kar 2012 0/52 0/51 Not estimable
Zeinalzadeh 2010 1/50 0/57 3.2 % 3.48 [ 0.14, 87.49 ]
Subtotal (95% CI) 102 108 3.2 % 3.48 [ 0.14, 87.49 ]
Total events: 1 (Aromatase inhibitors), 0 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
2 AI versus Clomiphene +rFSH and rFSH only
Ganesh 2009 9/372 26/1015 96.8 % 0.94 [ 0.44, 2.03 ]
Subtotal (95% CI) 372 1015 96.8 % 0.94 [ 0.44, 2.03 ]
Total events: 9 (Aromatase inhibitors), 26 (Other agents for OI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 474 1123 100.0 % 1.03 [ 0.49, 2.13 ]
Total events: 10 (Aromatase inhibitors), 26 (Other agents for OI)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Chi2 = 0.60, df = 1 (P = 0.44), I2 =0.0%
0.2 0.5 1 2 5
Favors Aromatase inhib Favours other OI agents
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Analysis 4.1. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 1
Live birth rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 4 Aromatase inhibitors compared to laparoscopic ovarian drilling
Outcome: 1 Live birth rate
Study or subgroup Aromatase inhibitor LOD Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdellah 2011 (1) 23/74 16/73 31.3 % 1.61 [ 0.77, 3.37 ]
Abu Hashim June 2010 (2) 32/128 33/132 68.7 % 1.00 [ 0.57, 1.75 ]
Total (95% CI) 202 205 100.0 % 1.19 [ 0.76, 1.86 ]
Total events: 55 (Aromatase inhibitor), 49 (LOD)
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LOD Favours Letrozole
(1) Clomiphene resistant women; Letrozole 5 mg/day versus LOD
(2) Clomiphene resistant women; Letrozole 2.5 mg/day versus LOD
Analysis 4.2. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 2
Ovarian hyperstimulation syndrome rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 4 Aromatase inhibitors compared to laparoscopic ovarian drilling
Outcome: 2 Ovarian hyperstimulation syndrome rate
Study or subgroup Aromatase inhibitor LOD
Risk
Difference
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abu Hashim June 2010 (1) 0/128 0/132 0.0 [ -0.01, 0.01 ]
-0.02 -0.01 0 0.01 0.02
Favours Letrozole Favours LOD
(1) Clomiphene resistant women; Letrozole 2.5 mg/day versus LOD
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Analysis 4.3. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 3
Clinical pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 4 Aromatase inhibitors compared to laparoscopic ovarian drilling
Outcome: 3 Clinical pregnancy rate
Study or subgroup Aromatase inhibitor LOD Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus LOD
Abdellah 2011 (1) 25/74 20/73 24.5 % 1.35 [ 0.67, 2.74 ]
Abu Hashim June 2010 (2) 36/128 37/132 48.2 % 1.00 [ 0.58, 1.73 ]
Subtotal (95% CI) 202 205 72.7 % 1.12 [ 0.73, 1.72 ]
Total events: 61 (Aromatase inhibitor), 57 (LOD)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
2 AI + metformin versus LOD
Elgafor 2013 26/73 23/73 27.3 % 1.20 [ 0.60, 2.39 ]
Subtotal (95% CI) 73 73 27.3 % 1.20 [ 0.60, 2.39 ]
Total events: 26 (Aromatase inhibitor), 23 (LOD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Total (95% CI) 275 278 100.0 % 1.14 [ 0.80, 1.65 ]
Total events: 87 (Aromatase inhibitor), 80 (LOD)
Heterogeneity: Chi2 = 0.46, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
0.01 0.1 1 10 100
Favours LOD Favours Letrozole
(1) Clomiphene resistant women; Letrozole 5 mg/day versus LOD
(2) Clomiphene resistant women; Letrozole 2.5 mg/day versus LOD
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Analysis 4.4. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 4
Miscarriage rate per woman randomised.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 4 Aromatase inhibitors compared to laparoscopic ovarian drilling
Outcome: 4 Miscarriage rate per woman randomised
Study or subgroup Aromatase inhibitor LOD Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus LOD
Abdellah 2011 (1) 2/74 4/73 37.1 % 0.48 [ 0.09, 2.70 ]
Abu Hashim June 2010 (2) 4/128 4/132 36.1 % 1.03 [ 0.25, 4.22 ]
Subtotal (95% CI) 202 205 73.2 % 0.75 [ 0.26, 2.20 ]
Total events: 6 (Aromatase inhibitor), 8 (LOD)
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
2 AI + metformin versus LOD
Elgafor 2013 4/73 3/73 26.8 % 1.35 [ 0.29, 6.27 ]
Subtotal (95% CI) 73 73 26.8 % 1.35 [ 0.29, 6.27 ]
Total events: 4 (Aromatase inhibitor), 3 (LOD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 275 278 100.0 % 0.91 [ 0.38, 2.19 ]
Total events: 10 (Aromatase inhibitor), 11 (LOD)
Heterogeneity: Chi2 = 0.82, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
0.01 0.1 1 10 100
Favours Letrozole Favours LOD
(1) Clomiphene resistant women; Letrozole 5 mg/day versus LOD
(2) Clomiphene resistant women; Letrozole 2.5 mg/day versus LOD
109Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.5. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 5
Miscarriage rate per pregnancies.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 4 Aromatase inhibitors compared to laparoscopic ovarian drilling
Outcome: 5 Miscarriage rate per pregnancies
Study or subgroup Aromatase inhibitor LOD Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus LOD
Abdellah 2011 (1) 2/25 4/20 39.7 % 0.35 [ 0.06, 2.13 ]
Abu Hashim June 2010 (2) 4/36 4/37 34.1 % 1.03 [ 0.24, 4.48 ]
Subtotal (95% CI) 61 57 73.8 % 0.66 [ 0.22, 2.03 ]
Total events: 6 (Aromatase inhibitor), 8 (LOD)
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 AI + metformin versus LOD
Elgafor 2013 4/26 3/23 26.2 % 1.21 [ 0.24, 6.09 ]
Subtotal (95% CI) 26 23 26.2 % 1.21 [ 0.24, 6.09 ]
Total events: 4 (Aromatase inhibitor), 3 (LOD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 87 80 100.0 % 0.81 [ 0.32, 2.01 ]
Total events: 10 (Aromatase inhibitor), 11 (LOD)
Heterogeneity: Chi2 = 1.18, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
0.01 0.1 1 10 100
Favours Letrozole Favours LOD
(1) Clomiphene resistant women; Letrozole 5 mg/day versus LOD
(2) Clomiphene resistant women; Letrozole 2.5 mg/day versus LOD
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Analysis 4.6. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 6
Multiple pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 4 Aromatase inhibitors compared to laparoscopic ovarian drilling
Outcome: 6 Multiple pregnancy rate
Study or subgroup Aromatase inhibitor LOD Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdellah 2011 (1) 0/74 0/73 Not estimable
Abu Hashim June 2010 (2) 0/128 0/132 Not estimable
Total (95% CI) 202 205 Not estimable
Total events: 0 (Aromatase inhibitor), 0 (LOD)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Letrozole Favours LOD
(1) Clomiphene resistant women; Letrozole 5 mg/day versus LOD
(2) Clomiphene resistant women; Letrozole 2.5 mg/day versus LOD
Analysis 5.1. Comparison 5 Letrozole compared to anastrozole, Outcome 1 Ovarian hyperstimulation
syndrome rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 5 Letrozole compared to anastrozole
Outcome: 1 Ovarian hyperstimulation syndrome rate
Study or subgroup Letrozole Anastrozole
Risk
Difference
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Badawy 2008 (1) 0/111 0/109 0.0 [ -0.02, 0.02 ]
-0.02 -0.01 0 0.01 0.02
Favours Letrozole Favours Anastrozole
(1) Clomiphene resistant women; Letrozole, 2.5 mg/day versus anastrozole, 1 mg/day
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Analysis 5.2. Comparison 5 Letrozole compared to anastrozole, Outcome 2 Clinical pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 5 Letrozole compared to anastrozole
Outcome: 2 Clinical pregnancy rate
Study or subgroup Letrozole Anastrozole Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al-Omari 2004 (1) 6/22 3/18 7.7 % 1.88 [ 0.40, 8.88 ]
Badawy 2008 (2) 36/111 42/109 92.3 % 0.77 [ 0.44, 1.33 ]
Total (95% CI) 133 127 100.0 % 0.85 [ 0.51, 1.43 ]
Total events: 42 (Letrozole), 45 (Anastrozole)
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Anastrozole Favours Letrozole
(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus anastrozole, 1 mg/day
(2) Clomiphene resistant women; Letrozole, 2.5 mg/day versus anastrozole, 1 mg/day
Analysis 5.3. Comparison 5 Letrozole compared to anastrozole, Outcome 3 Miscarriage rate per woman
randomised.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 5 Letrozole compared to anastrozole
Outcome: 3 Miscarriage rate per woman randomised
Study or subgroup Letrozole Anastrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Badawy 2008 (1) 4/111 4/109 0.98 [ 0.24, 4.03 ]
0.01 0.1 1 10 100
Favours Letrozole Favours Anastrozole
(1) Clomiphene resistant women; Letrozole, 2.5 mg/day versus anastrozole, 1 mg/day
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Analysis 5.4. Comparison 5 Letrozole compared to anastrozole, Outcome 4 Miscarriage rate per
pregnancies.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 5 Letrozole compared to anastrozole
Outcome: 4 Miscarriage rate per pregnancies
Study or subgroup Letrozole Anastrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Badawy 2008 (1) 4/36 4/42 1.19 [ 0.27, 5.13 ]
0.01 0.1 1 10 100
Favours Letrozole Favours Anastrozole
(1) Clomiphene resistant women; Letrozole, 2.5 mg/day versus anastrozole, 1 mg/day
Analysis 5.5. Comparison 5 Letrozole compared to anastrozole, Outcome 5 Multiple pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 5 Letrozole compared to anastrozole
Outcome: 5 Multiple pregnancy rate
Study or subgroup Letrozole Anastrozole Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al-Omari 2004 (1) 0/22 0/18 Not estimable
Badawy 2008 (2) 2/111 0/109 100.0 % 5.00 [ 0.24, 105.35 ]
Total (95% CI) 133 127 100.0 % 5.00 [ 0.24, 105.35 ]
Total events: 2 (Letrozole), 0 (Anastrozole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Letrozole Favours Anastrozole
(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 2.5 mg/day versus anastrozole, 1 mg/day
(2) Clomiphene resistant women; Letrozole, 2.5 mg/day versus anastrozole, 1 mg/day
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Analysis 6.1. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 1
Ovarian hyperstimulation syndrome rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 6 Five days compared to 10 days administration protocol of letrozole
Outcome: 1 Ovarian hyperstimulation syndrome rate
Study or subgroup 5 days Letrozole 10 days Letrozole
Risk
Difference
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Badawy July 2009 (1) 0/110 0/108 0.0 [ -0.02, 0.02 ]
-0.02 -0.01 0 0.01 0.02
Favours 5 days letrozole Favours 10 days letrozole
(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus 2.5 mg/day
Analysis 6.2. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 2
Clinical pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 6 Five days compared to 10 days administration protocol of letrozole
Outcome: 2 Clinical pregnancy rate
Study or subgroup 5 days Letrozole 10 days Letrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Badawy July 2009 (1) 28/110 38/108 0.63 [ 0.35, 1.13 ]
0.01 0.1 1 10 100
Favours 10 days Letrozole Favours 5 days Letrozole
(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus 2.5 mg/day
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Analysis 6.3. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 3
Miscarriage rate per woman randomised.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 6 Five days compared to 10 days administration protocol of letrozole
Outcome: 3 Miscarriage rate per woman randomised
Study or subgroup 5 days Letrozole 10 days Letrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Badawy July 2009 (1) 5/110 7/108 0.69 [ 0.21, 2.24 ]
0.01 0.1 1 10 100
Favours 5 days Letrozole Favours 10 days Letrozole
(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus 2.5 mg/day
Analysis 6.4. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 4
Miscarriage rate per pregnancies.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 6 Five days compared to 10 days administration protocol of letrozole
Outcome: 4 Miscarriage rate per pregnancies
Study or subgroup 5 days Letrozole 10 days Letrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Badawy July 2009 (1) 5/28 7/38 0.96 [ 0.27, 3.42 ]
0.01 0.1 1 10 100
Favours 5 days Letrozole Favours 10 days Letrozole
(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus 2.5 mg/day
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Analysis 6.5. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 5
Multiple pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 6 Five days compared to 10 days administration protocol of letrozole
Outcome: 5 Multiple pregnancy rate
Study or subgroup 5 days Letrozole 10 days Letrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Badawy July 2009 (1) 0/110 1/108 0.32 [ 0.01, 8.05 ]
0.01 0.1 1 10 100
Favours 5 days Letrozole Favours 10 days Letrozole
(1) Unknown if primary fertility treatment or CC-resistant; Letrozole, 5 mg/day versus 2.5 mg/day
Analysis 7.1. Comparison 7 Dosage studies of letrozole, Outcome 1 Ovarian hyperstimulation syndrome
rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 7 Dosage studies of letrozole
Outcome: 1 Ovarian hyperstimulation syndrome rate
Study or subgroup Letrozole Letrozole
Risk
Difference
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5mg vs 7.5mg letrozole
Ramezanzadeh 2011 (1) 0/40 0/40 0.0 [ -0.05, 0.05 ]
-0.1 -0.05 0 0.05 0.1
Favours Letrozole Favours Letrozole
(1) No previous ovulation induction treatment
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Analysis 7.2. Comparison 7 Dosage studies of letrozole, Outcome 2 Clinical pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 7 Dosage studies of letrozole
Outcome: 2 Clinical pregnancy rate
Study or subgroup Letrozole Letrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5mg vs 7.5mg letrozole
Ramezanzadeh 2011 (1) 7/40 7/40 1.00 [ 0.32, 3.17 ]
0.01 0.1 1 10 100
Favours Letrozole Favours Letrozole
(1) No previous ovulation induction treatment
Analysis 7.3. Comparison 7 Dosage studies of letrozole, Outcome 3 Miscarriage rate per woman
randomised.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 7 Dosage studies of letrozole
Outcome: 3 Miscarriage rate per woman randomised
Study or subgroup Letrozole Letrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5mg vs 7.5mg letrozole
Ramezanzadeh 2011 (1) 0/40 1/40 0.33 [ 0.01, 8.22 ]
0.01 0.1 1 10 100
Favours Letrozole Favours Letrozole
(1) No previous ovulation induction treatment
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Analysis 7.4. Comparison 7 Dosage studies of letrozole, Outcome 4 Miscarriage rate per pregnancies.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 7 Dosage studies of letrozole
Outcome: 4 Miscarriage rate per pregnancies
Study or subgroup Letrozole Letrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5mg vs 7.5mg letrozole
Ramezanzadeh 2011 (1) 0/7 1/7 0.29 [ 0.01, 8.39 ]
0.01 0.1 1 10 100
Favours Letrozole Favours Letrozole
(1) No previous ovulation induction treatment
Analysis 7.5. Comparison 7 Dosage studies of letrozole, Outcome 5 Multiple pregnancy rate.
Review: Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Comparison: 7 Dosage studies of letrozole
Outcome: 5 Multiple pregnancy rate
Study or subgroup Letrozole Letrozole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5mg vs 7.5mg letrozole
Ramezanzadeh 2011 (1) 1/40 1/40 1.00 [ 0.06, 16.56 ]
0.01 0.1 1 10 100
Favours Letrozole Favours Letrozole
(1) No previous ovulation induction treatment
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A D D I T I O N A L T A B L E S
Table 1. Subgroup characteristics for aromatase inhibitors versus other ovulation induction agents
Study LBR (AI ver-
sus other)
CPR (AI
versus other)
Age in years
(AI group vs
other group)
Exclu-
sion criteria
on age
BMI (AI
group versus
other group)
Exc. crit. on
BMI
Duration
of infertility
in years (AI
group versus
other group)
Exc. crit. on
duration of
infertility
Abu
Hashim
Sept 2010
36/123
vs
36/127
42/123
vs
43/127
28.3±2.7
vs
26.2±2.2
None stated 29.1±3.2
vs
30.1±2.3
None stated Not
reported
None stated
Atay 2006 Not
reported
11/51
vs
5/55
27.1±0.9
vs
26.2±1.1
None stated 26.1±1.91
vs
25.8±1.77
None stated 2.2±0.7
vs
2.4±0.9
None stated
Badawy Sept
2009
Not
reported
82/218
vs
94/220
27.1±3.2
vs
29.3±2.9
None stated 28.1±3.2
vs
27.1±3.1
None stated Not
reported
None stated
Bayar 2006 8/40
vs
7/40
9/40
vs
7/40
32.2±3.9
vs
30.6±4.0
None stated Not
reported
None stated 5 (1-10)
vs
3 (3-11)
None stated
Begum
2009;
12/32
vs
6/32
13/32
vs
6/32
25.47±3.98
vs
26.09±3.62
None stated 22.72±2.77
vs
23.63±3.23
None stated 2.66±1.11
vs
2.58±1.10
None stated
Davar 2011 Not
reported
4/50
vs
1/50
28.54±3.13
vs
29.55±3.47
None stated 28.98±3.83
vs
29.21±2.92
None stated 3.81
vs
3.76
None stated
Dehbashi
2009
10/50
vs
6/50
13/50
vs
7/50
23.62±2.92
vs
24.32±3.43
None stated 27.45±4.61
vs
27.09±3.61
None stated 2.00±1.34
vs
2.30±1.85
None stated
Foroozan-
fard
2011
18/60
vs
16/60
22/60
vs
16/60
25.8±3.75
vs
25.33±4.14
Aged 20 - 35
years
24.12±2.33
vs
24.87±2.00
None stated 2.76±2.27
vs
2.60±2.07
Infertility at
least for 1
year
Legro 2014 103/374
vs
73/376
117/374
vs
81/376
29±5
vs
28±4
Aged 18 - 40
years
35±10
vs
35±9
None stated Not
reported
None stated
Nazik 2012 Not
reported
7/31
vs
8/33
25.55±4.45
vs
27.80±6.18
None stated 24.66±3.57
vs
24.90±4.80
None stated 3.40±3.04
vs
4.40±3.58
None stated
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Table 1. Subgroup characteristics for aromatase inhibitors versus other ovulation induction agents (Continued)
Ray 2012 20/69
vs
13/78
20/69
vs
14/78
28 (19-35)
vs
29 (20-35)
None stated 28.8 (23.2-
34.6)
vs
28.5
(24.2 - 33.6)
None stated 2.2
vs
2.4
None stated
Roy 2012 39/104
vs
21/108
43/104
vs
28/108
26.1±1.8
vs
26.5±1.3
>35y were
excluded
25.8±2.1
vs
25.4±1.56
>28 were ex-
cluded
6.4±3.8
vs
5.8±3.1
<1 year in-
fertility
Selim 2012 Not
reported
29/102
vs
20/99
26.0±2.7
vs
25.1±3.1
None stated 24.4±4.3
vs
23.8±3.7
None stated 2.9±0.6
vs
2.6±0.7
None stated
Sh-El-Arab
Elsedeek
2011
Not
reported
20/62
vs
16/62
24.95±3.11
vs
25±3.59
None stated 27.7±3.48
vs
29.18±3.47
>35 were ex-
cluded
Not
reported
>5 years of
infertility
Sohrabvand
2006
10/30
vs
3/30
10/30
vs
5/30
28.24±3.11
vs
29.55±3.47
None stated 29.98±4.83
vs
30.21±3.92
None stated 3.78
vs
3.81
None stated
A P P E N D I C E S
Appendix 1. MDSG search strategy
Menstrual Disorders and Subfertility Group (MDSG) specialised register search for SFR1820 04.07.12
KeywordsCONTAINS “PolycysticOvary Syndrome”or “PCOS”or “*Ovulation Induction”or“ovulation stimulation”or “ovarian hyper-
stimulation”or“superovulation”or Title CONTAINS“Polycystic Ovary Syndrome”or “PCOS”or “*Ovulation Induction”or“ovulation
stimulation”or “ovarian hyperstimulation”or“superovulation”
AND
Keywords CONTAINS “aromatase inhibition”or“aromatase inhibitor” or “aromatase P450” or “Anastrozole” or “letozole” or “letro-
zole” or “Exemestane” or “arimidex” or Title CONTAINS “aromatase inhibition”or“aromatase inhibitor” or “aromatase P450” or
“Anastrozole” or “letozole” or “letrozole” or “Exemestane” or “arimidex”
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Appendix 2. CENTRAL search strategy
Database: EBM Reviews - Cochrane Central Register of Controlled Trials <August 2012>
Search Strategy:
1 exp Polycystic Ovary Syndrome/ (654)
2 Polycystic Ovar$.tw. (950)
3 PCOS.tw. (648)
4 PCOD.tw. (23)
5 stein leventh$.tw. (3)
6 (ovar$ adj2 sclerocystic).tw. (0)
7 (ovar$ adj2 degeneration).tw. (1)
8 PCO.tw. (309)
9 exp ovulation induction/ or exp superovulation/ (913)
10 (ovulat$ adj2 induc$).tw. (570)
11 superovulation.tw. (118)
12 (ovari$ adj2 hyperstimulat$).tw. (545)
13 (ovari$ adj2 stimulat$).tw. (725)
14 or/1-13 (2886)
15 exp aromatase inhibitors/ or exp aminoglutethimide/ or exp fadrozole/ (382)
16 aromatase inhibitor$.tw. (413)
17 aminoglutethimide.tw. (153)
18 Anastrozole.tw. (294)
19 Arimidex.tw. (142)
20 Letrozole.tw. (349)
21 Femara.tw. (27)
22 Exemestane.tw. (161)
23 Aromasin.tw. (16)
24 Vorozole.tw. (16)
25 Rivizor.tw. (3)
26 Formestane.tw. (33)
27 Lentaron.tw. (7)
28 Fadrozole.tw. (28)
29 Afema.tw. (0)
30 or/15-29 (1094)
31 14 and 30 (79)
This search was updated on 24 October 2013.
This search was again updated on 9 September 2014.
Appendix 3. MEDLINE search strategy
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
Search Strategy:
1 exp Polycystic Ovary Syndrome/ (9215)
2 Polycystic Ovar$.tw. (9130)
3 PCOS.tw. (5069)
4 PCOD.tw. (251)
5 stein leventh$.tw. (581)
6 (ovar$ adj2 sclerocystic).tw. (82)
7 (ovar$ adj2 degeneration).tw. (95)
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8 PCO.tw. (3483)
9 exp ovulation induction/ or exp superovulation/ (9645)
10 (ovulat$ adj2 induc$).tw. (6375)
11 superovulation.tw. (1611)
12 (ovari$ adj2 hyperstimulat$).tw. (3473)
13 (ovari$ adj2 stimulat$).tw. (4369)
14 or/1-13 (30073)
15 exp aromatase inhibitors/ or exp aminoglutethimide/ or exp fadrozole/ (5470)
16 aromatase inhibitor$.tw. (4418)
17 aminoglutethimide.tw. (1347)
18 Anastrozole.tw. (1141)
19 Arimidex.tw. (233)
20 Letrozole.tw. (1404)
21 Femara.tw. (76)
22 Exemestane.tw. (683)
23 Aromasin.tw. (27)
24 Vorozole.tw. (107)
25 Rivizor.tw. (5)
26 Formestane.tw. (121)
27 Lentaron.tw. (14)
28 Fadrozole.tw. (287)
29 Afema.tw. (4)
30 or/15-29 (7854)
31 14 and 30 (311)
32 randomized controlled trial.pt. (335020)
33 controlled clinical trial.pt. (84917)
34 randomized.ab. (250120)
35 placebo.tw. (142679)
36 clinical trials as topic.sh. (161941)
37 randomly.ab. (183109)
38 trial.ti. (107599)
39 (crossover or cross-over or cross over).tw. (54410)
40 or/32-39 (820536)
41 exp animals/ not humans.sh. (3771273)
42 40 not 41 (756998)
43 31 and 42 (90)
This search was updated on 24 October 2013.
This search was again updated on 9 September 2014.
Appendix 4. EMBASE search strategy
Database: Embase <1980 to 2012 Week 26>
Search Strategy:
1 exp ovary polycystic disease/ (14819)
2 Polycystic Ovar$.tw. (11706)
3 PCOS.tw. (6951)
4 PCOD.tw. (306)
5 stein leventh$.tw. (538)
6 (ovar$ adj2 sclerocystic).tw. (81)
7 (ovar$ adj2 degeneration).tw. (97)
8 PCO.tw. (2819)
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9 exp ovulation induction/ (10176)
10 (ovulat$ adj2 induc$).tw. (7214)
11 (ovari$ adj2 hyperstimulat$).tw. (4638)
12 superovulation.tw. (1691)
13 (ovari$ adj2 stimulat$).tw. (5910)
14 or/1-13 (36936)
15 exp aromatase inhibitor/ (17443)
16 aromatase inhibitor$.tw. (5958)
17 aminoglutethimide.tw. (1394)
18 Anastrozole.tw. (1668)
19 Arimidex.tw. (1489)
20 Letrozole.tw. (2124)
21 Femara.tw. (881)
22 Exemestane.tw. (1041)
23 Aromasin.tw. (423)
24 Vorozole.tw. (128)
25 Rivizor.tw. (27)
26 Formestane.tw. (159)
27 Lentaron.tw. (129)
28 Fadrozole.tw. (312)
29 Afema.tw. (25)
30 or/15-29 (18269)
31 14 and 30 (696)
32 Clinical Trial/ (870009)
33 Randomized Controlled Trial/ (327258)
34 exp randomization/ (59096)
35 Single Blind Procedure/ (16267)
36 Double Blind Procedure/ (110342)
37 Crossover Procedure/ (34696)
38 Placebo/ (203094)
39 Randomi?ed controlled trial$.tw. (77731)
40 Rct.tw. (9804)
41 random allocation.tw. (1170)
42 randomly allocated.tw. (17495)
43 allocated randomly.tw. (1825)
44 (allocated adj2 random).tw. (709)
45 Single blind$.tw. (12431)
46 Double blind$.tw. (129721)
47 ((treble or triple) adj blind$).tw. (277)
48 placebo$.tw. (177837)
49 prospective study/ (211224)
50 or/32-49 (1267084)
51 case study/ (16626)
52 case report.tw. (229076)
53 abstract report/ or letter/ (841093)
54 or/51-53 (1082122)
55 50 not 54 (1231853)
56 31 and 55 (281)
57 (2010$ or 2011$ or 2012$).em. (2809950)
58 56 and 57 (94)
This search was updated on 24 October 2013.
This search was again updated on 9 September 2014.
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Appendix 5. PSYCINFO search strategy
Database: PsycINFO <1806 to June Week 4 2012>
Search Strategy:
1 exp Endocrine Sexual Disorders/ (825)
2 Polycystic Ovar$.tw. (221)
3 PCOS.tw. (128)
4 PCOD.tw. (5)
5 or/1-4 (979)
6 aromatase inhibitor$.tw. (143)
7 Anastrozole.tw. (16)
8 Arimidex.tw. (2)
9 Letrozole.tw. (32)
10 Femara.tw. (0)
11 Exemestane.tw. (10)
12 or/6-11 (162)
13 5 and 12 (3)
This search was updated on 24 October 2013.
This search was again updated on 9 September 2014.
WH A T ’ S N E W
Last assessed as up-to-date: 18 September 2014.
Date Event Description
24 September 2014 Amended This review has been amended. A new search was conducted on 18.9.14 and new ongoing studies
added
H I S T O R Y
Protocol first published: Issue 12, 2012
Review first published: Issue 2, 2014
Date Event Description
17 July 2014 Amended Addition of new data made available for Legro 2014. New secondary outcome has been added:
Miscarriage rate per pregnancy
26 February 2014 Amended Correction of search date in Abstract and Methods sections
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
A new secondary outcome has been added as an amendment: Miscarriage rate per pregnancy
I N D E X T E R M S
Medical Subject Headings (MeSH)
Aromatase Inhibitors [∗therapeutic use]; Birth Rate; Clomiphene [therapeutic use]; Coitus; Fertility Agents, Female [therapeutic use];
Infertility, Female [∗drug therapy; etiology]; Nitriles [∗therapeutic use]; Ovary [surgery]; Ovulation Induction [methods]; Polycystic
Ovary Syndrome [∗complications]; Pregnancy Outcome; Randomized Controlled Trials as Topic; Triazoles [∗therapeutic use]
MeSH check words
Female; Humans; Pregnancy
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